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ABSTRACT 
Egg allergy is among the most common food allergies in European children below the 
age of three, with a prevalence ranging between 0.2 and 2%. The management of this allergic 
disease is limited to strict avoidance of the offending food, although total evasion is difficult 
from a practical standpoint since egg and egg-derived products are ubiquitous ingredients. In 
this regard, oral immunotherapy (OIT) using whole egg white (EW) appears as an effective 
treatment option for egg allergy, with a success rate between 50 and 90%. However, a major 
drawback of OIT using intact egg allergens is the high risk of severe side effects. This obstacle 
has prompted the investigation of strategies aimed at reducing the allergenicity of the egg-
derived preparations used for IT. Among the most promising approaches currently studied, 
stands the possibility of using allergen-derived immunomodulating peptides to induce oral 
tolerance towards offending food proteins or even to prevent allergic sensitization. In this 
respect, hydrolysis of egg white proteins appears as an attractive and safe alternative for a 
reproducible and standardized production of immune-active peptides with low associated costs. 
Given this scenario, the aim of this thesis was the development of enzymatic 
hydrolysates of egg white proteins with hypoallergenic and immunomodulating properties that 
could be used in the prevention and treatment of egg allergy. With this purpose, enzymatic 
hydrolysates of ovalbumin (OVA), lysozyme, ovomucoid and EW were prepared using pepsin, 
Neutrase and alcalase. These hydrolysates were fractionated, characterized by chromatographic 
and mass spectrometric techniques, and their potential residual allergenicity assessed by in vitro 
and in vivo assays. All the hydrolysates produced with alcalase presented a very low binding to 
IgE from egg allergic patients and that of OVA with pepsin also showed a decreased IgE 
binding capacity. The hypoallergenicity of these hydrolysates was confirmed by the evaluation 
of the local allergic responses induced after their administration to mice passively sensitized to 
egg white proteins. 
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The immunomodulating effect of the hydrolysates was first evaluated in murine spleen 
and mesenteric lymph node cells stimulated with T or B cell mitogens. The results suggested 
that the hydrolysates produced with alcalase decreased the production of Th2-biased cytokines. 
In addition, these hydrolysates, together with that of OVA with pepsin, inhibited IgG1 class 
switching, which is also part of the IL-4 mediated Th2 response, and reduced the release of 
reactive oxygen species (ROS). We next assessed their ability to hinder cytokine and IgE 
production by Th2-skewed human peripheral blood mononuclear cells (PBMCs), as well as the 
release of pro-inflammatory factors and generation of ROS from Th1-stimulated peripheral 
blood leukocytes (PBLs). Data showed that the hydrolysates with alcalase and that of OVA with 
pepsin helped to re-establish the Th1/Th2 balance in Th2-biased PBMCs, while they also 
inhibited the release of pro-inflammatory mediators and reduced oxidative stress in PBLs 
treated with inflammatory stimuli. Together, these cellular models allowed us to select 
hydrolysates with the ability to down-modulate Th2 cytokine and IgE secretion and to attenuate 
inflammatory responses.  
Based on these previous screening tests, we explored the possibility that the selected 
hypoallergenic and immunostimulating hydrolysates could modulate T cell cytokine responses 
to egg allergens ex vivo, using splenocytes from BALB/c mice sensitized to individual egg 
proteins or to their mixtures in different proportions. The results obtained revealed that OVA 
hydrolysed with alcalase and pepsin could be regarded as two good candidates for peptide-based 
IT on the grounds of their ability to reduce Th2 cytokines induced by egg allergens in the spleen 
cell cultures. In addition, the hydrolysate of OVA with pepsin also enhanced Th1-related 
responses.  
In the last part of this thesis, we evaluated the sensitizing and eliciting capacities of the 
selected hydrolysates, as well as their preventive and therapeutic ability, using a mouse model 
of egg allergy. Results revealed that the hydrolysate of OVA with pepsin was weakly 
immunogenic and lacked sensitizing and eliciting capacity. For its part, in vivo testing of OVA 
hydrolysed with alcalase revealed immunogenic and antigenic capacities not previously detected 
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by in vitro methods. OVA hydrolysed with pepsin offered preventive and therapeutic protection 
against allergy to EW, exerting a marked reduction of Th2 and Th1 systemic responses, through 
the induction of regulatory T cells and the upregulation of TGF-β, IL-10 and IL-17 in intestinal 
tissues. This hydrolysate was more effective than intact OVA in desensitizing mice by virtue of 
its lower allergenicity and its immunomodulating capacity.  
In general terms, the screening strategy followed in this work proved useful to select a 
hydrolysate that combines tolerance induction with the absence of undesired effects of IgE-
crosslinking and inflammatory cell activation. The results presented in this thesis show that 
OVA hydrolysed with pepsin is hypoallergenic and contains immunomodulating peptides which 
lead to the prevention of egg allergy development and the promotion of long term 
desensitization to egg white proteins, as well as to linked-epitope suppression. 
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RESUMEN 
La alergia al huevo es una de las alergias alimentarias más comunes entre los niños 
europeos menores de tres años, con una prevalencia que oscila entre el 0,2 y el 2 %. El 
tratamiento de esta patología se limita a evitar el consumo de los alimentos ofensivos, aunque su 
evasión completa es complicada desde un punto de vista práctico ya que el huevo y sus 
productos derivados son ingredientes presentes en un amplio número de preparaciones 
culinarias. En este sentido, la inmunoterapia oral (OIT) utilizando clara de huevo completa 
(EW) se presenta como una de las mejores opciones para el tratamiento de la alergia al huevo, 
con una tasa de éxito que varía entre el 50 y el 90%. Sin embargo, el mayor problema que 
presenta la OIT con el alérgeno intacto es el alto riesgo de aparición de efectos adversos. Este 
obstáculo ha promulgado la investigación de estrategias dirigidas a la reducción de la 
alergenicidad de las preparaciones utilizadas en la OIT. Entre los procedimientos más 
prometedores, la posibilidad de utilizar péptidos inmunomodulantes derivados de las proteínas 
alergénicas aparece como una de las mejores opciones para inducir tolerancia oral a los 
alimentos ofensivos o incluso para prevenir la sensibilización alérgica. En este aspecto, la 
hidrólisis de las proteínas de clara de huevo se presenta como una alternativa atractiva y segura 
para la producción reproducible y estandarizada, con un bajo coste asociado, de péptidos 
inmunológicamente activos.  
Dado este escenario, el objetivo de esta tesis doctoral fue el desarrollo de hidrolizados 
enzimáticos a partir de proteínas de clara de huevo con propiedades hipoalergénicas e 
inmunomodulantes que puedan ser utilizados en la prevención y el tratamiento de la alergia al 
huevo. Con este propósito se prepararon hidrolizados de ovalbúmina (OVA), lisozima, 
ovomucoide y EW utilizando pepsina, Neutrasa y alcalasa. Estos hidrolizados fueron 
fraccionados y caracterizados por técnicas cromatográficas y de espectrometría de masas. 
Además, su alergenicidad residual fue estudiada mediante ensayos in vitro e in vivo. Todos los 
hidrolizados producidos con alcalasa, presentaron una baja unión a la IgE de pacientes alérgicos 
al huevo, además, el hidrolizado de OVA con pepsina también mostró una reducida capacidad 
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de unión a IgE. La hipoalergenicidad de estos hidrolizados fue confirmada mediante la 
evaluación de la respuesta alérgica local tras su administración a ratones pasivamente 
sensibilizados a las proteínas de la clara de huevo.  
El efecto inmunomodulante de los hidrolizados fue, en primer lugar, evaluado en 
células de ratón procedentes del bazo y de los nódulos linfáticos mesentéricos, estimuladas con 
mitógenos de células T o B. Los resultados obtenidos sugirieron que los hidrolizados 
producidos con alcalasa eran capaces de disminuir la producción de citoquinas del tipo Th2. 
Además, estos hidrolizados, junto al de OVA con pepsina, inhibieron la producción de 
anticuerpos IgG1, los cuales forman parte de la respuesta Th2 mediada por IL-4, y redujeron la 
liberación de especies reactivas de oxígeno (ROS). A continuación, evaluamos su habilidad para 
regular la producción de citoquinas e IgE en un modelo de células mononucleares humanas de 
sangre periférica (PBMCs) polarizadas hacia una respuesta Th2, así como la liberación de 
factores pro-inflamatorios y la generación de ROS en leucocitos humanos de sangre periférica 
(PBLs) inducidos hacia una respuesta del tipo Th1. Los datos mostraron que los hidrolizados 
producidos con alcalasa, así como el de OVA con pepsina, ayudaban a restablecer el balance 
Th1/Th2 en PBMCs polarizadas hacia Th2, mientras que también fueron capaces de inhibir la 
liberación de mediadores pro-inflamatorios y de reducir el estrés oxidativos en PBLs tratados 
con estímulos inflamatorios. En conjunto, estos modelos celulares nos permitieron seleccionar 
hidrolizados con habilidad para reducir la secreción de IgE y de citoquinas Th2, así como para 
atenuar las respuestas inflamatorias.  
Basándonos en los métodos de evaluación previos, exploramos la posibilidad de que los 
hidrolizados hipoalergénicos e inmunomodulantes seleccionados pudiesen regular ex vivo la 
producción de citoquinas de células T inducidas en respuesta a los alérgenos del huevo, 
utilizando esplenocitos procedentes de ratones BALB/c sensibilizados a las proteínas de la clara 
de huevo, individualmente o a su mezcla en diferentes proporciones. Los resultados obtenidos 
revelaron que los hidrolizados de OVA con alcalasa y pepsina eran posibles candidatos para ser 
utilizados en la IT basada en péptido, ya que poseían la habilidad de reducir la producción de 
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citoquinas Th2 inducida por los alérgenos del huevo en los cultivos de células esplénicas. 
Además el hidrolizado de OVA con pepsina mostró también una mejora de las respuestas del 
tipo Th1. 
En la última parte de esta tesis, evaluamos la capacidad sensibilizante de los 
hidrolizados seleccionados y su aptitud para inducir reacciones anafilácticas in vivo, así como su 
habilidad preventiva y curativa en un modelo múrido de alergia al huevo. Los resultados 
mostraron que el hidrolizado de OVA con pepsin era muy poco inmunogénico y no poseía 
capacidad ni para sensibilizar a los ratones ni para inducir respuestas anafilácticas en los 
animales sensibilizados. Por su parte, la evaluación in vivo del hidrolizado de OVA con alcalasa 
mostró que éste presentaba características inmunogénicas y antigénicas que no habían sido 
previamente detectadas en los modelos in vitro. La OVA hidrolizada con pepsina ofreció una 
protección a la alergia al huevo, tanto preventiva como terapéutica. La administración oral de 
este hidrolizado mostró una marcada reducción en las respuestas sistémicas del tipo Th2 y Th1 a 
través de la inducción de células T reguladoras y del incremento de TGF-β, IL-10 and IL-17 en 
los tejidos intestinales. Además, la hidrólisis de OVA con pepsina fue más efectiva que el uso 
de la proteína intacta en la desensibilización de los ratones dada su menor alergenicidad y su 
capacidad inmunomodulante. 
En términos generales, la estrategia de evaluación seguida en este trabajo mostró ser útil 
en la selección de un hidrolizado que es capaz de combinar la inducción a la tolerancia con la 
ausencia de efectos indeseados relacionados con el entrecruzamiento de las moléculas de IgE y 
la activación celular. Los resultados presentados en esta tesis doctoral mostraron que la OVA 
hidrolizada con pepsina es hipoalergénica y contiene péptidos inmunomodulantes que permiten 
la prevención de la alergia al huevo y proporciona una desensibilización mantenida en el tiempo 
a las proteínas de la clara del huevo basada en la supresión de epítopos.  
 
 
  
Abbreviations 
9 
ABBREVIATIONS 
ACN: acetonitrile 
AE-OP: peptide fractions of the 
hydrolysate of ovalbumin with pepsin 
separated by anion exchange FPLC 
B reg: regulatory B cells 
CFSE: carboxyfluorescein succinimidyl 
ester 
Cox-2: cyclooxygenase-2 
CT: cholera toxin 
DCs: dendritic cells 
DCFH-DA: dichloro-dihydro-fluorescein 
diacetate  
DHB: 2.5-dihydroxybenzoic acid matrix 
DTT: dithiothreitol  
EA: hydrolysate of whole egg white with 
alcalase 
EDTA: ethylenediaminetetraacetic acid  
EN: hydrolysate of whole egg white with 
Neutrase 
EP: hydrolysate of whole egg white with 
pepsin 
EW: whole egg white 
EW+CT: administration of whole egg 
white plus cholera toxin 
FBS: Fetal bovine serum 
FcεRI: high-affinity IgE receptor type I 
FcεRII: low-affinity IgE receptor type II 
(also called CD23) 
GALT: gut associated immune system 
HLA: Human leukocyte antigen 
HLA-DR: Human Leukocyte Antigen - 
antigen D Related 
i.p.: intraperitoneal 
IECs: intestinal epithelial cells 
IκBα: nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor alpha 
IKK: nuclear factor of kappa kinase  
ILC2: type 2 innate lymphoid cells 
iNOS: inducible nitric oxide synthase 
IT: immunotherapy 
LA: hydrolysate of lysozyme with alcalase 
LN: hydrolysate of lysozyme with Neutrase 
LP: hydrolysate of lysozyme with pepsin 
LPS: lipopolysaccharide 
LYS: lysozyme 
MA: hydrolysate of ovomucoid with 
alcalase 
MAPKs: mitogen-activated protein kinases 
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MHC: major histocompatibility complex  
MHC-II: major histocompatibility complex 
class II 
MLN: mesenteric lymph nodes 
mMCP-1: mouse mast cell protease-1 
MN: hydrolysate of ovomucoid with 
Neutrase 
MP: hydrolysate of ovomucoid with pepsin 
MTT: 3-[4,5-dimethylthiazol-2-yl]-2-,5-
diphenyltetrazoliumbromide 
Muc2: mucin type 2 
NF-B: nuclear factor kappa-light-chain-
enhancer of activated B cells 
NO: nitric oxide 
OA: hydrolysate of ovalbumin with 
alcalase 
OA+CT: administration of ovalbumin 
hydrolysed with alcalase plus cholera toxin 
OIT: oral immunotherapy 
OM: ovomucoid 
ON: hydrolysate of ovalbumin with 
Neutrase 
OP: hydrolysate of ovalbumin with pepsin  
OP+CT: administration of ovalbumin 
hydrolysed with pepsin plus cholera toxin 
OVA: ovalbumin 
PBLs: peripheral blood leukocytes 
PBMCs: peripheral blood mononuclear 
cells 
PCA: passive cutaneous anaphylaxis 
PGE2: prostaglandin E2 
PBS: phosphate buffered saline 
PP: Peyer’s patches 
RMCPII: rat mast cell protease II 
ROS: reactive oxygen species 
RP-HPLC: reverse phase high-
performance liquid chromatography  
RP-OP: peptide fractions of the 
hydrolysate of ovalbumin with pepsin 
separated by RP-HPLC 
T reg: regulatory T cells 
t-BOOH: tert-butyl hydroperoxide 
TFA: trifluoroacetic acid. 
Th: T-helper cell 
TLR: toll-like receptor 
TSLP: thymic stromal lymphopoietin 
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IMMUNOMODULATING PEPTIDES 
IgE-mediated food allergy is a hypersensitivity reaction whose prevalence is rapidly 
increasing in the western world (Sicherer et al., 2011; Nwaru et al., 2014). Food allergy results 
from a failure in stablishing oral tolerance or a breakdown in existing tolerance (Burks et al., 
2008). Allergic sensitization occurs when antigenic proteins enhance T lymphocyte 
differentiation into Th2 cells that synthetize cytokines such as IL-4, IL-5 and IL-13. This leads 
to the activation of B lymphocytes to IgE-producing plasma cells and the binding of the protein-
specific IgE antibodies to the surface of tissue mast cells and blood basophils. Fig. 1.1 
summarises the main events underlying the immune response to oral allergens in the gut lamina 
propria and draining mesenteric lymph nodes. Re-exposure to the allergen leads to cross-linking 
of the cell bound IgE, which triggers the release of mediators responsible for the allergic 
reaction (Berin and Sampson, 2013). In addition to an individual susceptibility, the ability of 
proteins or their accompanying food matrix components to promote Th2 effector pathways over 
Th1 immunity is considered to determine their capacity to induce an allergic response (Berin 
and Shreffler, 2008). In turn, activation of Th1 cells releases cytokines such as IL-2 and IFN-, 
which elicit the production of pro-inflammatory mediators, TNF-α and IL-8, and reactive 
oxygen species (ROS), boosting cellular anti-microbial and anti-tumour defense mechanisms 
(Barnes, 2011). Both types of T cells, with the contribution of Th17,  regulatory T (T reg) and 
regulatory B (B reg) cells, play crucial direct and indirect roles in the maintenance of immune 
tolerance and suppression of allergic inflammation (Palomares et al., 2010; van de Veen et al., 
2013). 
Although allergen-specific immunotherapy (IT) has proved effective in allergic asthma 
and rhinitis, despite huge efforts to desensitize food allergic patients, there are still no validated 
therapies to induce tolerance or provide effective protection from unintentional exposures, 
mainly because of the occurrence of severe adverse side effects, the varying efficiency of the 
traditional allergen extracts used for therapy and the excessive duration of the treatments 
(Muraro et al., 2014; Nowak-Wegrzyn and Albin, 2015). Thus, in most instances, the 
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management of food allergy is limited to strict dietary avoidance and emergency treatment in 
case of adverse reactions.  
 
Figure 1.1. Immune response to food allergens. The increased allergen entry promotes the secretion of 
the epithelium-derived cytokines IL-25, IL-33 and TSLP that trigger the immune system towards a Th2 
cell response. In particular, IL-33 and TSLP induces the expression of OX40L in DCs that promotes Th2 
cell differentiation of naïve CD4+ T cells and IL‑25 secretion aid the expansion of ILC2 population. 
These events, together with Th2 cytokine secretion (IL-4, IL-5 and IL-13), promote IgE class switching 
by B cells and the accumulation of eosinophils and basophils. DC, dendritic cell; FcεRI, high-affinity IgE 
receptor type I; IgE, immunoglobulin E; IL, interleukin; ILC2, type 2 innate lymphoid cells; MHC, major 
histocompatibility complex; OX40L, (CD252) ligand for CD134; Th, T-helper cell; T reg, regulatory T 
cell; TSLP, thymic stromal lymphopoietin (reprinted with permission from Nature Publishing Group. Yu 
et al., 2016). 
Among the most promising strategies currently assayed against IgE-mediated allergic 
diseases stands the possibility of using immunomodulatory peptides to stimulate oral tolerance 
towards offending food allergens or even to prevent allergic sensitization (Haney and Hancock, 
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2013; Berin, 2014). Antimicrobial peptides secreted by Paneth cells and peptide hormones 
secreted by enteroendocrine cells, both crucial for intestinal homeostasis, are good examples of 
endogenous immunomodulatory peptides. Antimicrobial host defense peptides shape and 
preserve intestinal microbiota, but are also protective without a direct antimicrobial action 
because they combine anti-inflammatory and immunostimulatory properties that include effects 
on cell migration, survival and proliferation, and induction of antimicrobial and immune 
mediators (Easton et al., 2009). For their part, peptide hormones not only detect luminal 
nutrients aiding their absorption, but also respond to pathogens and microbial metabolites and 
exert direct immunomodulatory effects on intestinal immune cells (Worthington, 2015).  
Food proteins are a rich and varied source of peptides bearing valuable and diverse 
biological activities. Bioactive peptides can be released from food proteins in vivo by the action 
of enzymes from digestive fluids and intestinal epithelial cells (IECs) or through processing by 
antigen-presenting cells. In vitro, they can be produced by enzymatic or chemical proteolysis or 
synthesis. In vitro generated peptides need to resist the influence of extreme pH, proteolytic 
enzymes and surfactants throughout digestion, to reach their sites of action and exert 
physiological functions. The beneficial effects of immunomodulatory peptides of food origin on 
food allergy could be directly executed in the intestinal tract, by maintaining and reinforcing 
barrier function and immune homeostasis, or once being absorbed, through their action on cells 
of the innate and adaptive immune system. Different IT experiments with food peptides in 
murine models have been reported, including approaches targeted to achieve desensitization or 
tolerance and to prevent allergy progression or the development of allergic sensitization.  
1.1. Peptides with local effects on the intestinal function 
The intestinal epithelium includes 4 main cell types: absorptive enterocytes, goblet cells 
-responsible for mucus secretion-, enteroendocrine cells and Paneth cells -which secrete, 
respectively, hormones and antimicrobial peptides-. In addition to its double function to act as a 
physical barrier with the external environment and to allow the uptake of nutrients, it is now 
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recognized that the cells that make up this protective interphase drive innate immune responses 
and ultimately act as modulators of adaptive immunity, therefore playing an essential role in the 
pathogenesis and development of food allergy. Food proteins and peptides influence the 
intestinal function by affecting barrier regulation, IEC-signalling to immune cells of the gut 
associated immune system (GALT) and mucus secretion (Martínez-Augustin et al., 2014). 
Moreover, the cross-talk of peptides with the microbiota, through prebiotic and antimicrobial 
actions, although out of the scope of this thesis, is crucial in the regulation of intestinal 
homeostasis in view of the key role of commensal flora in the development and functioning of 
the GALT. 
The barrier function of the intestine prevents the entrance of pathogens and antigens 
from the intestinal lumen to the mucosal tissue. In addition to commensal and probiotic bacteria, 
different components of the diet promote the maintenance of the barrier integrity and thus, 
contribute to regulate the passage of water and nutrients, and to protect against inflammatory, 
autoimmune and allergic diseases (Ulluwishewa et al., 2011; Kotler et al., 2013). It has been 
shown that fish protein hydrolysates can potentiate gut integrity and repair by virtue of both pro-
migratory and proliferative activities, as demonstrated on rat (RIE-1) and human (HT29) IECs, 
and that they are also able to reduce sustained injury in an in vivo gastric damaging model 
(Fitzgerald et al., 2005). Similarly, bovine colostrum hydrolysed with pepsin and chymotrypsin 
contains protein fractions responsible for promoting the growth of the human intestinal 
epithelial cell line T84, with potential application in gastrointestinal restoration (Morgan et al., 
2014). 
On the other hand, milk proteins fed to rodents can strengthen the tight junctions -which 
seal the space between IECs and control the paracellular transport of water, ions and small 
molecules- through changes in the expression of transmembrane and/or intracellular proteins 
that form the junctional complexes. However, while the beneficial effect of whey proteins on 
intestinal epithelial integrity, attributed to an increased the expression of claudin-4, was 
mediated by the presence of the anti-inflammatory cytokine TGF- in the whey protein 
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preparation (Ozawa et al., 2009; Hering et al., 2011), caseins may increase the expression of the 
pore-sealing protein claudin-1, and reduce that of the pore-forming claudin-2, through a TGF- 
independent pathway (Visser et al. 2010). In fact, casein hydrolysates, unlike amino acid 
mixtures, were found to reinforce the intestinal barrier function in vivo through an effect on the 
tight junction proteins. This suggests the specific involvement of the peptides contained in the 
casein hydrolysates, although it remains to be stablished to what extent they modulate intestinal 
permeability by directly targeting signal transduction pathways, promoting the release of 
regulatory cytokines, such as IL-10 or TGF-, stimulating mucin secretion, or inducing 
interactive support by the gut microbiota (Visser et al., 2012). 
For instance, the peptide NPWDQ (S2-casein 107-111), the active form of 
GPIVLNPWDQ (S2-casein 102-111) identified in an enzymatic cheese hydrolysate, 
upregulates the expression of the occludin gene and the production of the protein (but not of 
claudin-1) in Caco-2 cells (Yasumatsu and Tanabe, 2010). NPWDQ inhibits the transport of 
ovalbumin in vitro, in Caco-2 cells cultured on filter supports (Tanabe et al., 2006), ex vivo, in 
jejunal and ileal loops, and in vivo, following oral feeding of ovalbumin to indomethacin-
administered rats (Isobe et al., 2008). A similar activity was reported for DKIHPF (-casein 47-
52), which hinders intestinal permeation of -lactoglobulin, suggesting a role in the prevention 
or treatment of food allergy by avoiding allergen passage through the fortification of the 
intestinal barrier (Tanabe, 2012). Indeed, it has been suggested that augmented intestinal 
permeability is a factor promoting sensitization to food antigens in susceptible individuals 
(Heyman, 2005). Furthermore, in sensitized patients, the increase in permeability that is 
produced as a consequence of occasional food allergic reactions, and contributes to amplify the 
inflammatory response, does not return to normal values even long after the last allergen 
exposure (Perrier and Corthésy, 2010).  
A contrasting example is that of gliadin, the 33-mer peptide that mediates T cell 
activation in celiac disease. Gliadin causes rearrangement of the cell cytoskeleton, loss of 
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occludin-ZO1 protein-protein interaction and increased monolayer permeability in rat (IEC6) 
and human (Caco-2) IECs (Drago et al., 2006). Enhanced intestinal permeability upon gliadin 
exposure does not appear to be limited to celiac patients, although an exaggerated increase in 
gliadin-induced permeability is a characteristic of active celiac disease (Hollon et al., 2015). 
The control of epithelial permeability, innate immune recognition and adaptive 
immunity are all associated with gut inflammation. Perturbations in epithelial or immune 
homeostasis, either induced by infectious diseases or dietary antigens, can lead to inflammation 
-an excessive immune activation characterized by an influx of inflammatory cells from the 
blood- and to increased concentrations of cytokines, free radicals and lipid mediators 
(MacDonald and Monteleone, 2005). Inflammation represents a critical determinant in the 
development of food allergy, but also its consequence. In a situation of inflammation, intestinal 
permeability may be increased and the altered rate, route and mode of antigen presentation may 
lead to abrogation of oral tolerance (Bischoff et al., 2014). It has recently been demonstrated 
that the initiation of peanut allergy in mice requires cellular damage or tissue injury that prevent 
the induction of tolerance through the overproduction of uric acid in the local microenvironment 
and the subsequent activation of dendritic cells (DCs) (Kong et al., 2015). On the other hand, as 
already mentioned, inflammation is the long term consequence of sporadic or repetitive 
exposures to allergens in sensitized patients (Galli et al., 2008). 
Food derived peptides can prevent and repair the damage caused by oxidative stress and 
inflammatory reactions (Sarmadi and Ismail, 2010; Samaranayaka and Li-Chan, 2011; Power et 
al., 2013). Several publications report antioxidant and anti-inflammatory effects of protein 
hydrolysates and food peptides on animal models of inflammatory bowel disease (Daddaoua et 
al., 2005; Lee et al., 2009; López-Posadas et al., 2010; Mochizuki et al., 2010; Espeche Turbay 
et al., 2012; Wada et al., 2013; Zhang et al., 2015), as well as on different human cell lines 
(Phelan et al., 2009; Huang et al., 2010; McCarthy et al., 2013 and 2016; Fernández-Tomé et 
al., 2014; ; Malinowski et al., 2014; Bamdad et al., 2015; Ko et al., 2016). In human IEC 
models, such as Caco-2 cells, subjected to oxidant stimuli, phosphopeptides from hen egg yolk 
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phosvitin exhibit antioxidant activity, reducing IL-8 secretion and increasing intracellular 
glutathione levels and glutathione reductase activity (Katayama et al., 2006). These 
phosphopeptides also down-regulate the gene expression of IL-8 and IL-12 in 
lipopolysaccharide (LPS)- and TNF-α-stimulated HT29 cells (Xu et al., 2012). It was suggested 
that, in addition to the particular peptide structure, the phosphorus content plays a role in their 
activity and, in fact, casein phosphopeptides also enhance the antioxidant defense systems 
involved in the glutathione cycle in the Caco-2 cell line (Laparra et al., 2008). Similarly, whey 
protein hydrolysates inhibit IL-8 secretion and ROS generation, and lunasin (a 43-mer soybean 
peptide) reduces ROS levels, induced by H2O2 and LPS, respectively, in Caco-2 cells 
(Piccolomini et al., 2012; García-Nebot et al., 2014). 
The nuclear factor NF-κB pathway represents a prototypical pro-inflammatory 
signalling route. The NF-κB group of proteins -which consists of homo- and heterodimeric 
subunits of the Rel family, including p50 and p65- is found in almost all animal cell types and 
controls the expression of pro-inflammatory genes involved in the production of cytokines, 
chemokines, and adhesion molecules. The activity of NF-κB is regulated by IκB kinase (IKK), 
which retains NF-κB in the cytoplasm complexed with the inhibitory protein IκBα. Upon 
stimulation, IKK is phosphorylated and, in turn, it phosphorylates the IκBα protein, leading to 
the dissociation of IκBα from NF-κB and to the activation and translocation of NF-κB to the 
nucleus, where it binds to its specific promoter elements and induces gene transcription. A 
variety of integral membrane receptors, such as Toll-like microbial pattern recognition receptors 
(TLR), switched by microbial products, or receptors which respond to pro-inflammatory 
cytokines -for instance, TNF-α and IL-1 that are rapidly released on tissue injury or infection- 
trigger the canonical NF-κB pathway (Lawrence, 2009). Although structurally different, these 
receptors use similar signal transduction mechanisms, that include phosphorylation of mitogen-
activated protein kinases (MAPKs) -like JNK, ERK1/2 and p38, involved in directing cellular 
responses to a diverse array of stimuli, such as mitogens, ROS and pro-inflammatory cytokines- 
or activation of IRAK1 -responsible for IL-1-induced upregulation of NF-κB-. 
Introduction 
20 
The inhibition of the NF-κB route has long been considered a key goal for anti-
inflammatory food components. A 10-mer peptide from durum wheat (QQPQDAVQPF), which 
reduces cyclooxygenase-2 (COX-2) activity and production of pro-inflammatory cytokines, 
such as IL-6 and IL-8, triggered by gliadin peptides in the Caco-2 cell model, hampers IRAK1 
activation and ERK1/2 and p38 MAPK phosphorylation, and thus, the NF-B function (Capozzi 
et al., 2013). The flavour enhancing γ-glutamyl dipeptides, γ-glutamyl cysteine and γ-glutamyl 
valine, decrease TNF-α-stimulated pro-inflammatory cytokine expression and increase IL-10 
expression in Caco-2 cells. It was demonstrated that these peptides inhibit JNK and IκBα 
phosphorylation through the activation of the calcium-sensing receptor (Zhang et al., 2015). A 
similar mechanism is followed by the dipeptide WH and by dietary poly-L-lysine, which 
attenuate the TNF-α-induced secretion of IL-8 from HT29 cells and reduce inflammation in 
dextran sodium sulphate-induced models of mouse colitis (Kobayashi et al., 2015; Mine and 
Zhang, 2015). Therefore, the calcium-sensing receptor, present on IECs among other cell types, 
could constitute a target for treating intestinal inflammation by virtue of its role in maintaining 
and restoring intestinal homeostasis. 
The investigation of immunomodulating food peptides has not only focused on their 
ability to maintain the integrity of the intestinal epithelial barrier by hindering strong 
inflammatory responses, but also by inducing the secretion of IgA, which prevents bacterial and 
toxin translocation and subsequent breakdown of the barrier function (LeBlanc et al., 2002; 
Otani et al., 2003; Chalamaiah et al., 2014 and 2015). In mice, the oral administration of 
pasteurized kefir, fish and egg yolk protein hydrolysates increases the number of IgA+ cells, 
along with the levels of IL-4, IL-6 and IL-10 in the lamina propria -which contribute to B cell 
activation and antibody production- and raises the IgA content of the intestinal lumen. The 
secretion of IL-10 is believed to counterbalance the potential actions of the pro-inflammatory 
cytokines INF- and TNF-, which are also enhanced as a result of these interventions, because 
peptide administration does not cause tissue damage (Vinderola et al., 2005; Duarte et al., 2006; 
Nelson et al., 2007; Ndiaye et al., 2012). It is likely that these outcomes are, at least partly, 
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mediated by the interaction of the peptides with the IECs and the subsequent conditioning of the 
underlying immune cells (Mallet et al., 2014). Indeed, egg yolk and yellow pea protein derived 
peptides increase IL-6 secretion by mouse IECs (Nelson et al., 2007; Ndiaye et al., 2012), while 
casein phosphopeptides induce the expression of IL-6 in Caco-2 and its production in human 
Int-407 IECs (Kawahara and Otani, 2004; Kitts and Nakamura, 2006).Thus, Nelson et al. (2007) 
argued that IL-6 produced by IECs as a result of peptide stimulation is enough to trigger B cell 
differentiation into plasma cells for the production of IgA. 
In fact, it is now broadly recognized that the IECs, which constitute the interface 
between the gastrointestinal contents and the GALT, most likely determine the immune 
response to food (Berin and Sampson, 2013). IECs release several factors involved in tolerance 
induction, such as TGF-, IL-10 and retinoid acid, which drive the differentiation of non-
inflammatory DCs and tolerogenic CD103+ DCs that, in turn, induce antigen-specific T reg 
cells (Coombes et al., 2007; Iliev et al., 2009). Conversely, IECs can act on DCs promoting 
sensitization through the production of chemokines and cytokines such as thymic stromal 
lymphopoietin (TSLP), IL-25 and IL-33 (Chu et al., 2013). In particular, IL-33 regulation in the 
small intestine was found to be essential for gastrointestinal Th2 priming and subsequent 
humoral or cellular peanut-induced allergic responses in mice (Chu et al., 2013). On the other 
hand, TSLP acts directly on T lymphocytes amplifying the activation of Th2 cells and the 
production of IL-4, IL-5 and IL-13 (Ziegler and Artis, 2010). It has been shown that incubation 
of Caco-2 cells with the peach allergen Pru p 3 increases the expression of the epithelial 
cytokines TSLP, IL-33 e IL-25 (Tordesillas et al., 2013). Similarly, thermal processing of the 
major peanut allergen Ara h 2 results in structural changes which impact its interactions with 
IECs and the subsequent cellular signalling, enhancing its immunogenicity (Starkl et al., 2011).  
It is speculated that, as opposed to allergenic proteins, certain factors derived from the 
diet and the microbiota, with direct access to the IECs, could indirectly prime DCs in the control 
of the immune response, stimulating tolerance rather than activating the development of an 
allergic phenotype (Berin and Shreffler, 2008). Leonard et al. (2012) described that, in mice, the 
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protection against anaphylaxis that arises from oral IT (OIT) is associated with significant 
changes in the intestinal expression of certain genes. This observation denotes the existence of a 
protective mechanism located in the intestinal mucosa, whose activation would depend on 
interaction and communication with IECs, and suggests that it may be switched by the stimulus 
of immunomodulating peptides. However, it remains to be elucidated to what extent food 
derived peptides exhibit intrinsic immunogenicity by interacting with IECs.  
The mucus layer that covers the intestinal epithelium, in addition to offering physical 
protection against mechanical, chemical and microbial challenges, provides it with enzymatic 
activities and filter properties that affect the availability of antigens for entering the mucosa. In 
this respect, several food protein hydrolysates and peptides have shown stimulatory effects on 
mucin secretion in rat jejunum that are linked to a structure favourable to binding to opioid 
receptors (Claustre et al., 2002; Trompette et al., 2003). Further research demonstrated the 
induction of mucin production by peptides derived from caseins and whey proteins (such as 
YPFPGPI --casein 60-66-, YGLF-NH2 --lactoglobulin 102-105-, YLLF-NH2 --lactalbumin 
50-53- and AYFYPEL -S2-casein 143-149-) through the modulation of the expression of mucin 
genes in human HT29-MTX goblet IECs (Zoghbi et al., 2006; Martínez-Maqueda et al., 2012 
and 2013). In particular, peptide sequences with the ability to stimulate the production of Mucin 
2 (Muc2), such as -casein 94-123 (Plaisancié et al., 2015), could play a tolerogenic role. Muc2 
-the major component of the mucus layer of the intestine- exerts anti-inflammatory properties 
on IECs and DCs (Shan et al., 2013). Furthermore, it has been shown that goblet cells of the 
small intestine can take up luminal material and deliver it to the tolerogenic CD103+ lamina 
propria DCs, with recent observations pointing at a coupling between goblet cell antigen uptake 
and mucus secretion (McDole et al. 2012; Pelaseyed et al., 2014). Consequently, Muc2 
enhances gut homeostasis and tolerance by suppressing inflammatory responses in DCs while 
imprinting them with a tolerogenic function (Shan et al., 2013). 
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1.2. Intestinal transport of peptides 
The passage of immunomodulating peptides across the intestinal barrier is a 
requirement for direct conditioning of the underlying immune cells of the GALT, as well as for 
systemic effects. As compared with intact proteins, hydrolysis products are endowed with 
distinct transport properties, both in terms of rate and pathway (Bernasconi et al., 2006). Fig. 1.2 
shows possible routes of antigen delivery across the epithelial barrier. Food peptides can use the 
antigen sample pathway, that involves microfold cells (M cells) located above isolated 
lymphoid follicles and Peyer’s patches (PP), which allows the trafficking of insoluble or 
particulate substances, although other transport mechanisms -such as the already mentioned 
paracellular passage regulated by tight junctions, passive diffusion through IECs, endocytosis 
and carrier-mediated transport systems- are also available to deliver soluble antigenic molecules 
to the lamina propria. Whereas there seems to be little unequivocal evidence that dietary 
bioactive peptides, other than di- and tri-peptides, are absorbed at physiologically relevant 
concentrations to produce systemic actions (Miner-Williams et al., 2014), the possibility exists 
that immunomodulating peptides can exert certain effects, at least those mediated by their 
interaction with cells of the adaptive immune system, at small concentrations, within the range 
of those required by large dietary antigens to induce tolerance.  
 
Figure 1.2. Passage of antigens across the epithelial barrier in the gut. (a) DCs extend processes through 
the epithelium and into the lumen. (b) M cells overlying Peyer’s patches take up particulate antigens and 
deliver them to subepithelial DCs. (c) Soluble antigens also cross the epithelium through transcellular or 
paracellular routes to encounter DCs and T cells in the lamina propria. DCs, dendritic cells; IgA, 
immunoglobulin A (Modified with permission from Elsevier. Burks et al., 2008).  
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Interestingly, it was found that IECs may constitute a powerful link between luminal 
antigens and local immune cells by mediating the transfer of only small amounts of soluble 
proteins or peptides. Most (90%) of the protein material that is taken by IECs is either totally 
(50%) or partially (40%) degraded in endosomes, yielding, in the latter case, peptides of around 
1500 Da of molecular mass, a size compatible with binding to major histocompatibility complex 
class II (MHC-II) molecules. In IECs, as in professional antigen-presenting cells, endosomes 
containing partially degraded antigens may encounter MHC-II compartments, what allows 
peptides to be loaded on MHC-II molecules. This gives rise to exosome-like vesicles that very 
efficiently transfer MHC-II-peptide complexes to the lamina propria, where they can interact 
with local DCs and stimulate specific T cells at a concentration 100 times lower than free 
peptides (Ménard et al., 2010). Thus, the human IEC lines HT29 and T84 secrete exosomes 
bearing accessory molecules which strongly potentiate peptide presentation to T cells (Van Niel 
et al., 2001; Mallegol et al., 2007). However, it has been reported that, in mice, epithelial 
exosomes prime for immunogenic rather than tolerogenic responses (Van Niel et al., 2003), 
although the outcome would definitely depend on the phenotype of the local DCs and on the 
signals delivered by the IECs themselves and by exogenous factors, such as inflammatory 
stimuli. Indeed, exosomes derived from the serum of ovalbumin fed mice were found to prevent 
allergic sensitization in a model of allergic asthma, with the tolerant animals showing a 
significantly higher frequency of activated T reg cells (Almqvist et al., 2008). 
On the other hand, in sensitized individuals, CD23 (FcεRII) -also called the low-affinity 
receptor for IgE- expressed by IECs and B cells, moves IgE and antigen-IgE complexes across 
the epithelium by transcytosis, exerting both negative and positive effects in the regulation of 
IgE production (Tu et al., 2005). This carrier-mediated transport enables, in cases of peptides 
with adequate length, activation of the high-affinity receptor of IgE, FcRI, on mast cells and 
promotion of allergic inflammation, secretion of IL-4 and IL-13, local IgE production, 
facilitated antigen presentation by B cells and sensitization to additional antigens (Galli and 
Tsai, 2012). However, and as it will be explained in the following sections, since FcRI is also 
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expressed by human DCs, its activation by peptide-IgE complexes can influence, maturation, 
functional activation, migration of DCs and antigen presentation with a beneficial impact in 
tolerance induction (Platzer et al., 2015).  
1.3. Effects on cells of the innate immune system: anti-inflammatory 
peptides  
It has been reported that the oral administration of several food protein hydrolysates can 
activate the effector mechanisms of the innate immune response. For example, the phagocytic 
activity of peritoneal macrophages, and consequently their ability to respond to pathogens, 
increases after the administration to mice of hydrolysates of milk, fish and yellow field pea 
proteins (Biziulevicius et al., 2006; Duarte et al., 2006; Ndiaye et al., 2012; Chalamaiah et al., 
2014).  
Macrophage activation leads to an inflammatory response. Inflammation is part of the 
defence mechanism against infectious agents and injuries, but it is also associated to adverse 
chronic conditions such as cardiovascular diseases, diabetes and cancer. Macrophages are 
activated in response to oxidative stress or pro-inflammatory cytokines, including IFN-, and by 
bacterial components, such as the TLR ligand LPS, resulting in the production of the pro-
inflammatory substances: IL-1, IL-6, TNF-, nitric oxide (NO) and prostaglandin E2 (PGE2). 
NO and PGE2 are generated during inflammatory processes by inducible nitric oxide synthase 
(iNOS) and COX-2 -which catalyse, respectively, the reactions that convert L-arginine and 
oxygen to NO and citruline, and arachidonic acid to prostaglandins-. In this respect, and as 
shown in Table 1.1, a number of food-protein hydrolysates and derived peptides, particularly 
from soy, fish and shellfish, have shown anti-inflammatory properties on LPS-stimulated 
murine RAW 264.7 cells, as estimated by different markers associated with beneficial effects 
against inflammation and oxidative stress. The RAW 264.7 cell line is considered one of the 
most suitable in vitro model systems for inflammation-related investigations. In addition, other 
food protein hydrolysates have shown anti-inflammatory properties in human cell lines, such as 
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monocyte (THP-1) derived macrophages (Millán-Linares et al., 2014; Montoya-Rodríguez et 
al., 2014). 
The cascade of LPS-induced events in macrophages is initiated by its binding to the 
LPS-binding protein and transfer to CD14 on the macrophage surface for further interaction 
with TLRs. Through MAPKs, TLRs activate the already mentioned NF-B pathway. A 
mechanism of action involving the inhibition of NF-B activation, leading to the down-
regulation of genes implicated in inflammatory processes in RAW 264.7 cells, such as COX-2, 
iNOS, IL-6, IL-1 or TNF-, has been described for lunasin and lunasin derived peptides (de 
Mejía and Dia, 2009). A reduced transcriptional activity of NF-B has also been deemed 
responsible for the antioxidant activity of hydrolysed common bean and soybean flours and 
amaranth hydrolysates (Oseguera-Toledo et al., 2011; Vernaza et al., 2012; Montoya-Rodríguez 
et al., 2014). Similarly, the anti-inflammatory properties of pyroglutamyl-leucine in the RAW 
264.7 cell line are probably due to the inhibition of NF-κB, via suppression of the 
phosphorylation of three types of MAPKs: JNK, ERK and p38, and of its dissociation from 
IκBα (Hirai et al., 2014). 
In addition to interfering with TLR signal transduction pathways, there are also peptides 
which supress LPS-induced activation of macrophages through interaction with LPS itself and 
neutralization of its action. Antimicrobial host defence peptides, which are generally small 
(commonly 12-50 amino acids) cationic and, frequently, quite hydrophobic and amphipathic, 
interact with the negatively charged surface of LPS and suppress the LPS-triggered release of 
pro-inflammatory cytokines from macrophages (López-Abarrategui et al., 2013).This is, for 
instance, the case of antimicrobial peptides derived from shrimp, such as the shrimp anti-LPS 
cyclic peptide (ECKFTVKPYLKRFQVYYKGRMWCP) (Lin et al., 2010). 
 
 
  
 
Table 1.1. Food protein hydrolysates and derived peptides with anti-inflammatory activity in the macrophage RAW 264.7 cell line 
Peptide/hydrolysate RAW 264.7 stimulation Main outcomes Reference 
Lunasin 
Lunasin pre-treatment for 6 h and LPS 
stimulation for 18 h 
ROS, TNF-α (23%) and IL-6 (37%) production 
Hernández-
Ledesma et 
al., 2009 
Lunasin-like peptide of 5000 Da 
Simultaneous lunasin treatment and LPS 
stimulation for 24 h 
NO (IC50= 28 M), PGE2 (IC50= 41 M),  IL-6 (IC50= 2 M) and          
 IL-1β (IC50= 13 M) production 
COX-1 (no change), iNOS (IC50= 37 M) and COX-2 (IC50= 25 M) 
protein expression 
NF-B (IC50= 21 M) transactivation 
P65 (IC50= 48 M) and P50 (IC50= 77 M) nuclear translocation 
de Mejía 
and Dia, 
2009 
Soy flour hydrolysed with alcalase 
Simultaneous hydrolysate treatment and 
LPS stimulation for 24 h 
NO (18-35%) and PGE2 (47-71%) production 
iNOS (31-53%) and COX-2 (30-52%) protein expression 
Martínez-
Villaluenga 
et al., 2009 
Common bean flours hydrolysed with alcalase 
Simultaneous hydrolysate treatment and 
LPS stimulation for 24 h 
NO (IC50= 4-48 M) and PGE2 (IC50= 14-61 M) production 
iNOS (IC50= 5-14 M) and COX-2 (IC50= 35-44 M) protein expression 
NF-B transactivation 
P65 nuclear translocation 
Oseguera-
Toledo et 
al., 2011 
Germinated soybean flour hydrolysed with alcalase 
Hydrolysate pre-treatment for 24 h and 
LPS stimulation 
NO (21-69%), PGE2 (64-88%) and TNF-α (94-96%) production 
iNOS (23-94%) and COX-2 (36-77%) protein expression 
Vernaza et 
al., 2012 
Commercially available soy products hydrolysed 
with pepsin and pancreatin 
Simultaneous hydrolysate treatment and 
LPS stimulation for 24 h 
NO (16-29%), IL-1β (22-40%), IL-6 (27-43%) and TNF-α (48-333%) 
production 
iNOS (65-88%) and COX-2 (41-70%) protein expression 
Dia et al., 
2014 
Yellow pea proteins hydrolysed with thermolysin of 
less than 3000 Da 
Hydrolysate pre-treatment for 12 h and 
LPS-IFN-γ stimulation for 24 h 
NO (20%), TNF-α (35%) and IL-6 (80%) production 
 
Ndiaye et 
al., 2012 
Phosphopeptides derived from partial alkaline 
dephosphorylation and tryptic digestion of egg yolk 
phosvitin 
Peptide pre-treatment for 2 h followed by 
LPS stimulation for 6 h 
IL-6, IL-1β, TNF-α and iNOS gene expression 
Xu et al., 
2012 
GCQQAVQSAV derived from clam (Ruditapes 
philippinarum) hydrolysed with alcalase 
Peptide pre-treatment for 4 h followed by 
LPS stimulation for 18 h 
IL6 (no change), PGE2 (no change) and NO (48%) production 
iNOS and COX-2 protein expression 
Lee et al., 
2012 
QCQCAVEGGL derived from Pacific oyster 
(Crassostrea gigas) hydrolysed with Protamex 
Simultaneous peptide treatment and LPS 
stimulation for 18 h 
NO (72%) production 
Hwang et 
al., 2012 
  
 
GVSLLQQFFL derived from mussel (Mytilus 
coruscus) hydrolysed with Flavourzyme 
Simultaneous peptide treatment and LPS 
stimulation for 18 h 
NO (62%) production 
Kim et al., 
2013 
Almond proteins hydrolysed with pepsin and 
pancreatin and the fraction higher than 5000 Da 
Simultaneous peptide treatment and LPS 
stimulation 
NO production 
TNF-α, IL-1β,  IL6 production and gene expression 
iNOS and COX-2 protein and gene expression 
Udenigwe 
et al., 2013 
Gluten-derived pyroglutamyl-leucine 
Simultaneous peptide treatment and LPS 
stimulation for various periods 
NO, TNF-α and IL6 production 
IBα degradation 
JNK, ERK and p38 phosphorylation 
Hirai et al., 
2014 
Extruded amaranth hydrolysed with pepsin and 
pancreatin 
Simultaneous peptide treatment and LPS 
stimulation for 24 h 
PGE2 (32%) and TNF-α (34%) production 
COX-2 (67%) protein expression 
IKK (88%) and IκBα (66%) phosphorylation 
Montoya-
Rodriguez 
et al., 2014 
Tuna hydrolysed with alcalase and synthetic peptides 
PRRTRMMDGGR and MGPAMMRTMPG 
Hydrolysate or peptide pre-treatment for 
24 h and LPS stimulation for 24/28 h 
IL-2, TNF-α and TNF-γ production 
Cheng et 
al., 2015 
Salmon myofibrillar protein conjugated with alginate 
hydrolysed with pepsin and trypsin 
Simultaneous hydrolysate treatment and 
LPS-IFN-γ stimulation for 24 h 
NO (66%), IL-6 (85%) and TNF-α (67%) production 
COX-1 (no change), iNOS, IL-6, COX-2 and TNF-α gene expression 
Saigusa et 
al., 2015 
Fermented (Lactobacillus plantarum) abalone 
(Haliotis discus hannai Ino) 
Hydrolysate pre-treatment for 24 h and 
H2O2 stimulation 
Simultaneous or hydrolysate pre-treatment 
(18 h) and LPS stimulation for 24/28 h 
ROS (IC50= 6.78 mg/mL), NO and PGE2 production 
Hasnat et 
al., 2015 
KAFAVIDQDKSGFIEEDELKLFLQNFSAGARAG
DSDGDGKIGVDEFAALVK and 
AFAVIDQDKSGFIEEDELKLFLQNFSAGARAGD
SDGDGKIGVDEFAALVK derived from tilapia 
(Oreochromis niloticus) hydrolysed with 
Flavourzyme 
Peptide pre-treatment for 1 h and H2O2 
stimulation 
Simultaneous peptide treatment and LPS 
stimulation for 48 h 
ROS (83%) and NO (40.9%) production 
Kangsanant 
et al., 2015 
PAY derived from salmon hydrolysed with pepsin 
Simultaneous peptide treatment and LPS 
stimulation for 24 h 
NO (64%), PGE2 (45%), IL-6 (44%), TNF-α (58%) and IL-1β (65%) 
production 
iNOS (0.75-fold) and COX-2 (0.48-fold) protein expression 
Ahn et al., 
2015 
Main outcomes: COX-1=cyclooxygenase-1; COX-2=cyclooxygenase-2; IκBα= nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha; IKK= IκB 
kinase; iNOS= inducible nitric oxide synthase; JNK, ERK and p38= mitogen-activated protein kinases;  NF-κB= nuclear factor kappa-light-chain-enhancer of activated B 
cells; PGE2= prostaglandin E2; p50/p65= members of the Rel family of transcription factors; ROS= reactive oxygen species; = increased or high levels; = decreased or low 
levels 
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In contrast to the previously mentioned examples, wheat gliadin and its proteolytic 
fragments arising from pepsin digestion, such as VSFQQPQQQYPSSQ and 
FQQPQQQYPSSQ, have the ability to activate mouse peritoneal macrophages inducing the 
secretion of TNF- and NO (Tuckova et al. 2002). Gliadin and its fragments also increase IL-8 
and TNF- production by human monocytes, what was suggested to be involved in the damage 
they cause to celiac intestinal mucosa. Unlike soy proteins, gliadin stimulates phosphorylation 
and subsequent degradation of the IB molecule and increases the DNA-binding activities of 
the NF-B subunits p50 and p65, with an activation pathway independent of CD14 (Jelinkova et 
al., 2004).  
It should be mentioned that it has been hypothesized that the suppression of Th1 
responses by antioxidant compounds, while beneficial in reducing the side effects of 
inflammatory processes, may provoke an up-regulation of Th2 type cytokines that promotes 
allergic sensitization and exacerbates allergic symptoms (Gostner et al., 2014). However, when 
the role of oxidative stress in allergic sensitization was investigated in humans, it was shown 
that it is the exposure to allergenic proteins combined with an inadequate antioxidant response 
what increases the likelihood for sensitization (Utsch et al., 2015). In fact, there is evidence that 
antioxidant and anti-inflammatory compounds that decrease the effects mediated by IFN-γ and 
slow down the intracellular pathways that lead to the generation of ROS, also reduce the 
expression of Th2 cytokines and IgE levels in response to food allergens in mice (Singh et al. 
2011; Masilamani et al. 2012). For instance, dietary omega-3 fatty acids prevent allergic 
sensitization in mice via suppression of Th2 type antibody responses and enhancement of 
intestinal and systemic Foxp3+ T reg cells (van den Elsen et al., 2013a). Noteworthy, the 
suppression of IL-4 and IL-13 secretion by mast cells, that contributes to decrease the 
susceptibility to develop allergy and the severity of the symptoms, is associated with the 
inhibition of the generation of ROS (van den Elsen et al., 2013b).  
In line with those observations, it was reported that the fraction smaller than 3000 Da 
from an enzymatic hydrolysate of the edible microalgae Spirulina maxima and, particularly, the 
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pentapeptides DAVNR and MMLDF, inhibit histamine release form RBL-2H3 mast cells 
sensitized with dinitrophenyl (DNP)-specific IgE and stimulated with DNP-BSA, in parallel 
with a suppressive effect on intracellular ROS production (Vo et al., 2013). Furthermore, the 
peptide PFNKGTFAS, derived from a gastrointestinal digest of abalone (Haliotis discus 
hannai), attenuates histamine release and production of pro-inflammatory cytokines (TNF-α, 
IL-1β and IL-6) from human HMC-1 cells. PFNKGTFAS hinders the phosphorylation of JNK 
and IκBα in the stimulated mast cells, which points at the inhibition of the MAPK and NF-𝜅B 
pathways as responsible for the restricted release of mediators (Ko et al., 2016). These results 
indicate that the ability of food peptides to favourably balance pro-inflammatory and anti-
inflammatory/antioxidant responses could provide a tolerogenic milieu. In addition, it has been 
described that there are peptides able to interact with the ε-heavy chain of IgE and block its 
binding to the high-affinity receptor, FcRI, on mast cells and basophils and protect mice from 
anaphylaxis (Zhou et al., 2013). These actions of peptides on mast cells and IgE signalling are 
highly interesting in view of the role of armed mast cells as effectors of anaphylaxis, but also as 
inducers of Th2 responses and suppressors of T reg cells (Burton et al., 2014). 
1.4. Effects of peptides on cells of the adaptive immune system: Th1 
and Th2 mediators 
As already anticipated, there is evidence that immunomodulating peptides alter T 
lymphocyte functions and can contribute to a balanced Th1 and Th2 response, with potential 
implications in various clinical conditions, including allergy and oral tolerance to antigens 
(Kiewiet et al., 2015).  
Antigen-presenting cells, such as DCs, are key initiators of innate immunity, although 
they also play a central role in shaping the properties of adaptive immunity by processing 
proteins or peptides and presenting them to T cells, together with co-stimulatory mediators that 
generate primary T cell responses (see Fig. 1.3, which outlines the main cytokines and 
transcription factors involved in T cell differentiation). As shown in Fig. 1.2., food antigens can 
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be directly sampled from the gut lumen by intestinal DCs, which extend their dendrites between 
IECs. Alternatively, they can be transported through M cells into the lymphoid follicles, or by 
transcytosis to the lamina propria, and presented by DCs to naïve T cells in the PP or the gut-
draining mesenteric lymph nodes (MLN) (Ménard et al., 2010). As already indicated, intestinal 
DCs, with the help of other cells involved in innate immunity, such as the nearby IECs, play a 
crucial role in the generation of tolerance to food proteins (Ruiter and Shreffler, 2012). Thus, 
while allergens, as well as certain food components, may exhibit intrinsic adjuvant capacity, 
stimulating DCs to enhance allergen-specific Th2 differentiation (Kean et al., 2006; Shreffler et 
al., 2006; Hsu et al., 2010; Gómez et al., 2012; Chu et al., 2013), it is also possible to prime DCs 
for allergy prevention or treatment. For instance, soybean isoflavones hinder allergic 
sensitization by inhibiting DC maturation and subsequent DC-mediated Th2 effector cell 
functions, which correlates in vivo with significantly reduced anaphylactic symptoms and mast 
cell degranulation upon allergen challenge (Masilamani et al., 2011). Accordingly, DCs are 
attractive targets for tolerance induction and the potential of food peptides to avoid Th2 type 
immunity by the enhancement of the tolerogenic properties of DCs warrants further 
investigation. 
It is known for some time that FcRI, in addition to mast cells and basophils, is also 
constitutively expressed on DCs and monocytes in humans, albeit not in mice (Shin and Greer, 
2015). Experiments with transgenic mice led to postulate that FcεRI contributes to the rapid 
internalization of IgE-bound antigens by DCs, facilitating their presentation to specific T cells 
in vivo and promoting the development and activation of Th2 cells (Sallmann et al., 2011). 
However, other studies showed that, when monovalent antigens, unable to cross-link IgE-FcRI 
complexes, are loaded by DCs, enhanced presentation results in a transient T cell proliferation, 
followed by systemic deletion of antigen-specific T cells (Baravalle et al., 2014). This 
mechanism, if confirmed in further studies, implies a role for peptides derived from allergenic 
proteins, focused by IgE-binding and transported by CD23, in the development of tolerance 
through the mediation of DCs. Furthermore, it was recently found that even antigen-specific 
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IgE-FcRI cross-linking fails to induce maturation and production of inflammatory mediators 
by human and FcRI-humanized DCs in vitro, which correlates with a reduced severity of food 
allergy in vivo (Platzer et al., 2015). These observations indicate that DC-intrinsic IgE signals 
function as feedback mechanisms to control allergic inflammation and suggest novel beneficial 
peptide-based approaches for allergy therapy. 
 
Figure 1.3. T cell differentiation: cytokines and transcription factors. Mature DCs polarize naive Th0 
cells into different T cell subsets (Th1, Th2, Th17 or T reg) through several signals, including antigen 
presentation to the TCR, secretion of cytokines and co-stimulatory signals. The archetypical cytokine of 
each subset is marked in bold. The complex interactions between the various CD4+ T cell subsets are 
represented schematically. Immature DCs also prime T reg cells to induce regulatory signals. CTLA-4, 
cytotoxic T lymphocyte antigen 4; DCs, dendritic cells; Foxp3, forkhead box protein P3; GATA-3, trans-
acting T-cell-specific transcription factor; IL, interleukin; MHC, major histocompatibility complex; ROR, 
retinoic acid-related orphan receptor transcription factor; STAT, signal transducer and activator of 
transcription; TBX21, T-box transcription factor (also known as T-bet); TCR, T-cell receptor; Th, T-
helper cells; T reg, regulatory T cells (reprinted with permission from Nature Publishing Group. Lahoute 
et al., 2011).  
As opposed to IgE-mediated food allergies, in the pathogenesis of celiac disease, and in 
addition to the inflammatory innate immune response that causes damage to the intestinal 
mucosa, the adaptive immune response to gliadin involves DCs that interact with gliadin-
specific Th1 cells, producing inflammatory cytokines such as IFN-γ (Green et al., 2015). 
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Stimulation of DCs with gliadin, unlike other food proteins, enhances the expression of 
maturation markers (CD80, CD83, CD86, and HLA-DR molecules) and the secretion of 
chemokines and cytokines (IL-6, IL-8, IL-10, TNF-α, growth-related oncogene, etc.), which 
results in more efficient processing and presentation of gliadin peptides to specific T cells 
(Palova-Jelinkova et al., 2005). However, two decapeptides naturally occurring in durum wheat, 
QQPQDAVQPF and its homologous QQPQRPQQPF, are able to prevent the gliadin-dependent 
functional DC maturation and T cell stimulating capacity, raising the perspective of a potential 
therapeutic strategy alternative to a gluten free diet (Giordani et al., 2014). 
Peptides from marine origin administered orally to mice enhance the proliferative 
response of spleen cells to concanavalin A (ConA) and the percentage of CD4+ T cells (Yang et 
al., 2009a) or both CD4+ and CD8+ T cells (Chalamaiah et al., 2014). In addition, several 
studies describe that food peptides (Kawahara et al., 2004; Jiehui et al., 2014) and hydrolysates 
(Mercier et al., 2004; Durrieu et al., 2006; Mao et al., 2007; Saint-Sauveur et al., 2008; Kong et 
al., 2008; Yang et al., 2009a; Hou et al., 2012; He et al., 2015) promote the proliferation of 
either resting or mitogen-treated murine spleen cells and human T cells in vitro, which was also 
interpreted as a stimulatory effect on cell-mediated immunity. However, in most cases, those 
works assessed cell viability -the number of healthy cells in a sample- rather than cell 
proliferation -the number of dividing cells-. 
The results available so far suggest that, beyond influencing proliferation, 
immunomodulating peptides can specifically drive lymphocyte responses in a certain direction. 
Milk protein hydrolysates have been reported to induce the secretion of Th1 cytokines (IL-2 and 
IFN-γ) by ConA-stimulated mice spleen cells and human Jurkat T cells, without an effect on the 
release of Th2 cytokines and thus, to play a role in fighting infections (Mao et al., 2007; Saint-
Sauveur et al., 2008; Phelan et al., 2009). Conversely, the casein peptide QEPVL enhances Th2 
type responses in vivo, as estimated by the concomitant up-regulation of IL-4 and down-
regulation of IFN-γ and TNF-α in mice serum, and inhibits LPS-induced inflammation (Jiehui et 
al., 2014). These observations imply that food peptides may preferentially guide Th1 type 
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immune responses or promote Th2 type responses, which are goals of recognized importance in 
infectious diseases, tumours and inflammatory processes.  
With regard to food allergy, it should be noted that the therapeutic effect of peptides in 
mouse models has been associated both to the inhibition of allergen-induced Th1 and Th2 
cytokine responses (Yang et al., 2009b), as well as to the promotion of Th1-biased responses to 
a detriment of the Th2 ones (Yang et al., 2010). Alternatively, other immunomodulating 
peptides could help to induce oral tolerance by stimulating T reg cells through the promotion of 
the secretion of regulatory cytokines, such as IL-10 (Prioult et al., 2004; Cian et al., 2012) or 
TGF-β (Rodriguez-Carrio et al., 2014).  
1.5. Peptide immunotherapy: T and B cell epitopes 
The production of allergen derivatives that are hypoallergenic and immunogenic is an 
attractive strategy for the development of IT agents for IgE-mediated allergies. Although its 
efficacy has not been formally demonstrated, OIT -which consists in the gradual administration 
of increasing amounts of the allergen- is one of the most promising treatment options. However, 
the associated high frequency of allergic adverse events has prompted the investigation of 
strategies aimed at reducing the allergenicity of the treatment preparations, while maintaining 
their immunogenicity, or even improving their immunomodulating potential, to achieve 
effective desensitization or sustained oral tolerance (Jutel et al., 2015; Vázquez-Ortiz and 
Turner, 2016; Wood, 2016). 
Peptide IT focuses on the properties of fragmented allergens, which contain T cell-
stimulating epitopes but are not capable of cross-linking IgE on basophils and mast cells. 
Peptides represent a safer alternative to full allergens, as they produce fewer side effects and 
increase adherence to therapy (Casale and Stokes, 2011; Moldaver and Larché, 2011). T cell 
epitope-mapping -that is the determination of the specific peptide sequences recognized by 
CD4+ T cells- can be performed by different methods but, in all cases, it needs to be checked 
that as many as possible distinct MHC-II molecules, representative of the HLA genotypic 
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frequencies of the patient population of interest, recognize and bind the selected epitopes 
(Malherbe, 2009). 
T cell epitopes that can be potential candidates for peptide-based vaccines have been 
identified from many food allergens, but particularly from peanut, in silico -by the use of 
predictive algorithms- and in vitro -by screening the proliferative responses and cytokines 
released by peripheral blood mononuclear cells (PBMCs) from allergic patients stimulated with 
consecutive overlapping peptides spanning the allergen sequence or by tetramer-guided epitope 
mapping- (DeLong et al., 2011; Prickett et al., 2011 and 2013; Pascal et al., 2013). Allergen-
specific T cell lines or clones have been used to overcome the limitation imposed by the low 
frequency or allergen-specific T cells (DeLong et al., 2011; Prickett et al., 2011 and 2013), 
although in vitro expansion can alter cell phenotypes or bias the results through the selection of 
the rapidly proliferating clones (Pascal et al., 2013). Specific T cell epitopes of food allergens, 
such as celery (Bohle et al., 2003), hazelnut (Bohle et al., 2005), shrimp-tropomyosin (Wang et 
al., 2012; Ravkov et al., 2013), β-lactoglobulin (Inoue et al., 2001; Kondo et al., 2008), αS1-
casein (Ruiter et al., 2006), ovomucoid (Holen et al., 2001), peach Pru P3 (Tordesillas et al., 
2009; Pastorello et al., 2010), anisakis (Garcia Alonso et al., 2015) and walnut (Archila et al., 
2015), among others, have also been described.  
There is a minimum core sequence of 9 to 15 amino acids required for recognition by 
reactive T cells. Consequently, -even if linear, soluble, 15-mer IgE-binding peptides are unlikely 
to act as full epitopes and cause allergic reactions (Albrecht et al., 2009)- the selection of 
peptides that combine the ability to stimulate T lymphocytes and modulate the immune response 
with a reduced capacity to trigger clinical symptoms implies a compromise, as longer peptides 
increase T cell epitope coverage but also the potential for IgE-cross-linking (Prickett et al., 2011 
and 2013). The lack of overlapping between T- and IgE-binding epitopes has to be evaluated by 
searching B epitopes reported in the literature, and confirmed by serum IgE-binding and 
basophil activation assays (Wai et al., 2014). Peptide microarray technology allows the 
assessment of epitope diversity and affinity of the IgE response associated to clinical reactivity 
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(Berin, 2015). Unfortunately, the evidence gathered so far highlights that B epitope multiplicity 
and variation in reactivity among allergic individuals is so large that the presence or absence of 
specific epitopes might not provide enough evidence for allergy prediction (Aalberse and 
Crameri, 2011; Ruiter and Shreffler, 2012; Scheurer et al., 2015). 
Cytokine detection assays typically reveal a prevalent Th2 cytokine profile in PBMCs 
or specific T cells from allergic patients stimulated with the T cell epitopes regarded as most 
significant, while control donors show a trend towards a Th1 profile (Tordesillas et al., 2009; 
Pastorello et al., 2010; DeLong et al., 2011; Prickett et al., 2011; Pascal et al., 2013). 
Nonetheless, beyond trying to reduce IgE reactivity and retain T cell reactivity, the possibility 
arises to exploit the immunomodulatory potential of peptides, in particular the ability to re-
direct the immune response of specific cell types and the lack of inflammatory properties, to 
enhance the effectiveness and reduce the length of the IT treatments. In this respect, B cell 
epitope therapy, which uses non IgE-reactive peptides derived from the IgE-binding sites of 
allergens -with a diminished potential to release Th2 cytokines and inflammatory mediators, but 
able to induce allergen-specific blocking IgG antibodies when fused to the appropriate carrier 
protein- can make IT safer and more efficient (Valenta et al., 2016). Regarding food allergies, as 
it will be explained in the next section, mouse experiments have shown that peptides that do not 
induce Th2 cytokines and/or are able to increase allergen-specific IgG can play a valuable 
therapeutic role by providing and extra-help to deviate predominantly Th2 to Th1 responses, by 
inducing T reg cells that downregulate both Th2 and Th1 responses, or by blocking allergen 
binding to IgE (Prioult et al., 2005; Yang and Mine, 2009; Wai et al., 2014 and 2016). 
Generally, many distinct fragments of food allergens are able to generate T and B cell 
responses (Prickett et al., 2011; Berin, 2015; Wai et al., 2016), although the final effect might 
depend on the occurrence of the right combination of peptides with synergistic or adjuvant 
actions, or on the peptides being in an aggregated state resembling the intact molecule (Yang et 
al., 2010; Bøgh et al., 2012; Meulenbroek et al., 2013). On this basis, enzymatically hydrolysed 
allergens are a practical alternative to synthetic dominant T cell epitopes specific for each HLA 
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type -as the former would contain enough peptides to address MHC-II diversity in patients- that 
could also provide non IgE-cross-linking B epitopes (Knipping et al., 2012; Kulis et al., 2012). 
Hydrolysis of food proteins emerges as an attractive and safe means for a reproducible and 
standardized production of immune-stimulating peptides at low cost, as compared with that 
associated with generating synthetic peptides on a large scale. 
Immunodominant T cell epitopes with negligible IgE-binding and lacking inflammation 
stimulating capacity have been used to modify beneficially the immune reaction to allergens in 
clinical trials of IT by subcutaneous injection, demonstrating persistent efficacy with few 
adverse events for cat, house dust mite and pollen allergy, even though the precise mechanism 
of action is not yet clear (O’Hehir et al., 2016). T cell epitopes induce anergy or deletion of 
specific T cells, resulting in down-regulation of T cell proliferative and cytokine responses to 
the allergens, as in whole allergen IT (see Fig. 1.4, which summarises the main immunological 
events in the oral desensitization to food allergens), although the peptides may be too small to 
induce IgG-blocking antibodies (Prickett et al., 2015). Furthermore, also similarly to 
conventional IT (Fig. 1.4), an important role of T reg cells, with an increased production of IL-
10 -that further induces the expansion of T reg cells and the inhibition of Th1, Th2 and 
inflammatory cells- has been reported (O’Hehir et al., 2016). Interestingly, cross-reactive T cell 
epitopes have been identified and, in some cases, tolerance to one T cell epitope is found to 
protect against other epitopes of the same molecule, providing evidence for the induction of 
linked epitope suppression (Moldaver and Larché, 2011). For its part, B cell epitope IT was 
proved to target different immune mechanisms aiding at pollen desensitization (Valenta et al., 
2016). B cell epitopes prevent activation of mast cells and basophils, boost of memory IgE 
production and IgE-facilitated presentation to T cells, through the induction of IgG4 (Akdis and 
Akdis, 2014; Jongejan and van Ree, 2014). In the case of food allergies, IT with peptides has 
almost exclusively been assayed in vivo in murine models.  
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Figure 1.4. Mechanisms of desensitization to food allergens. Initially during desensitization, a shift 
occurs from the predominance of Th2 cells to that of allergen-specific T reg cells, which in turn may lead 
to the observed shift in allergen-specific antibodies from the IgE to the IgG4 isotype. T reg cells inhibit 
DCs, which is probably mediated by CTLA4 and LAG, and mast cells, via contact involving OX40–
OX40L interaction. CTLA4, cytotoxic T lymphocyte antigen; DC, dendritic cell; FcγRIIb, inhibitory low-
affinity IgG receptor type IIb; Ig, immunoglobulin; IL, interleukin; LAG3, lymphocyte activation gene 3; 
MHC, major histocompatibility complex; OX40, (CD134) member 4 of the tumour necrosis factor 
receptor superfamily; OX40L, (CD252) ligand for CD134; Tfh, T-follicular helper cell; Th, T-helper cell; 
T reg, regulatory T cell (reprinted with permission from Nature Publishing Group. Yu et al., 2016). 
1.6. In vivo immunotherapeutic assays with food peptides  
The results of a double-blind placebo-controlled randomized IT study with a 
hypoallergenic hydrolysate of whole egg white in egg allergic children have been recently 
published by Giavi et al. (2016). A significant increase in egg-specific IgG4 and a decreased 
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reactivity of basophils, usually associated with desensitization, was detected in the group of 
patients treated with the hydrolysate. The treatment, with few side effects, could be safely taken 
at home. However, the lack of statistically significant differences upon the final oral food 
challenge between the treatment and placebo groups suggests that further studies with a larger 
number of patients are needed to validate this therapeutic strategy and reveal the underlying 
mechanisms. To the best of our knowledge, this is the only published human trial with 
hydrolysates or peptides as IT for food allergy. For the meantime, promising findings have been 
obtained from studies using animal models of food allergy. 
Mainly due to ethical reasons, animal models have become valuable tools to increase 
our understanding of the complex immunological and pathophysiological mechanisms involved 
in the development of food allergy (Finkelman, 2007; Van Gramberg et al., 2013). Such models 
allow the identification of factors responsible for the breakdown of oral tolerance and the 
implementation of experimental studies to establish prevention strategies and curative 
approaches, as well as to investigate novel therapies (Oyoshi et al., 2014). Rodents are 
frequently used in the field of the food allergy because of their small size, short breeding cycle, 
well characterized immunology and ability to product protein-specific IgE; in particular, murine 
strains, with or without genetic modifications, such as BALB/c, C3H/HeJ, DBA/2, A/J, BDF-1 
and C57B1/6 and Brown Norway rats (Fritsché, 2009; Ladics et al., 2010).  
As already mentioned, a pre-requisite of food peptides for being good candidates for IT 
is the lack of IgE reactivity and, consequently, of anaphylactic potential. In vivo assessments of 
the allergenicity of food protein hydrolysates, mainly hydrolyzed milk proteins, have been 
conducted by passive cutaneous anaphylaxis (PCA) tests, which measure the extravasation of a 
dye into the tissues after intravenous challenge of sensitized rodents or naïve rodents that 
previously received an intradermal injection of sera from sensitized ones (López-Expósito et al., 
2012; Bøgh et al., 2015). Acute allergic skin responses -ear swelling- and local release of mouse 
mast cell protease-1 (mMCP-1)- can also be measured in sensitized mice following intradermal 
injection of allergen hydrolysates (van Esch et al., 2010). Furthermore, graded oral 
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administration of hydrolyzed and intact proteins to mice sensitized to the intact allergen allows 
comparing the doses that induce allergic symptoms and reduce body temperature (Kulis et al., 
2012). 
Table 1.2 summarises the main outcomes of the studies evaluating food protein derived 
hydrolysates and synthetic peptides for the treatment of food allergy in mice sensitized to the 
intact food allergens. In general terms, 2-4 weekly doses were administered, either orally or 
intraperitoneally, for 1 to 4 weeks. Many of the listed IT treatments were found to decrease 
adverse reactions upon subsequent challenge with the allergen, as measured by symptom scores 
and/or body temperature drops, in parallel with reductions in serum histamine release (Yang et 
al., 2010; Rupa and Mine, 2012) or mMCP-1 (Wai et al., 2016), that denote reduced activation 
and degranulation of mast cells. However, none of these studies re-assessed protection from 
anaphylaxis after a sufficiently extended period of discontinuation of the treatment and, 
therefore, sustained unresponsiveness (Pesek and Jones, 2016) cannot be guaranteed. 
As shown in Table 1.2, desensitization with immunomodulatory hydrolysates and 
epitope peptides usually correlates with a significant reduction in allergen-specific IgE levels. 
However, the role of other allergen-specific antibodies, such as IgG and IgA, in mouse models, 
is under debate. Kulis et al. (2012) associated successful IT in the absence of changes in the IgE 
levels with significant increases in allergen-specific IgG1 and IgG2a, which would act as 
protective blocking antibodies. However, in other studies, no significant variations in allergen-
specific total IgG levels were detected in the effectively treated mouse groups (Yang et al., 
2009b and 2010), although, on further examination, alleviation of allergy signs was found to 
correlate with reduced IgG1 and increased IgG2a (Rupa and Mine, 2012). Wai et al. (2016) 
referred reductions in specific IgE, no change in specific IgG1, and high levels of specific 
IgG2a whose blocking effect was verified in vitro and in vivo. In humans, many studies 
demonstrate that increases in specific IgG4 levels accompany clinical improvements (Akdis and 
Akdis, 2014).  
  
 
Table 1.2. Summary of successful immunotherapy trials in mouse models of food allergy with peptides and hydrolysates from allergenic proteins 
Peptide/hydrolysate Experimental design Main outcomes Reference 
Egg white (EW) hydrolysed with a 
food grade aminopeptidase from 
Aspergillus sp. (EWH)  
Animal model: BALB/c mice  
Sensitization: EW (5 mg) + CT (10 μg) i.g. (2 weekly doses for 
4 weeks) 
IT:  EWH (5mg) i.g. (3 weekly doses for 3 weeks) 
Challenge: EW (20 mg) i.g. 
Histamine release 
EW-specific IgE  
IL-4 and  IFN-γ released by EW stimulated splenocytes 
IL-4, IL-13, IFN-γ, IL-12p40, IL-8, IL-5,Foxp3 and TGF-β 
intestinal (ileum) gene expression 
Yang et al., 
2009b 
Mixture of ovalbumin (OVA) 
immunodominant T cell epitopes 
(15-mer): 
 
AMVYLGAKDSTRTQ  
SWVESQTNGIIRNVL  
AAHAEINEAGREVVG  
Animal model: BALB/c mice  
Sensitization: OVA (1 mg) + CT (10 μg)  i.g. (2 weekly doses 
for 4 weeks) 
IT: peptide mix (100 µg each) s.c. (3 weekly doses for 3 weeks) 
Challenge: OVA (20 mg) i.g. 
Symptom score 
Histamine release 
OVA-specific IgE 
OVA-specific faecal IgA 
IL-4 and IFN-γ released by OVA stimulated splenocytes  
IL-5, IL-13, IFN-γ, Foxp3 and TGF-β intestinal (ileum) gene 
expression 
Yang et al., 
2010 
Ovomucoid (OM) 
immunodominant T cell epitope 
(15-mer): 
 
DNKTYGNKSNFSNAV  
Animal model: BALB/c mice  
Sensitization: OM (1 mg) + CT (10 μg) i.g. (2 weekly doses for 
4 weeks) 
IT: peptide (1 mg) i.g. (3 weekly doses for 4 weeks) 
Challenge: OM (20 mg) i.g. 
Symptom score 
Histamine release 
OM-specific IgE, IgG1,IgG2a, faecal IgA  
IL-4, IL-12, IL-10 released by OM stimulated splenocytes  
circulating T reg cells (CD4+CD25+, CD4+Foxp3+ cells) 
Rupa and 
Mine, 2012 
Native cashew protein (nCSH) 
hydrolysed with pepsin (pCSH) 
Animal model: C3H/HeJ mice 
Sensitization: nCSH (2 mg) + CT (10 μg) i.g. (4 weekly doses 
for 4 weeks) 
IT: pCSH  (from 50 to 200 µg) i.p. (3 weekly doses for 4 
weeks)  
Challenge: nCSH (0.25 mg) i.p. or pCSH (1 mg) i.p 
Symptom score and body temperature drop 
No change in nCSH specific IgE 
nCSH-specific IgG1  
nCSH-specific IgG2a  
IL-5 and IL-13 released by nCSH stimulated splenocytes 
Kulis et al., 
2012 
β-lactoglobulin (BLG)  
immunodominant T cell epitope 
 
AQKKIIAEKTKIPAVFKIDALN  
 
Animal model: BALB/c mice 
Sensitization: BLG (50 μg) + alum i.p. (1 weekly dose for 3 
weeks) 
IT: peptide (1 mg) i.p. (3 weekly doses for 4 weeks)  
Challenge: BLG (50 mg)  i.g. 
Symptom score and body temperature drop 
No change in BLG-specific IgE, IgG1, IgG2 or faecal IgA 
IFN-γ, IL-12, IL-10 released by BLG stimulated splenocytes  
Thang and 
Zhao, 2015 
  
 
Mixture of 6 shrimp tropomyosin 
(Met e 1) immunodominant T cell 
epitopes 
Animal model: BALB/c mice 
Sensitization: recombinant Met e 1 (0.1 mg) + CT (10 μg) i.g. 
(1 weekly dose for 5 weeks) 
IT: peptide mix (1.2 mg each) i.g. (2 weekly doses for 4 weeks)  
Challenge: recombinant Met e 1 (0.5 mg) i.g. 
Symptom score, diarrhoea and intestinal inflammation 
mMCP-1 
Met e 1-specific IgE 
Met e 1-specific IgG2a  
IL-4, IL-5, IFN-γ, IL-12 released by Met e1 stimulated splenocytes 
IL-10, Foxp3, CD25, RUNX1, RUNX3, IL-5, IL-13, FN-γ 
intestinal (ileum) gene expression 
Wai et al., 
2016 
Experimental design: i.g.= intragastric; i.p..= intraperitoneal; s.c.= subcutaneous; CT= cholera toxin. Main outcomes: mMCP-1= mouse mast cell protease 1; RUNX1= 
Runt-related transcription factor 1; RUNX3= Runt-related transcription factor 3;= increased or high levels; = decreased or low levels 
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However, homology between mouse and human IgG subclasses is difficult to stablish, and there 
are differences in class switching: in mice, IL-4 induces IgG1 and IgE, whereas in humans, IL-4 
induces switching to IgG4 and IgE (Mestas and Hughes, 2004; Finkelman, et al., 2016). 
Circulating IgG antibodies can neutralize allergens before they cross-link mast cell-
bound IgE, although this ability to physically inhibit the binding of allergens to IgE is saturable 
and depends on the challenge dose (Finkelman, 2005). Furthermore, it has been described that 
anaphylaxis in the mouse can occur through two independent pathways, comprising either the 
classical mechanism associated with human allergy -that is the cross-linking of IgE bound to 
FcεRI on mast cells- or a second, alternative, pathway that requires IgG antibodies, FcγRIII 
receptors and macrophages (see Fig. 1.5, which outlines the mechanisms of anaphylaxis 
mediated by basophils, mast cells and macrophages in mice). Both share similar time courses 
and symptoms, but much higher antibody and antigen concentrations are required to induce 
anaphylaxis by the alternative IgG-mediated pathway, in line with the much higher affinity of 
FcεRI for IgE than FcγRIII for IgG and with the need for antigen-IgG complexes to form in 
blood before they bind FcγRIII on macrophages (Finkelman, 2007). IgE-mediated anaphylaxis 
predominates in the presence of low levels of IgG and allergen, even if the IgE levels are also 
low. 
In some mouse models of allergy, sensitization stimulates high levels of specific IgG 
and mice are challenged with large quantities of allergen, which could inhibit IgE-mediated 
anaphylaxis, but also induce IgG-mediated anaphylaxis (Strait et al., 2006). This implies that the 
protective effect of blocking IgG antibodies could be restricted to a situation when the quantity 
of challenge allergen is less than that required to trigger IgG-mediated anaphylaxis; but when 
the dose increases, IgG or both IgG and IgE pathways could be triggered (Fig. 1.5) (Strait et al., 
2006). Thus, the outcomes of different IT experiments with respect to changes in relative 
antibody levels may not be comparable, due to the use of different immunization protocols that 
produce different ratios of IgE to IgG and different amounts of allergen for challenge, 
particularly if antibody analyses are performed short after challenge. Furthermore, the IgE/IgG 
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response may also vary depending on the administration route (oral, subcutaneous or 
intraperitoneal) of the sensitizing allergens and IT preparations (Finkelman et al., 2005; Kulis et 
al., 2012). 
 
Figure 1.5. The role of antigen (Ag)-specific IgE and IgG antibodies (Ab) in anaphylaxis. When Ab 
levels are low (a), only IgE-mediated anaphylaxis can occur. When Ag and Ab levels are both high but 
Ab levels are in excess to Ag levels (b), IgGs block the binding of Ag to FcεRI-bound IgE, but IgG/Ag 
complexes can bind to FcγRs; consequently, only IgG-mediated anaphylaxis occurs. When Ag levels are 
low but Ab levels are high (c), IgG “blocking” Abs prevent IgE-mediated anaphylaxis by intercepting Ag 
before it can bind to FcεRI-associated IgE and by binding to the inhibitory receptor FcγRIIB, but the 
quantity of IgG/Ag complexes is too low to trigger IgG-mediated anaphylaxis; consequently, anaphylaxis 
does not occur. When Ag and Ab levels are both high but Ag levels are in excess (d), IgG/Ag complexes 
are sufficient to trigger IgG-mediated anaphylaxis, and enough Ag escapes IgG blockade to bind to 
FcεRI-associated IgE and trigger IgE-mediated anaphylaxis. FcγRIII, stimulatory low-affinity IgG 
receptor type III; FcγRIIb, inhibitory low-affinity IgG receptor type IIb; FcεRI, high-affinity IgE receptor 
type I; Ig, immunoglobulin; IL, interleukin; PAF, platelet-activating factor; I, basophil; II, mast cell; III, 
macrophage (reprinted with permission from Elsevier. Finkelman et al., 2016). 
I II III
Conditions:
High Ag and Ab; Ab > Ag
Result: IgG-dependent anaphylaxis
b)
I II III
Conditions:
High Ag and Ab; Ag > Ab
Result: IgE- and IgG-dependent anaphylaxis
d)
I II III
Conditions:
Low Ag; High Ab
Result: No anaphylaxis
c)
I II III
Conditions:
Low or high Ag; Low Ab
Result: IgE-dependent anaphylaxis
a)
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Secretory IgA has an important role in immune homeostasis in the gut, with low levels 
of intestinal allergen-specific IgA being associated with the development of food allergy, 
although its role is still unclear (Kukkonen et al., 2010). Following some effective IT studies 
with food peptides, increased levels of fecal allergen-specific IgA have been reported (Yang et 
al., 2010; Rupa and Mine, 2012).  However, the hypothesis that IgA secreted at mucosal 
surfaces can bind allergens before they are absorbed, in a way similar to its neutralizing effect 
towards pathogens and toxins, could not be substantiated. Instead, the property of IgA to block 
systemic anaphylaxis by binding to allergens appears to be restricted to serum IgA and not to 
IgA contained in the gut lumen (Strait et al., 2011). 
With respect to cellular responses, a consistent reduction in the production of Th2 
cytokines (whether IL-4, IL-5 or IL-13) was observed when splenocytes from treated animals 
were stimulated with the whole allergens (Table 1.2). However, the reports refer either an 
associated increase in Th1 cytokines (IFN-γ or IL-12) and restoration of the immunological 
balance (Yang et al., 2010; Rupa and Mine, 2012; Wai et al., 2016), or a concomitant  Th1 
decrease (Yang et al., 2009b). Ileum expression levels of Th2 and Th1 cytokine genes parallel 
systemic changes in the Th2 and Th1 cytokine profiles (Yang et al., 2009b; Yang et al., 2010; 
Wai et al., 2016). Upregulation of TGF-β and IL-10 or of the transcription factor Foxp3 in 
intestinal tissues points at a role of T reg cells in tolerance induction by food peptides (Yang et 
al., 2009b and 2010; Wei et al., 2016). Increased percentages of T reg cells (CD4+ Foxp3+ and 
CD4+ CD25+ cells) were also detected in the blood of the desensitized animals (Rupa and 
Mine, 2012). 
While the administration of multiple T cell epitopes appears more effective than that of 
the corresponding individual peptides (Yang et al., 2010), it is noteworthy that a single 
immunodominant T cell peptide can offer protection against challenge with the whole allergen, 
which reinforces the concept of linked epitope suppression (Table 1.2). In this respect, it is 
speculated that the only effective way to provide tolerance towards multiple epitopes within a 
protein -or even towards other allergens during co-exposure- by the use of a single peptide is 
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through the induction of a regulatory function versus a delectional function, which may depend 
on the choice of route, dose and timing of administration of IT (Mackenzie et al., 2012). 
Decreased allergic symptoms following IT were induced by strong Th2-stimulating 
hydrolysates, which maintain the immunogenicity of the intact allergen and its sensitizing 
potential, but lack eliciting potential (Kulis et al., 2012). In any case, immunomodulating 
peptides, selected on the basis of their strong proliferative activity, IFN-γ stimulating properties 
and absence of IL-4 inducing capacity, stand as an interesting option (Yang et al., 2010; Wei et 
al., 2016). Nonetheless, the observation that different peptides that reduce allergen-induced 
clinical signs produce different immunological changes highlights the need for a deeper 
knowledge on the structure-function relationships to go deeper into their mechanism of action 
(Yang et al., 2010; Rupa and Mine, 2012).  
1.7. In vivo allergy prevention assays with food peptides 
A recognized advantage of IT lays in its potential to restrain the progression of mild to 
severe forms of allergy. This suggests its use in sensitized individuals to avoid the development 
of allergic symptoms or, even as a prior strategy, to prevent sensitization (Valenta et al., 2016). 
In fact, it has been shown that, rather than their avoidance, the early introduction of eggs or 
peanuts in the diet significantly decreases the frequency of egg or peanut allergy among 
genetically predisposed children, which, in both cases, correlates with increased levels of 
peanut-specific IgG4 (Palmer et al., 2013; Du Toit et al., 2015). Furthermore, prophylactic 
house dust mite therapy in children at high heredity risk was demonstrated to reduce 
sensitization to common allergens (Zolkipli et al., 2015). However, as already indicated for 
curative treatments of food allergy, the use of intact allergens for preventive treatments poses a 
risk of anaphylactic reactions and it does not fully exclude the possibility of a progress in the 
development of sensitization. Once more, peptides or hydrolysates appear as an attractive 
alternative, but it is necessary to assure that they lack sensitizing potential. 
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The sensitizing capacity of food hydrolysates can be evaluated in Brown Norway rats 
immunized by the intraperitoneal route without adjuvant, by analyses of specific antibody 
responses. Induction of specific IgE, IgG1 and IgG2a is taken as a measure of sensitization, 
together with the demonstration of the biological activity of the generated IgE in basophil 
activation assays (Bøgh et al. 2009 and 2013; Kroghsbo et al., 2014). Release of rat mast cell 
protease II (RMCPII) indicates IgE-mediated mucosal mast cell degranulation (Fritsché et al., 
1997). The use of aluminum hydroxide as adjuvant enhances immunogenicity and narrows 
heterogeneity between experimental data, but may bias the results by changing antigen 
presentation to the immune system (Bøgh et al., 2015). On the other hand, the oral route, more 
physiologically relevant, gives comparable outcomes, but with different dose-response ratios, 
with respect to the intraperitoneal route (Kroghsbo et al., 2014). 
Mice have also been used as models of food allergy for the evaluation of the sensitizing 
capacity of hydrolyzed proteins. Sensitization of mice to food proteins requires the use of Th2-
polarizing adjuvants -such as staphylococcal enterotoxin B and, more commonly, cholera toxin 
(CT)- to overcome their strong tendency to develop oral tolerance, although this practice may 
conceal the intrinsic sensitizing properties of the co-administered proteins (Berin and Shreffler, 
2008). In C3H/HeOuJ mice, comparison between the levels of allergen-specific IgE, IgG1 and 
IgG2a, induced by hydrolysed and intact allergens administered orally with CT is used for the 
assessment of lack of sensitizing potential of the formers, which can be confirmed by 
subsequent challenge with the whole allergen and measurement of anaphylactic symptoms, 
body temperature and mMCP-1 (van Esch et al. 2011a). An inter-laboratory evaluation of this 
model in four different research centers evidenced its transferability and adequacy to the 
prediction of the residual sensitization capacity of hydrolysed milk-based infant formulas (van 
Esch et al., 2013), which, according to European guidelines on hypoallergenic and follow-on 
infant formulas, should not be able to sensitize animals to the protein source they derive from 
(Commission Directive 96/4/EC).  
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Most interventions aimed at inducing protective responses against food allergy have 
been conducted with infant hypoallergenic formulas derived from enzymatic hydrolysis of 
cow’s milk proteins. These have concluded that certain hydrolyzed infant formulas, in particular 
partially hydrolyzed whey formulas, have a role in the reduction of risk of atopic disease 
(Szajewska and Horvath, 2010; Vandenplas et al., 2014). Further evidence for the efficacy and 
mechanisms of action of protein hydrolysates in allergy prevention were obtained from mice 
trials, as shown in Table 1.3. 
Administration of intact and hydrolyzed milk proteins avoid subsequent sensitization, as 
measured by inhibition of the generation of allergen-specific IgE, release of mast cell mediators 
and allergic symptoms (Table 1.3). However, in certain studies, only the intact proteins were 
able to significantly reduce serum levels of specific IgE and/or IgG1, indicating a more effective 
prevention of sensitization (Adel-Patient et al., 2011 and 2012; van Esch et al., 2011b). In any 
case, protection against the development of an allergic response can also be induced by specific 
peptides present in partially hydrolyzed preparations but absent from extensively hydrolysed 
formulas (Fritsché et al., 1997; van Esch et al., 2011b), although more prolonged treatments 
may be necessary to achieve effects similar than those of the intact allergens (Peng et al., 2004). 
In addition, the effect is dose-dependent, with peptide enrichment decreasing the efficient oral 
dose, although correlation between peptide structure and tolerogenic properties has not been 
described (Pecquet et al., 2000; Hacini-Rachinel et al., 2014). 
Simultaneous immunization of rats with intact β-lactoglobulin plus hydrolysed β-
lactoglobulin reduces the sensitizing capacity of the former, which was attributed to a 
tolerogenic affect exerted by the digestion products (Bøgh et al. 2013). A single peptide from β-
lactoglobulin (β-lactoglobulin 31-48) was reported to reduce sensitization and allergic response 
to the whole intact protein in CeH/HeOuJ mice, thus inducing linked epitope suppression, with 
stronger effects on its own than when present in a peptide mixture (Meulenbroek et al., 2013). 
However, the peptide β-lactoglobulin 25-107, which represents 50% of the protein sequence and 
comprises the former, was not found to decrease further sensitization in BALB/c, despite it  
  
 
Table 1.3. Summary of successful preventive treatment trials in mouse models of food allergy with peptides and hydrolysates from allergenic proteins 
Peptide/ hydrolysate Experimental design Main outcomes Reference 
Standard formula of intact cow’s 
milk proteins 
Whey proteins (WP) partially 
hydrolysed with trypsin  
Animal model: Sprague-Dawley rats 
Preventive treatment: Oral administration in the drinking water 
during 19 days (ad libitum) 
Sensitization: β-lactoglobulin (BLG) (100 µg) + AH i.p. (1 
dose)   
Challenge: WP (1 g) i.g. 
RMCPII 
BLG-specific IgE  
BLG-specific IgG 
Lymphocyte proliferation by BLG-stimulated PLN cells 
 
Fritsché et 
al., 1997 
β-lactoglobulin (BLG)  
BLG hydrolysed with trypsin 
(TTH-BLG) 
Peptide fractions separated from 
TTH-BLG by ion exchange 
chromatography 
 
Animal model: BALB/c mice 
Preventive treatment: BLG (5 mg/g body weight), TTH-BLG 
(2.5 mg/g) or peptide fractions (0.125 mg/g) i.g. 
Sensitization: BLG (80 µg) + AH (1 dose) 
Challenge: BLG (100 µg) i.d. in the footpad 
Footpad thickness  
BLG-specific IgE  
Lymphocyte proliferation by BLG-stimulated splenocytes 
Pecquet et 
al., 2000 
Standard formula of intact cow’s 
milk proteins (CM, Nan) 
CM partially hydrolysed (Nan-HA) 
Animal model: C3H/HeN mice 
Preventive treatment: Oral administration at 2% (1 to 4 weeks)  
Sensitization: β-lactoglobulin (BLG), α-lactalbumin (ALA) or 
BSA (10 µg) + alum i.p. (1 dose)  
BLG, ALA and BSA-specific IgE (1 week for Nan, 4 weeks for Nan-
HA) 
BLG, ALA and BSA -specific IgG (1 week for Nan, 4 weeks for 
Nan-HA) 
BLG ALA and BSA, specific IgG1 (1 week for Nan, 4 weeks for 
Nan-HA) 
Peng et al., 
2004 
Whey proteins (WP) 
Partially hydrolysed WP (pWH) 
 
Animal model: C3H/HeOuJ mice 
Preventive treatment: WP and pWH (50 mg) i.g. (1 daily dose 
for 6 days)  
Sensitization: WP (20 mg) + CT (10 μg)  i.g. (1 weekly dose 
for 6 weeks)  
Challenge: WP (10 µg) i.d. 
Acute skin response  
mMCP-1 
WP-specific IgE and IgG1 (WP) 
MLN T reg cells (pWH), MLN Th1 (WP), MLN Th2 (pWH and 
WP) 
van Esch et 
al., 2011b 
β-lactoglobulin (BLG)  
BLG  hydrolysed with trypsin 
(BLG-Try) 
 
Animal model: BALB/c mice 
Preventive treatment: BLG (0.05-4 mg) and BLG-Try (2 mg) 
i.g. (6 doses in 10 days)  
Sensitization: BLG (5 µg) + alum i.p. (2 doses in 14-18 days) 
Challenge: BLG (10 mg)  i.g. 
mMCP-1 (BLG) 
BLG-specific IgE  
BLG-specific IgG1: (BLG) 
IL-4, IL-5 IL-10 IL-12 IL-17 IL-5 released by BLG 
stimulated splenocytes (BLG) 
MLN T reg cells ( CD4+CD25+Foxp3+ cells) 
PP and spleen T reg cells ( CD4+CD25+Foxp3+ cells) (BLG) 
Adel-Patient 
et al., 2011 
  
 
Native β-lactoglobulin (nBLG)  
Denatured BLG (dBLG) 
nBLG hydrolysed with CNBr 
(nBLG-CBr) 
dBLG  hydrolysed with CNBr 
(dBLG-CBr) 
 
Animal model: BALB/c mice 
Preventive treatment: nBLG, dBLG, nBLG-CNBr and dBLG-
CNBr (2.4 mg) i.g.  (6 doses in 10 days) 
Sensitization: nBLG (5 µg) + alum i.p. (1 dose) 
 
BLG-specific IgE  
BLG-specific IgG1 
IL-4, IL-5, IL-13, IL-10 released by BLG stimulated splenocytes  
 
Adel-Patient 
et al., 2012 
β-lactoglobulin (BLG)  
immunodominant T cell epitopes: 
 
BLG 31-48 
Mix 1: 13-30, 19-36, 25-42, 31-48 
Mix 3: 139-156, 145-162 
Animal model: CeH/HeOuJ mice 
Preventive treatment: peptide mix or single peptide (4 mg 
each) i.g. (1 daily dose during 6 days)  
Sensitization: WP (20 mg) + CT (10 μg) i.g. (1 weekly dose for 
5 weeks) 
Challenge: WP (10 µg) i.d. and  WP (100 mg) i.g. 
 Acute skin response  
 WP-specific IgE  
 WP-specific IgG2a 
 MLN T reg cells ( CD4+CD25+Foxp3+ cells) (BLG 31-48) 
 MLN DCs (CD11b+CD103+) (BLG 31-48) 
Meulenbroek 
et al., 2013 
Whole hen’s egg  (WE) 
WE hydrolysed with Protamex and 
Flavourzyme 1000L (HE) 
Animal model: C57BL/6J mice 
Preventive treatment: Oral administration of OVA, WE, and 
HE (5 times more concentrated) in the drinking water during 5 
days (ad libitum) 
Sensitization: Ovalbumin (OVA) (100 µg) + alum (2 doses in 
13 days) s.c. 
Challenge: OVA (20 µg ) i.d. 
Acute skin response 
OVA-specific IgE  
OVA-specific IgG1 
Proliferation of OVA stimulated splenocytes  
IL-5,  IL-4, IFN-γ, IL-10,  IL-12 released by OVA stimulated 
splenocytes   
MLN T reg cells ( CD4+CD25+Foxp3+ICOS+cells)  
Hacini-
Rachinel et 
al., 2014 
Partially hydrolysed whey proteins 
(pWP) 
Animal model: C3H/HeOuJ 
Preventive treatment: pWP (50 mg) i.g. (1 daily dose for 5 
days)  
Sensitization: WP (20 mg) +  CT (10 μg) i.g.  (1 weekly dose 
for 6 weeks) 
Challenge: WP (10 µg) i.d. and WP (50 mg) i.g. 
Acute skin response and symptoms score 
WP-specific IgE 
  
 
Van 
den Elsen et 
al. 2015 
Peptide/hydrolysate: CNBr=cyanogen bromide. Experimental design: i.g.= intragastric; i.d.= intradermal;  i.p.= intraperitoneal; s.c.= subcutaneous; CT= cholera toxin, 
AH= aluminium hydroxide. Main outcomes: mMCP-1= mouse mast cell protease 1; RMCPII= rat mast cell protease II; MLN= mesenteric lymph nodes; PLN= peripheral 
lymph nodes; PPs = Peyer’s patches; DCs= dendritic cells; = increased or high levels; = decreased or low levels 
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exerts immunostimulating properties in splenocytes from β-lactoglobulin sensitized mice (Adel-
Patient et al., 2012).  
Preventive approaches using hydrolysates or peptides lead to reduced numbers of 
activated Th2 cells in the MLNs, following sensitization and allergen challenge of mice (van 
Esch et al., 2011b), as well as to decreased systemic Th2 responses, as shown by a diminished 
release of IL-4, IL-5 and IL-13- upon stimulation of spleen cells with the allergens used for 
sensitization (Adel-Patient et al., 2012; Hacini-Rachinel et al., 2014). Changes in the Th1 
response are, however, less consistent among the studies (Table 1.3). Combination of peptide 
treatment with a prebiotic diet that skews the immune response to a Th1 response may increase 
its tolerance-driving capacity (Meulenbroek et al., 2013). Conversely, co-administration of 
omega-6 polyunsaturated fatty acid-rich soya oil, which increases the Th2/Th1 ratio, abrogates 
peptide-induced tolerance (van den Elsen et al., 2015). 
In addition, some studies showed a key role of T reg cells induced at the MLN level in 
the prevention of sensitization and development of food allergy (Adel-Patient et al., 2011; van 
Esch et al., 2011b; Meulenbroek et al., 2013; Hacini-Rachinel et al., 2014). MLNs connect the 
local and systemic immune system, making it possible to translate gut-induced regulatory 
responses to systemic tolerance. Indeed, adoptive transfer of MLN cells from tolerized donor 
mice inhibits sensitization and reduces consequent anaphylactic effects in recipient mice (van 
Esch et al., 2011b). The generation of a regulatory response by peptides is supported by a 
correlation between T reg cells and augmented tolerogenic CD103+ DCs (Meulenbroek et al., 
2013). 
Progress in the understanding of the stimulating and anti-inflammatory properties of 
food peptides on cells of the innate and adaptive immune system has made apparent that they 
represent an attractive means to enhance safety and efficacy of IT against food allergy. 
Moreover, the conclusions drawn from in vivo curative and preventive trials are promising, 
although there is a need for more studies to further explore the immunomodulating strategy and 
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its mechanisms to maximise effective clinical translation. In particular, knowledge of the 
peptide sequence and structural requirements which determine the immunomodulatory action 
depending on the cell type, currently still poorly understood, will open new possibilities to 
impact the outcome of IT by differentially influencing the mechanisms by which oral tolerance 
to allergens is stablished. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 2. OBJECTIVE AND  
WORK PLAN 
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Egg allergy is among the most common food allergies in European children below the 
age of three, with a prevalence ranging between 0.2 and 2%, as judged by objective appraisals 
(Nwaru et al., 2014). Despite many children spontaneously outgrow this condition, up to 15-
20% remains allergic and, within the population with persistent egg allergy, the severity of the 
adverse reactions to egg usually increases over the years (Sicherer et al., 2014). The 
management of egg allergy is limited to strict avoidance of the offending food and emergency 
treatment of adverse reactions in case of accidental exposure. However, total avoidance is 
exceedingly difficult from a practical standpoint since egg and egg-derived products are 
ubiquitous ingredients (Martorell et al., 2013; Wood, 2016). 
OIT using whole egg white (EW) is one of the most promising treatment options for egg 
allergy (Vickery, 2012). This type of OIT has shown to be efficient in the induction of 
desensitization, with a rate of success between 50-90% (Iacono et al., 2013; Meglio et al., 2013; 
Perezábad et al., 2015). However, a major drawback of OIT using intact egg allergens is the 
high risk of severe side effects, which has prompted the investigation of strategies aimed at 
reducing the allergenicity of egg-derived preparations used as treatment (heat treatment, 
fermentation, genetic modification, sugar conjugation and enzymatic hydrolysis). These 
preparations have to maintain or improve their immunomodulating potential to achieve effective 
desensitization or sustained oral tolerance (O’Hehir et al., 2016; Pesek and Jones, 2016; 
Vázquez-Ortiz and Turner, 2016).  
Among the most promising strategies currently assayed against IgE-mediated allergic 
diseases stands the possibility of using immunomodulating peptides to stimulate oral tolerance 
towards offending food allergens or even to prevent allergic sensitization (Yang et al., 2010; 
Casale and Stokes, 2011; Moldaver and Larché, 2011). In this framework, enzymatically 
digested allergens could be a more practical therapeutic option than synthetic dominant T cell 
epitopes, as the former would provide multiple allergen-derived peptides with adequate T cell-
stimulating capacities for HLA-diverse patients (Yang et al., 2009b; Kulis et al., 2012). Thus, 
hydrolysis of the major egg white allergens, ovomucoid (OM -Gal d 1-), ovalbumin (OVA -Gal 
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d 2-) and lysozyme (LYS -Gal d 4-), appears as an attractive and safe alternative for a 
reproducible and standardized production of immune-active peptides with low costs that would 
allow their consumption in the form of functional foods. 
Given the importance of immunologically active peptides in food allergy, the aim of 
this thesis was the development of enzymatic hydrolysates of egg white proteins with 
hypoallergenic and immunomodulating properties that could be used in the prevention and 
treatment of egg allergy. For this purpose, we addressed the preparation and characterization of 
various hydrolysates and their evaluation using in vitro and ex vivo model systems of increasing 
complexity for assessing their potential in the regulation of immune and inflammatory processes 
typical of allergic diseases. Finally, we confirmed the efficacy of selected hydrolysates in an in 
vivo model of egg allergy. 
The first step was the preparation and characterization of a collection of enzymatic 
hydrolysates from OVA, LYS, OM and EW with pepsin, Neutrase and alcalase. The potential 
effects of these hydrolysates on oxidative stress, cell proliferation and modulation of immune 
responses were then evaluated on cultures of murine spleen and MLN cells unspecifically 
stimulated with T or B cell mitogens (Fig. 2.1).  
 
Figure 2.1. Work plan I for the preparation and characterization of hydrolysates of egg white proteins and 
the study of their ability to modulate immune responses in unspecifically stimulated murine cells. Con A, 
concanavalin A; EW, whole egg white; LPS, lipopolysaccharide; LYS, lysozyme; MLN, mesenteric 
lymph nodes; OM, ovomucoid; OVA, ovalbumin; RP-HPLC, reverse phase high-performance liquid 
chromatography. 
Once evidenced that the hydrolysates could drive immune responses in a certain 
direction, we next assessed their ability to deviate the unbalanced immune status typical of food 
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allergy. Thus, the second stage was to evaluate the immunomodulating potential of the 
hydrolysates as their ability to hinder, on the one hand, cytokine and IgE production by Th2-
skewed human PBMCs and, on the other hand, the release of pro-inflammatory factors and ROS 
generation from peripheral blood leukocytes (PBLs) subjected to a Th1 stimulus. The binding to 
IgE from egg allergic patients was also determined (Fig. 2.2.) 
 
Figure 2.2. Work plan II for the study of the allergenicity of the hydrolysates and their ability to regulate 
exacerbated responses in Th1- and Th2-skewed human peripheral blood cells. . LPS, lipopolysaccharide; 
LYS, lysozyme; OM, ovomucoid; OVA, ovalbumin; PBLs, peripheral blood leukocytes; PBMCs, 
peripheral blood mononuclear cells; Th, T-helper cell. 
It was shown that low IgE-binding hydrolysates could modify the cellular and humoral 
immune responses of human peripheral blood cells to different stimuli, suggesting potential 
activities that could be used to polarize Th2 and Th1 immune functions. Therefore, we next 
assessed the effects of the peptides contained in the hydrolysates in a specific ex vivo model of 
egg allergy. The ability of the hydrolysates to modulate T cell cytokine responses to egg 
allergens was evaluated in splenocytes from mice sensitized to individual egg proteins, or their 
mixture in different proportions, and their allergenicity in vivo was also estimated (Fig. 2.3). In 
addition, the hydrolysates were fractionated, in an attempt to enrich the immunostimulating and 
immunomodulating peptides, and the sequences contained in each fraction were identified by 
mass spectrometry.  
Finally, the most promising hydrolysates were selected and their ability to modify 
beneficially the immune reaction to egg allergens was tested in vivo using a mouse model of egg 
allergy. As a first step, the lack of sensitizing and eliciting potential was evaluated, to then 
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determine the efficacy of the hydrolysates both as preventive and therapeutic agents. Special 
attention was paid to the elucidation of the mechanism of clinical protection. 
 
Figure 2.3. Work plan III for the in vivo assessment of the allergenicity of the hydrolysates and the study 
of their capacity to modulate allergen responses induced ex vivo on spleen cells from mice sensitized to 
egg white proteins. AEC, anion exchange chromatography; EW, whole egg white; LYS, lysozyme; OM, 
ovomucoid; OVA, ovalbumin; RP-HPLC, reverse phase high-performance liquid chromatography. 
 
Figure 2.4. Work plan IV for the in vivo assessment of the sensitizing capacity of selected hydrolysates 
and the study of their ability to prevent and treat egg allergy. EW, whole egg white; mMCP-1, mouse 
mast cell protease 1; RT-qPCR, quantitative reverse transcription polymerase chain reaction.  
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3.1. Production of enzymatic hydrolysates from egg white proteins 
OVA grade VI, LYS and OM were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). EW was separated from fresh eggs, lyophilized, and its protein content was determined 
by the Kjeldahl method. LPS level of the proteins was quantified by the Pierce LAL 
Chromogenic Endotoxin Quantitation Kit (Thermo Scientific, Waltham, MA, USA), according 
to the instructions of the manufacturer. The LPS contamination of LYS, OM and EW was lower 
than 1 UE/mg and they were used as such; while OVA was purified from LPS using size 
exclusion chromatography, as described by Pablos-Tanarro et al. (2016). This procedure 
reduced the LPS content of OVA from 445.8 UE/mg to 3 UE/mg. 
Protein solutions (5 mg/mL) were prepared in either MilliQ water adjusted to pH 1.5 
(for hydrolysis with pepsin) or in phosphate buffer pH 7.0 (for hydrolysis with Neutrase and 
alcalase). Protein solutions were pre-incubated at the reaction temperature for 10 min prior to 
the addition of either 172 U/mg protein of porcine pepsin (EC 3.4.23.1, 3440 U/mg, Sigma-
Aldrich), 0.025 U/mg of Neutrase or 0.005 U/mg of alcalase (both from Novozymes A/S, 
Bagsvaerd, Denmark). Hydrolyses were conducted, under continuous shaking, at 37ºC for 24 h 
with pepsin or at 50ºC for 60 min with Neutrase and alcalase. The reaction with pepsin was 
neutralized to pH 7.0 and all the enzymes were inactivated by heating at 95ºC for 15 min. The 
samples were then centrifuged at 5000 x g for 10 min (4ºC), the supernatants collected and, 
when required, fractionated using high performance ultrafiltration units of 10 and 3 kDa cut-off 
(Amicon Ultra, Millipore, Eschborn, Germany). The hydrolysates and their fractions were 
stored at -20ºC prior to subsequent analyses. The protein content of the hydrolysates and their 
fractions was determined using the bicinchoninic acid assay (Pierce BCA Protein Assay Kit, 
Thermo Scientific) and the resulting values were used to standardize their concentration for in 
vitro and ex vivo experiments. For in vivo assays, the protein content of the hydrolysates was 
determined by the Kjeldahl method. 
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3.2. Analytical techniques 
3.2.1. Characterization of the hydrolysates by RP-HPLC 
The hydrolysates and their fractions were analysed in a Waters 600 HPLC system 
(Waters, Milford, MA, USA) using a RP318 column (250x4.6mm, Bio-Rad, CA, USA). The 
operating conditions were: flow rate, 1 mL/min; injection volume, 50 μL; solvent A, 0.37 mL/L 
trifluoroacetic acid (TFA) in Milli-Q water; and solvent B, 0.27 mL/L TFA in HPLC grade 
acetonitrile (ACN). Elution was performed with a linear gradient of solvent B in A going from 0 
to 70% in 75 min, followed by 100% B for 30 min. Absorbance was recorded at 214 nm with a 
Waters 2487 dual detector and the software Empower 2000 system data (Waters) was used. 
3.2.2. Isolation of peptide fractions by chromatographic techniques 
Semi-preparative RP-HPLC was performed on a Waters Series 600 HPLC equipped 
with a Millennium 3.2 Software for data acquisition (Waters), using a Prep Nova Pak® HR C18 
column (300 x7.8 mm i.d., 6 µm particle size; Waters). The operating conditions were: column 
temperature, 30ºC; flow rate, 4 mL/min; injection volume, 400 μL (4 mg of protein); solvent A, 
1 mL/L TFA in Milli-Q water and solvent B, 0.8 mL/L TFA in HPLC grade ACN. Elution was 
conducted with a linear gradient of solvent B in A from 0 to 60% B in 100 min, followed by 
washing with 100% B and conditioning the column. Five fractions were collected using a 
Waters Fraction Collector II. ACN was removed by rotary evaporation and aliquots were 
lyophilized for further use. 
Alternatively, fractionation was also conducted by anion exchange chromatography on 
an ÄKTA Explorer FPLC System (GE Healthcare, Freiburg, Germany) using a Mono Q HR 5/5 
column (50 x 5 mm i.d., 10 µm particle size; GE Healthcare). The operating conditions were: 
flow rate, 1 mL/min; injection volume 1 mL (10 mg of protein); solvent A, 20 mM Tris pH 9.0 
and solvent B, 20 mM Tris pH 9.0 containing 1M NaCl. Elution was conducted with a linear 
gradient of solvent B in A from 0 to 100% B in 15 min, followed by washing with 100% B and 
Materials and methods 
63 
 
conditioning the column. Two fractions were collected using a Fraction Collector Frac-950 (GE 
Healthcare). These were purified by solid phase extraction on OASIS HLB Plus-short-cartridges 
(225 mg, 60 µm; Waters) and lyophilized for further use. 
3.2.3. Peptide mass distribution by MALDI-TOF 
Peptide mass distribution of the hydrolysates was analyzed by MALDI-TOF using a 
Bruker AUTOflex Speed spectrometer (Bruker Daltonik GmbH, Bremen, Germany). The 
hydrolysates (0.5 μL dissolved at a concentration of 5 μg/mL) were loaded on a dry 2.5-
dihydroxybenzoic acid (DHB) matrix spot (0.5 μL of 20 mg/mL DHB in ACN/methanol, 
70/30%, containing 1% TFA) onto a Bruker Anchorchip target. All mass spectra were initially 
calibrated with Peptide Calibration Standard and Protein Calibration Standard I (Bruker 
Daltonik). Mass spectra were acquired in positive reflection, by summing 50 laser pulses at a 
fixed slide target position, using a 337 nm nitrogen laser and an acceleration voltage of 20 kV. 
Molecular mass detection limit was 562 Da due to signals arising from fragments and adduct 
ions of the DHB matrix. 
3.2.4. Peptide identification by RP-HPLC-MS/MS  
RP-HPLC with UV detection (214 nm), connected on-line to an electrospray ion source 
and a quadrupole ion trap mass analyser (ESI-MS/MS), was performed using an Agilent 1100 
Series HPLC equipment (Agilent Technologies, Waldbronn, Germany) with a Hi-Pore® 
Reversed Phase RP-318 Column (250 x 4.6 mm i.d.; Bio-Rad) and an Esquire 3000 mass 
spectrometer (Bruker Daltonik). To aid the identification of disulphide linked fragments, the 
samples were analyzed after a reducing step using dithiothreitol (DTT), at a final concentration 
of 70 mM and pH 7.0, for 1 h at 37ºC (Chicón et al., 2006).   
The operating conditions were: flow rate, 0.8 mL/min; injection volume, 50 μL; solvent 
A, 0.37 mL/L TFA in Milli-Q water and solvent B, 0.27 mL/L TFA in HPLC grade ACN. 
Elution was conducted with a linear gradient of solvent B in A from 0 to 70% in 75 min, 
followed by 100% B for 30 min. Ion source parameters were: nebulizer pressure, 60 psi; dry 
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gas, 8 L/min and dry temperature, 350ºC. Using Data Analyses TM (version 3.0; Bruker 
Daltonik), the m/z spectral data were processed and transformed to spectra representing mass 
values. Biotools (version 2.1; Bruker Daltonik) was used to process the MS(n) spectra and 
Mascot software (version 2.3.3, Matrix Science, London, UK) to perform peptide sequencing. 
For each sample, a minimum Mascot score corresponding to P < 0.05 was considered as a pre-
requisite for validation of peptide identification. 
3.3. Cell cultures 
3.3.1. Murine spleen and mesenteric lymph node cells stimulated with mitogens 
Nine 6-week-old female BALB/c mice, obtained from Charles River Laboratories (Saint 
Germain sur l´Arbresle, France), were sacrificed by CO2 inhalation. Whole spleens and MLNs 
were excised, separately pooled in 3 groups (which were used to perform biological replicates) 
and processed as described by Jiménez-Saiz et al. (2011). Splenocytes and MLN cells were 
cultured in RPMI 1640 supplemented with 10% of fetal bovine serum (FBS), L-glutamine (2 
mM), penicillin (50 U/mL) and streptomycin (50 μg/mL) (all from Biowest SAS, Nuaillé, 
France), at a cellular density of 4x106 cells/mL in 48-well plates (non-stimulated control), and 
incubated with either 1 μg/mL ConA or 1 μg/mL LPS (both from Sigma-Aldrich) and different 
concentrations (20-200 μg/mL) of the egg white proteins and their hydrolysates (Sharma et al., 
2007). The effect of the heat-inactivated enzymes was evaluated in a separate experiment, using 
splenocytes isolated from 4 mice pooled in 2 groups and incubated with a concentration of 
enzyme equivalent to that present in 200 μg/mL of the hydrolysates. The supernatants were 
collected after 72 h of culture in a 5% CO2 incubator at 37ºC, and stored at -80ºC until their 
analyses. 
3.3.2. Th2-primed human peripheral blood mononuclear cells 
Th2-skewed PBMCs were obtained as previously described by Holvoet et al. (2013). 
Human blood from 8 healthy donors was sterilely collected into EDTA tubes. PBMCs were 
isolated by density gradient centrifugation on Ficoll-Histopaque (GE healthcare) and 
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resuspended in IMDM medium supplemented with 10% FBS, 1% L-glutamine, 1% 
penicillin/streptomycin and 0.1% gentamicin (all from Biowest SAS) at a cellular density of 
1.5x106 cells/mL in 48-well plates. PBMCs were stimulated with 50 U/mL of IL-4 (Peprotech, 
Hamburg, Germany) and 1µg/mL of anti-CD40 antibody (eBioscience, San Diego, CA, USA) 
to induce a Th2 phenotype. After 3 days in a 5% CO2 incubator at 37ºC, the intact proteins and 
their hydrolysates were added at different concentrations (20-200 µg/mL) and cultured for a 
further 3 days in triplicate. As positive control, 1µg/mL of LPS (Sigma-Aldrich) was used. 
Inactivated enzymes were also tested at a concentration equivalent to that present in 200 µg/mL 
of the hydrolysates. Following incubation, the supernatants were collected and stored at -80ºC 
until their analysis. 
3.3.3. Th1-primed human peripheral blood leukocytes 
PBLs were isolated from human blood from 10 healthy donors and Th1-skewed as 
described by Richard et al. (2005). Blood was mixed with one volume of 3% (w/v) dextran 
(Sigma-Aldrich) in 0.9% (w/v) NaCl solution. After 30 min of incubation, PBLs were recovered 
from the upper layer, erythrocytes were lysed in 0.2% (w/v) NaCl for 30 s, and isotonic 
osmolarity was re-established by adding one volume of 1.6% (w/v) NaCl. Isolated PBLs were 
cultured in RPMI 1640 medium supplemented with 0.25% of FBS, 1% L-glutamine and 0.5% 
penicillin/streptomycin (all from Biowest SAS) at a cellular density of 1x106 cells/mL in 48-
well plates. PBLs were stimulated with 100 ng/mL of LPS (Sigma-Aldrich) and 20 U/mL of 
IFN-γ (Peprotech) for 24 h. The intact proteins, their hydrolysates and low molecular mass 
fractions (< 10 and < 3 kDa), were added together with LPS/IFN-γ at a concentration of 200 
µg/mL in triplicate. Inactivated enzymes were also tested at a concentration equivalent to that 
present in 200 µg/mL of the hydrolysates. The supernatants were collected and stored at -80ºC 
until their analysis.  
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3.3.4. Spleen cells from mice sensitized to egg white proteins 
Six-week-old female specific-pathogen-free BALB/c mice, purchased from Charles 
River Laboratories, were sensitized with 1 mg of either OVA, OM or LYS, poly-sensitized with 
a mixture of 1 mg of each of the three proteins or sensitized with 5 mg of EW, using CT as 
adjuvant, as described in section 3.4.1. Naïve mice just received sterile phosphate buffered 
saline (PBS). Each group consisted of 5 mice. On day 49, mice were euthanized by CO2 
inhalation and spleen cells were collected and processed under sterile conditions. Pooled 
splenocytes from each group (n=5) were cultured in 48-well plates (4×106 cells/mL) and 
stimulated in triplicate with ConA (2.5 μg/mL), as positive control; RPMI-1640 medium, as 
negative control; and the intact proteins, their hydrolysates or peptide fractions at different 
concentrations (10-200 μg/mL). Inactivated enzymes were also tested at a concentration 
equivalent to that present in 200 μg/mL of the hydrolysates. The immunomodulating effect of 
the hydrolysates and their selected fractions, at a concentration of 200 μg/mL, was also tested 
concomitantly with the intact allergens (200 μg/mL). Supernatants were collected after 72 h at 
37°C in 5% CO2, and stored at -80°C until their analysis. 
3.3.5. Cell proliferation and viability  
The proliferation assays were carried out as described by Quah and Parish (2012), with 
some modifications. Before their culture, cells were labelled with carboxyfluorescein 
succinimidyl ester (CFSE) (5 μM in non-supplemented RPMI culture medium) using a 
CellTrace CFSE cell proliferation kit (Life Technologies, Carlsbad, USA) and incubated at 37ºC 
for 10 min. The reaction was stopped by adding 5 volumes of supplemented RPMI culture 
medium and cells were then incubated at 4ºC for 10 min, followed by 3 washes with PBS. After 
incubation period with the stimuli, cells were harvested and analytical flow cytometry was 
performed using a Gallios instrument (Beckman Coulter, Krefeld, Germany). Statistical analysis 
of CFSE distributions was based on histogram profiling using Overton subtraction as applied by 
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the FlowJo software version 9.1 (Treestar Inc., Ashland, OR, USA). The results were expressed 
as the percentage of cells in the final population that divided at least once.  
Cytotoxicity of the hydrolysates was determined on spleen cell cultures using the 3-
[4,5-dimethylthiazol-2-yl]-2-,5-diphenyltetrazoliumbromide (MTT) method described by 
Hansen et al. (1989), with modifications. After incubation with the stimuli in 96-well plates, 
150 μL of 1 mg/mL MTT (Sigma-Aldrich) were added to each well and incubated for a further 
3 h. The plates were centrifuged at 500 x g for 10 min and the supernatants discarded. The 
formazan precipitate was dissolved by the addition of 50 μL of dimethyl sulfoxide and the 
absorbance of each well was measured at 570 nm in a plate reader (Multiskan FC, Thermo 
Scientific). Cell viability was expressed as percentage of the value of the corresponding control 
depending of the stimulus.  
3.3.6. Intracellular reactive oxygen species 
The intracellular formation of ROS was assessed using the dichloro-dihydro-fluorescein 
diacetate (DCFH-DA) assay. After the incubation period, cells were labelled with 2.5 µM 
DCFH-DA in Hanks balanced salt solution (Biowest SAS) and incubated in dark for 45 min at 
37ºC (Cosentino et al., 2008). Afterwards, cells were washed twice with PBS and subjected to 
chemical oxidative stress with 0.5 mM tert-butyl hydroperoxide (t-BOOH) (Sigma-Aldrich) for 
15 min. Fluorescence emission due to the oxidation of DCFH-DA by intracellular ROS was 
read at excitation and emission wavelengths of 485 nm and 528 nm, respectively, in a Polarstar 
Galaxy plate reader (BMG Labtechnologies GmbH, Offenburg, Germany).  
3.4. In vivo experiments 
Three- to six-week-old female specific-pathogen-free BALB/c mice were purchased 
from Charles River Laboratories, housed under standard conditions and fed an animal protein-
free diet (SAFE, Route de Saint Bris, France). 
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3.4.1. Sensitization and challenge protocols 
In the sensitization experiments, six-week-old mice (n=5 per group) were administered 
by intragastric gavage, during three consecutive days on the first week and once per week 
during the following 5 weeks, the antigen (1 mg of either OVA, OM or LYS, a mixture of 1 mg 
of each of the three proteins, 5 mg of EW or 5 mg of either OA or OP) plus 10 μg of CT (List 
Biologicals, Campbell, USA). Sham-sensitized mice only received 10 μg of CT. 
Challenges were performed one week after the last sensitization dose. Oral challenge 
with 50 mg of antigen per mouse was followed by i.p. challenge with 100 µg of antigen per 
mouse, 40 min apart. 30 min after each challenge (oral and i.p.), anaphylactic responses were 
evaluated by scoring clinical signs and rectal temperature as described in Pablos-Tanarro et al. 
(2016). Blood and faecal samples were collected at different time points throughout the 
experiments. Three hours after the last challenge, mice were euthanized by CO2 inhalation, and 
samples from duodenum, MLNs and PPs collected for further analyses. Spleens were 
individually excised and isolated cells were cultured with RPMI-1640 medium (as negative 
control) or 200 μg/mL of the egg white proteins or their hydrolysates as described in section 
3.3.4. 
3.4.2. Preventive and therapeutic treatments 
The preventive potential of OVA and its hydrolysates was evaluated using 5 groups of 
three-week-old mice (n=5) which were orally pre-treated with PBS (two groups), OVA, OA or 
OP (5 mg per mouse) 3 times per week during 3 weeks. One week after the last preventive dose, 
a group treated with PBS and the groups treated with OVA, OA and OP were sensitized to EW 
as indicated, while the remaining group treated with PBS only received 10 μg of CT during the 
sensitization period. All groups were orally and i.p. challenged with EW, as described above.  
Finally, the therapeutic effect of the intact protein and its hydrolysates was studied in 5 
groups of six-week-old mice (n=5), four of them sensitized to EW and one sham-sensitized. 
Three groups were orally treated with OVA, OA or OP (5 mg per mouse) 3 times per week 
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during 3 weeks. An additional group sensitized to EW and the sham-sensitized group just 
received PBS during the treatment period. Three days after the completion of the treatment 
period, all the groups were orally and i.p. challenged with EW, as described above. Mice treated 
with OVA and OP were kept for a further three weeks without any treatment, in order to 
evaluate the maintenance of the tolerance status acquired and challenged 3 days after. Blood, 
faeces and intestinal tissue samples were collected as indicated in section 3.4.1. 
3.4.3. Passive cutaneous anaphylaxis assays 
PCA tests were performed as described by López-Expósito et al. (2012). Briefly, naïve 
BALB/c mice were injected intradermically in the right ear pinna with 20 µL of pooled sera 
(n=5) from OVA-, LYS- or OM-sensitized mice and with pooled sera from naïve BALB/c mice 
in the left ear pinna. Twenty four hours later, mice (2 per test) were injected intravenously with 
200 µg of the respective intact antigen (OVA, OM or LYS) or the corresponding hydrolysates in 
100 µL of 1% Evans blue dye (Sigma-Aldrich). One hour after protein administration, mice 
were euthanized by CO2 inhalation and ears were individually collected and incubated overnight 
in N,N-dimethylformamide (Sigma-Aldrich). The absorbance of the supernatant was measured 
at 655 nm in order to quantify the extravasation of the dye. 
The participation of IgE and IgG1 in the induction of anaphylaxis in the BALB/c model 
was evaluated following the protocol described above, with some modifications. Shortly, naïve 
mice (2 per test) were injected with 20 μL of either unheated or heated (56°C for 3 h to 
inactivate IgE; Li et al., 2000) pooled sera from sensitized mice, and with pooled sera from 
sham-sensitized mice in the left ear pinna (all serum samples were collected after sacrifice). 
Twenty four hours later, mice were injected intravenously with 200 μg of the respective antigen 
in 100 μL of 1% Evans blue dye (Sigma-Aldrich).  
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3.5. Quantification of cytokines, antibodies and mast cell degranulation  
3.5.1. Cytokines in cell culture supernatants 
The levels of IL-4, IL-5, IL-13, IL-8, IL-10, IL-17, IL-12p70, TNF-α and IFN-γ in the 
supernatants of cell cultures after incubation with the stimuli were quantified by ELISA or 
Luminex commercial kits according to the manufacturer’s instructions (eBioscience).  
3.5.2. Mouse IgG isotypes in cell culture supernatants 
The levels of total IgG1 and IgG2a in the supernatants of cells from section 3.3.1 were 
determined by ELISA. Briefly, 96-well plates were coated with 0.1 µg/well of anti-mouse IgG1 
and IgG2a (BD Biosciences, San José, CA, USA) and, after an overnight incubation at 4ºC, 
plates were blocked and incubated at 4ºC with diluted culture supernatants (1:5 v/v) for 12 h. 
Plates were then incubated with 0.2 µg/well of biotinylated anti-mouse IgG1 and IgG2a, 
followed with avidin-horseradish peroxidase (HRP) (all from BD Biosciences). A signal 
amplification system, based on the subsequent addition of tyramide-biotin and streptavidin-
HRP, was used following the instructions of the manufacturer (ELAST ELISA amplification 
system, Perkin-Elmer Life Sciences, Waltham, MA, USA). The reactions were developed using 
ABTS as substrate (Roche, Mannheim, Germany) and read at 405 nm in a plate reader 
(Multiskan FC, Thermo Scientific). 
3.5.3. Human IgE in cell culture supernatants 
The levels of IgE in the supernatants of cells from section 3.3.2 were determined by 
ELISA. 96-well plates were coated with 0.2 µg/well of anti-human IgE (Dako, Glostrup, 
Denmark) and, after an overnight incubation at 4ºC, plates were blocked and incubated at 4ºC 
with diluted culture supernatants (1:2 v/v) for 12 h. Detection was carried out by adding 0.5 
µg/well of biotinylated anti-human IgE (Dako), followed with an avidin-HRP incubation step 
(BD Biosciences). The reactions were developed using ABTS as substrate (Roche) and read at 
405 nm.  
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3.5.4. Serum and faecal levels of antigen-specific antibodies 
Mouse sera were obtained by centrifugation at 2500 x g for 10 min and kept at -20ºC 
until analysis, and faeces were lyophilised. EW-specific IgE, IgG1 and IgG2a and those against 
the hydrolysates (OA and OP) were quantified by ELISA as previously explained by Pablos-
Tanarro et al. (2016) with some modifications. Briefly, 96-well plates were coated with 0.5 
µg/well of either EW, OA, OP or with 0.1 µg/well of anti-mouse IgE, IgG1 and IgG2a (BD 
Biosciences) for the reference curves. After an overnight incubation at 4ºC, plates were blocked 
and incubated with diluted (v/v) serum samples (1:20 for IgE, 1:2000 for IgG1 and 1:100 for 
IgG2a against EW; 1:5 for IgE, 1:200 for IgG1 and 1:50 for IgG2a against OA and OP) or serial 
dilutions of mouse IgE, IgG1 and IgG2a isotypes (BD Biosciences). Detection was carried out 
by adding 0.2 µg/well of biotinylated anti-mouse IgE, IgG1 and IgG2a, followed with an avidin-
HRP incubation step (BD Biosciences). Reactions were developed with ABTS as substrate 
(Roche) and read at 405 nm. Detection of specific IgA against EW, OA and OP was carried out 
in the supernatants of lyophilized faecal samples homogenized in PBS during 3 h and 
centrifuged at 4000 x g for 10 min. Quantification of IgA levels was performed as described 
above except for the use of anti-mouse IgA antibodies and IgA isotype control for the reference 
curves (BD Biosciences). Faecal supernatants were diluted 1:50 (v/v) for EW-specific IgA and 
1:5 (v/v) for IgA specific against the hydrolysates. 
3.5.5. Human IgE-binding by inhibition ELISA  
Human IgE binding of the samples was assessed by inhibition ELISA as previously 
reported (Jiménez-Saiz  et al., 2013), using a pool of 8 different sera from egg allergic children 
with IgE specific to OVA, LYS and OM ranging between 35.2-1326.5 kU/L, 2.3-36.6 kU/L and 
19.3-120.0 kU/L, respectively. Briefly, OVA, LYS and OM were used as coating antigens (0.5, 
2.5 and 1.75 µg, respectively). Serial dilutions of the hydrolysates were incubated with the 
pooled sera (1:1 v/v) and, after 2 h, added to the appropriate coated plate. Detection was carried 
out by adding 0.1 µg/well of polyclonal rabbit anti-human IgE (Dako), followed with 0.2 
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µg/well of polyclonal swine anti-rabbit immunoglobulin HRP-labelled (Dako). A tyramide-
biotin and streptavidin-HRP amplification system was employed, following the instructions of 
the manufacturer (ELAST ELISA amplification system, Perkin-Elmer Life Sciences). The 
reactions were developed using TMB as substrate, stopped with 0.5 M sulfuric acid and the 
absorbance read at 450 nm in a plate reader (Multiskan FC, Thermo Scientific). Results were 
expressed as EC50 value, that is, the effective sample concentration (μg/mL) for 50% of the 
maximum binding to IgE. 
3.5.6. Mouse IgG1-binding by inhibition ELISA  
Mouse IgG1-binding capacity was assessed by inhibition ELISA, coating the plates 
with 0.5 µg/well of EW or OA. Serial dilutions of samples (EW, OP, OA and its fractions below 
and above 10 kDa, as well as the alcalase enzymatic extract) were incubated with pooled sera 
(1:1 v/v) from mice administered EW or OA plus CT and, after 2 h of incubation, added to the 
appropriate coated plate. Detection was carried out by adding 0.2 µg/well of biotinylated anti-
mouse IgG1, followed with an avidin-HRP incubation step (BD Biosciences). The reactions 
were developed using TMB (Sigma-Aldrich) as substrate, stopped with 0.5 M sulfuric acid and 
the absorbance read at 450 nm. Results were expressed as B/Bo, where B and Bo represent, 
respectively, the amount of IgG1 bound to immobilised antigen (EW or OA) in the presence and 
absence of a known concentration of inhibitors (EW, hydrolysates, OA fractions or the enzyme).  
3.5.7. Serum levels of mouse mast cell protease I 
Mast cell degranulation was evaluated in serum samples collected after oral and i.p. 
challenges by determining the concentration of mMCP-1 using a commercial ELISA kit 
according to the manufacturer’s instructions (eBioscience). 
3.6. Relative gene expression 
Total RNA was individually extracted from duodenum tissues and cells isolated from 
MLNs and PPs by using NucleoSpin RNA Kit (Macherey-Nagel Gmbh & Co., Düren, 
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Germany), according to the manufacturer’s instructions. Duodenum samples were previously 
homogenized using an Ultra-Turrax T8 (IKA Labortechnik, Staufen, Germany). Total RNA was 
qualitatively evaluated and quantified with an Agilent 2100 Bioanalyzer (Agilent 
Technologies), and 2 µg were used to synthesize cDNA using PrimeScript RT reagent kit 
(TaKaRa Bio Inc., Shiga, Japan). 
qPCR was performed in a real-time thermocycler (ViiA7 Real-Time PCR System, 
Applied Biosystems, Foster, USA) using SYBR Premix ExTaq II (Tli RNaseH Plus) (TaKaRa). 
The primer pairs, shown in table 3.1, were purchased from Integrated DNA Technologies (IDT, 
Coralville, USA) and used at a final reaction concentration of 166.7 nM (for β-actin, IL-10 and 
TGF-β) or 312.5 nM (for IL-33, IL-25, IL-17, TSLP, GATA-3, T-bet and Foxp3). The thermal 
cycling conditions included 2 min incubation at 50°C, followed by 10 min pre-incubation at 
95°C, and 40 cycles consisting on a denaturation step of 15 s at 95°C and, for primer annealing 
and polymerase extension, 45 s at 58ºC followed by 15 s at 60ºC (for β-actin, IL-10 and TGF-β) 
or 60 s at 60°C (for IL-33, IL-25, IL-17, TSLP, GATA-3, T-bet and Foxp3). Melting curve 
analysis was used to confirm specific product formation. The efficiency of each qPCR reaction 
was estimated between 90% and 110%. The relative gene expression was calculated by 
normalizing data to the expression of the reference gene β-actin, using the corresponding sham-
sensitized group of each experiment (which only received CT and was treated, if applicable, 
with PBS) as calibrator, as described by Livak and Schmittgen (2001). All the amplification 
reactions were performed in triplicate. 
3.7. T cell subsets by flow cytometry 
Isolated spleen cells were recovered in a solution of PBS containing 2% FBS and 1mM 
EDTA and, afterwards, Fc receptors were blocked using anti-CD16/CD32 (clone 2.4G2, BD 
Biosciences). The determination of live cells for analyses was conducted using LIVE/DEAD® 
Fixable Near-IR Dead Cell Stain Kit (Thermo Scientific). T cell subsets were analysed using the 
follow antibodies: anti-CD4-Alexa Fluor 700 (clone GK1.5), anti-CD69-PerCP-Cy5.5 (clone 
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H1.2F3), anti-CXCR3-APC (clone CXCR3-173), anti-ST2-PE (clone RMST2-2), anti-CD25-
FITC (clone 3C7) and anti-CD39-PE-Cy7 (clone Duha59; all from Biolegend, San Diego, US). 
Approximately 1 x 105 cells were acquired using a Gallios flow cytometer (Beckman Coulter). 
All the analyses were performed using Kaluza Analysis software (version 1.3, Beckman 
Coulter). Samples were first inspected in all light scatter patterns and fluorescence channels to 
confirm quality and abnormal population were excluded. Unlabelled processed samples were 
used for reporting the percentage of positive cells.  
Table 3.1. Primer sequences used for RT-qPCR analyses of relative gene expression. 
Gen Primer pair Reference 
β-actin 
fw  5´ AGCTGCGTTTTACACCCTTT 3´ 
Cardoso et al., 2009 
rv  5´ AAGCCATGCCAATGTTGTCT 3´ 
FoxP 3 
fw 5' ACAACCTGAGCCTGCACAAGT 3' 
Cardoso et al., 2009 
rv 5' GCCCACCTTTTCTTGGTTTTG 3' 
GATA 3 
fw 5' CCTTAAAACTCTTGGCGTCC 3' 
Zhang et al., 2013 
rv 5' AGACACATGTCATCCCTGAG 3' 
IL-10 
fw 5' GCCTTATCGGAAATGATCCA 3' 
Yang et al., 2009b 
rv 5' AGGGGAGAAATCGATGACAG 3' 
IL-17 
fw 5' TGCCTGTGGCACTGAAGTAG 3' 
Lenoir et al., 2016 
rv 5' TTCATGGCTGCAGTGAAAAG 3' 
IL-25 
fw 5' ACAGGGACTTGAATCGGGTC 3' 
Li et al., 2013 
rv 5' TGGTAAAGTGGGACGGAGTTG 3' 
IL-33 
fw 5' ATTTCCCCGGCAAAGTTCAG 3' 
Li et al., 2013 
rv 5' AACGGAGTCTCATGCAGTAGA 3' 
T-bet 
fw 5' GTATCCTGTTCCCAGCCGTTTC 3' 
Zhao et al., 2010 
rv 5' ACTGTGTTCCCGAGGTGTCC 3' 
TGF-β 
fw 5' TTGCTTCAGCTCCACAGAGA 3' 
Yang et al., 2009b 
rv 5' TACTGTGTGTCCAGGCTCCA 3' 
TSLP 
fw 5' AGGCTACCCTGAAACTGAGA 3' 
Negishi et al., 2012 
rv 5' GGAGATTGCATGAAGGAATAC 3' 
fw, forward primer; rv, reverse primer 
3.8. Ethics statement 
All protocols involving animals followed the European legislation (Directive 2010/ 
63/UE) and were approved by the CSIC Bioethics Committee and the Comunidad de Madrid 
(Ref PROEX 089/15). All human samples were obtained with written consent from the donors 
involved in the study and all experiments were approved by the CSIC Bioethics Committee.  
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3.9. Statistical analyses 
Data were subjected to one-way ANOVA followed by post hoc multiple-comparison 
using the Tukey’s test, except for results derived from the assays with human peripheral blood 
cells (section 4.2) where ANOVA analyses were followed by Dunnett’s post hoc multiple-
comparison test. Statistical differences of the clinical sign scores and gene expression results 
were evaluated by Mann-Whitney U test. In all cases, P values< 0.05 were considered to be 
statistically significant. The statistical analyses were performed using GraphPad Prism v5 
(GraphPad Software Inc., San Diego, USA) and STATISTICA software (Version 7.1; StatSoft 
Inc., 2006, www.statsoft.com). 
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During the past few years, increasing evidence has pointed out the existence of peptides 
which specifically act on the immune system. The immunomodulating activity of these peptides 
comprises effects on cell migration, survival and proliferation, as well as stimulation of 
antimicrobial and immune signalling molecules (Easton et al., 2009). Although existing studies 
on the effects of immunomodulating peptides have focused mainly on cells of the innate 
immune system, there is evidence that they alter T and B lymphocyte functions and could 
contribute to a balanced Th1 and Th2 response (Hilchie et al., 2013).  
Whereas the use of known bioactive peptides as templates to synthetize optimized 
peptides with the ability to modulate the immune response has proved effective in the 
formulation of new sequences with better properties, the high cost associated with generating 
synthetic peptides on a large scale is an important obstacle to their production (Easton et al., 
2009). In this respect, hydrolysis of food proteins appears as an attractive and safe alternative 
for a reproducible and standardized production of immune-active peptides with low costs that 
would allow their consumption in the form of functional foods. However, while a number of 
potentially immunomodulating peptides have been described as arising from food proteins, such 
as milk whey proteins, contradictory results are frequently reported regarding their biological 
properties, which could be due to the use of assay systems that fail to correlate with a specific 
immune response or to the contamination of the peptide preparations with immunostimulating 
substances (Brix et al., 2003; Gauthier et al., 2006). 
Egg white protein hydrolysates are good candidates for non-pharmacological 
approaches to prevent and treat complex diseases by virtue of their multifunctional properties, 
which comprise antihypertensive, antioxidant, antimicrobial and lipid-lowering activities 
(García-Redondo et al., 2010; Yu et al., 2014). As a first step in the search for 
immunomodulating enzymatic hydrolysates of egg proteins, we used as an assay method an in 
vitro model system of murine cells stimulated with T and B cell mitogens (Fig. 4.1.1). 
Hydrolysates of OVA, LYS, OM and EW with pepsin, Neutrase and alcalase were produced 
and their constituent peptides characterized by RP-HPLC and MALDI-TOF. Subsequently, the 
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effects of these hydrolysates on cytokine secretion, antibody production, oxidative stress and 
proliferation of murine spleen and MLN cells stimulated with ConA and LPS were assessed 
(Fig. 4.1.1).  
 
Figure 4.1.1. Scheme of the experimental procedure followed in section 4.1. CFSE, method based on 
carboxyfluorescein succinimidyl ester; ConA, concanavalin A; EW, whole egg white; LPS, 
lipopolysaccharide; LYS, lysozyme; MLNs, mesenteric lymph nodes; MTT, method based on 3-[4,5-
dimethylthiazol-2-yl]-2-,5-diphenyltetrazoliumbromide; OM, ovomucoid; OVA, ovalbumin; RP-HPLC, 
reverse phase high-performance liquid chromatography. 
4.1.1. Results 
4.1.1.1. Egg white protein hydrolysates with alcalase are characterized by low molecular mass 
peptides 
Individual egg white proteins (OVA, LYS and OM) and EW were hydrolyzed with pepsin, 
Neutrase and alcalase. The hydrolysis conditions were optimized to obtain a complete 
degradation of the substrates and the absence of intact proteins was confirmed by RP-HPLC 
(Fig. 4.1.2). As expected, OVA was quite resistant to pepsin action (Benedé et al., 2014), and its 
hydrolysis required 24 h at 37ºC. LYS and OM also disappeared after 24 h of hydrolysis with 
pepsin at 37ºC and pH 1.5. OM is usually readily digested by pepsin, but it gives rise to 
Hydrolysates of egg white proteins modulate T and B cell responses in mitogen-stimulated murine cells 
83 
 
proteolysis fragments linked by disulfide linkages, which is also the case of pepsin-treated LYS, 
because these proteins are stabilized by 9 and 4 disulfide bridges, respectively (Benedé et al., 
2013; Jiménez-Saiz et al., 2014). Neutrase and alcalase hydrolyzed the egg white proteins in 
less than 1 h at 50ºC, yielding similar chromatographic profiles. 
The peptide mass distribution of the hydrolysates was analysed by MALDI-TOF (Table 
4.1.1). The occurrence of unspecific signals from DHB matrix, such as small fragments and 
adduct ions, established the limit of detection in 562 Da. Molecular masses lower than 10 kDa 
were found in all cases, although, comparatively, alcalase led to the smallest fragments: 85-97% 
of the peptides were lower than 1500 Da, with more than 50% of them between 601 and 900 
Da. Almost 30% of the peptides present in the hydrolysates produced with pepsin and Neutrase 
had molecular masses higher than 1500 Da. 
Table 4.1.1. Peptide mass distribution in the hydrolysates of OVA (O), LYS (L), OM (M) and EW (E) 
with pepsin (P), Neutrase (N) and alcalase (A). The masses included in each mass range are expressed as 
percentage of all the masses detected by MALDI-TOF analyses. 
Mass 
Range 
(Da) 
Frequency (%) 
OP ON OA LP LN LA MP MN MA EP EN EA 
≤ 600 7.72 6.97 15.52 5.29 4.79 13.33 3.41 4.23 8.17 4.86 3.42 5.96 
601- 
900 
37.40 30.31 55.75 32.60 35.21 50.67 30.30 23.78 49.03 35.07 28.57 50.47 
901- 
1200 
24.39 20.91 22.99 17.18 22.25 19.11 17.80 14.98 21.40 25.00 19.88 19.44 
1201-
1500 
6.50 11.50 2.87 14.54 18.03 10.67 9.85 12.05 12.06 15.63 11.49 9.72 
1501-
3000 
10.98 21.25 0.57 25.99 14.37 4.00 18.18 15.31 7.00 6.25 22.36 6.90 
≥ 3001 13.01 9.06 2.30 4.41 5.35 2.22 20.45 29.64 2.33 13.19 14.29 7.52 
4.1.1.2. Egg white protein hydrolysates modulate T cell responses in ConA-stimulated 
splenocytes 
Incubation of splenocytes from BALB/c mice with ConA, a mitogen able to stimulate 
mouse T lymphocytes (Sharma et al., 2007), induced a vigorous T cell proliferation, as assessed 
by CFSE labelling (Table 4.1.2), and secretion of Th1 (IFN- and TNF-, Fig. 4.1.3a and b) and 
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Th2 cytokines (IL-13 and IL-10, Fig. 4.1.3c and d). The concomitant addition of the 
hydrolysates of OVA, LYS and OM with pepsin, Neutrase and alcalase did not significantly 
affect the release of IFN- by ConA-stimulated cells (Fig. 4.1.3a). However, the hydrolysates 
modified the production of TNF- in a dose-dependent manner, with the lowest dose (20 
µg/mL) usually reducing the ConA-induced release of TNF-, which subsequently increased 
with the hydrolysate concentration (particularly in the hydrolysate of OVA with pepsin, as well 
as the hydrolysates of OVA, LYS and OM with Neutrase). A low TNF-production was 
detected as a result of the addition of the hydrolysate of LYS with pepsin, although intact LYS 
and OM also decreased the release of TNF- at the three concentrations tested (Fig. 4.1.3b). 
Regarding Th2 cytokines, the ConA-induced secretion of IL-13 decreased with increasing 
concentrations of the hydrolysates of OVA, LYS and OM with alcalase and LYS with pepsin, 
while the highest concentration of the hydrolysates of OVA and OM with pepsin (200 µg/mL) 
led to an increase in the release of IL-13 (Fig. 4.1.3c). IL-10 secretion by ConA-stimulated 
splenocytes decreased following incubation with the hydrolysates of OVA with alcalase and 
LYS with pepsin, as well as with intact LYS and OM at the highest concentrations (Fig. 4.1.3d). 
The effects exerted by hydrolysates of EW were then assessed. As shown in Fig. 4.1.3a, 
the levels of IFN- were not significantly influenced by the addition of the hydrolysates. 
However, the highest concentrations of the hydrolysate of EW with Neutrase increased the 
ConA-induced production of TNF-, IL-13 and IL-10, while the hydrolysate with alcalase 
reduced the production of TNF-IL-13 and IL-10 (Fig. 4.1.3b-d). 
Altogether, these results indicate that, while intact OVA increased TNF-, intact LYS 
and OM reduced the levels of TNF- IL-13 and IL-10 and EW, those of IL-13 and IL-10; the 
hydrolysates produced by Neutrase enhanced Th1 responses (ON, LN, MN and EN; Fig. 4.1.3b) 
and, to a lesser extent, Th2 responses (EN; Fig. 4.1.3c) and those produced by alcalase reduced 
Th2 responses (OA, LA, MA and EA; Fig. 4.1.3c). On the other hand, the hydrolysate of LYS 
with pepsin exerted a suppressive effect on both Th1 (TNF-) and Th2 mediators (IL-13 and 
  
 
Figure 4.1.2. RP-HPLC patterns of OVA (O), LYS (L), OM (M) and EW (E) hydrolysates produced with pepsin (P), alcalase (A) and Neutrase (N). OVT designates 
ovotransferrin. The profile of the respective intact protein is drawn with a pale grey line. 
  
Table 4.1.2. Effects of OVA (O), LYS (L), OM (M), EW (E) and their hydrolysates with pepsin (P), Neutrase (N) and alcalase (A) on proliferation and viability of 
splenocytes. Proliferation of ConA- and LPS-stimulated splenocytes cultured with 200 μg/mL of the intact proteins and their hydrolysates was assessed by CFSE labelling and 
the results expressed as the percentage of cells in the final population that divided at least once. Viability was measured by the MTT assay either on non-stimulated (RPMI), 
ConA- or LPS- stimulated splenocytes (taken as 100%) and the corresponding percentage was calculated in the cultures treated with 200 μg/mL of the proteins and their 
hydrolysates. 
 
Proliferation                   
ConA-stimulated cells 
Proliferation                                      
LPS-stimulated cells 
Viability RPMI 
Viability                     
ConA-stimulated cells 
Viability                        
LPS-stimulated cells 
RPMI       4.27 ± 0.10 *    12.95 ± 0.78 * 100.00 ± 0.00 - - 
ConA  74.25 ± 0.49 - -
 100.00 ± 0.00 - 
LPS - 29.30 ± 0.28 - - 100.00 ± 0.00 
O  75.95 ± 0.92 25.60 ± 0.99 152.12 ± 16.35 106.30 ± 1.35   79.91 ± 4.31 * 
OP 72.00 ±1.13    22.95 ± 0.64 * 160.25 ± 17.12 107.12 ± 2.68 92.34 ± 1.22 
ON        65.25 ± 0.92 * • 27.20 ± 1.27 170.63 ± 21.13 110.06 ±  2.67 82.06 ± 2.46 
OA        66.75 ± 0.78 * •    22.65 ± 0.21 * 144.10 ± 11.32 105.81 ± 4.25   78.11 ± 6.10 * 
L  73.25 ± 0.92 25.65 ± 1.06 93.98 ± 4.02 109.32 ± 3.60 83.14 ± 4.02 
LP  70.45 ± 1.20    25.20 ± 0.42 * 127.03 ± 1.35 104.50 ± 1.24 88.63 ± 1.87 
LN       64.55 ± 0.92 * • 26.25 ± 1.06 145.00 ± 1.37 106.21 ± 4.56 86.78 ± 1.69 
LA       67.75 ± 0.07 * •    24.70 ± 0.85 * 123.21 ± 10.11 110.00 ± 3.26 89.08 ± 1.30 
M 72.00 ± 1.27 29.05 ± 1.20 121.25 ± 7.32 100.36 ± 4.11    81.41 ± 3.32 * 
MP 69.80 ± 1.13 26.75 ± 0.49 138.31 ± 12.35 111.21 ± 1.96 87.22 ± 9.03 
MN 71.10 ± 1.13      25.45 ± 0.78 * • 171.10 ± 29.64 109.45 ± 3.97 83.86 ± 7.31 
MA 70.40 ± 0.57      23.60 ± 0.85 * • 117.45 ± 23.96 113.13 ± 9.13 89.64 ± 1.65 
E 74.70 ± 1.41 28.30 ± 0.99 133.08 ± 39.45 102.35 ± 1.25 90.49 ± 4.06 
EP 71.15 ± 1.06 31.10 ± 0.57 119.20 ± 33.56 106.01 ± 4.78 94.12 ± 3.98 
EN      65.40 ± 0.57 * •     33.45 ± 0.21 * • 141.20 ± 27.12 105.60 ± 1.95 93.30 ± 5.15 
EA      69.15 ± 1.34 * • 31.15 ± 0.32 126.00 ± 25.32 107.19 ± 4.36 87.49 ± 8.23 
* P < 0.05 compared to the respective control within columns. 
• P < 0.05 compared to the respective intact protein within columns. 
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Figure 4.1.3. Effects of different concentrations (20, 100 and 200 μg/mL) of OVA (O), LYS (L), OM 
(M), EW (E) and their hydrolysates produced with pepsin (P), Neutrase (N), and alcalase (A) on ConA-
induced secretion of IFN-γ (a), TNF-α (b), IL-13 (c), and IL-10 (d) by mouse splenocytes. Data are means 
± SD of triplicates. * P < 0.05 compared to the ConA-stimulated control. 
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IL-10), similar to that produced by intact LYS (LP; Fig. 4.1.3b-d). When the effect of the 
highest concentration of the hydrolysates (200 µg/mL) on the proliferation of ConA-stimulated 
splenocytes was assessed, a significant decrease was observed after the addition of those of 
OVA, LYS and EW with Neutrase and alcalase, which also exerted a pronounced influence on 
Th1 and/or Th2 cytokines (ON, LN, EN, OA, LA and EA; Table 4.1.2). The MTT assay showed 
no significant effects of egg white proteins or their hydrolysates on the viability of non-
stimulated, ConA- or LPS-stimulated splenocytes, ensuring that inhibition of proliferation was 
not due to toxicity of the hydrolysates (Table 4.1.2). It should be mentioned that the inactivated 
enzymes did not have any impact on proliferation or cytokine secretion by ConA-treated 
splenocytes, except for Neutrase, which significantly enhanced the production of TNF- and 
IL-10 (Fig. 4.1.4). 
 
Figure 4.1.4. Effects of inactivated pepsin (P), Neutrase (N) and alcalase (A), at a concentration 
equivalent to that present in 200 μg/mL of the hydrolysates, on the ConA-induced proliferation (a) and 
secretion of IFN-γ (b), TNF-α (c), IL-13 (d) and IL-10 (e) by mouse splenocytes. Data are means ± SD of 
duplicates. * P < 0.05 compared to the ConA-stimulated control. 
4.1.1.3. Egg white protein hydrolysates influence B cell responses induced by LPS and reduce 
oxidative stress in spleen and MLN cells 
LPS was next used to stimulate murine spleen and MLN cells and estimate the effect of 
the addition of the egg white protein hydrolysates on antibody production and oxidative status. 
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LPS is an immunostimulating product of Gram-negative bacteria that signals through TLR4, 
acknowledged as a crucial pathogen recognition receptor in innate responses, as well as in 
triggering adaptive immunity (Lu et al., 2008). TLRs have been mainly identified in immune 
cells, especially monocytes, macrophages and DCs, as well as in other cell types, where they 
participate in responses associated to oxidative stress and inflammation. LPS is also as a potent 
mouse B lymphocyte mitogen which promotes expansion, class switch recombination and 
immunoglobulin secretion; and it is known that LPS-activated B cells acquire differential 
modulatory effects on T cell polarization (Xu et al., 2008). 
LPS enhanced spleen cell proliferation (although less than ConA; Table 4.1.2) and 
secretion of IgG1 (Fig. 4.1.5) and IgG2a (not shown), which are, respectively, Th2- and Th1-
biased antibodies, from spleen and MLN cells. All the individual egg white proteins (but not 
EW) and their hydrolysates with pepsin, Neutrase and alcalase, reduced the production of IgG1 
by LPS-stimulated spleen cells, although the lowest levels, which were in turn significantly 
different from those produced by the intact proteins, were induced by the hydrolysates of OVA, 
LYS and OM with alcalase (Fig. 4.1.5a). Likewise, these hydrolysates, as well as that of LYS 
with pepsin, reduced IgG1 secretion from MLN cells (Fig. 4.1.5b). Incubation of spleen and 
MLN cell cultures with the egg white proteins and their hydrolysates also decreased the LPS-
induced secretion of IgG2a, although, in this case, there were no significant differences between 
them (not shown). 
The inhibiting effect of the hydrolysates produced by alcalase and that of LYS with 
pepsin on IgG1 secretion by LPS-stimulated spleen and MNL cells (OA, LA, MA and LP, Fig. 
4.1.5) is consistent with the reduction observed in the secretion of Th2-related cytokines by the 
cells stimulated with ConA in the presence of these hydrolysates, indicated above (Fig. 4.1.3c). 
In addition, these hydrolysates also significantly decreased LPS-induced splenocyte 
proliferation (OA, LA, MA and LP; Table 4.1.2). Furthermore, while, in general terms, all the 
hydrolysates inhibited ROS generation in t-BOOH-stimulated spleen and MLN cells, the 
highest antioxidant activity corresponded to those produced by alcalase (Fig. 4.1.6). The 
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inactivated enzymes did not affect the proliferation or the production of IgG1 and ROS by LPS-
stimulated spleen cells (Fig. 4.1.7). 
When the mean values of the effects exerted by the highest concentration (200 g/mL) 
of hydrolysates with pepsin, Neutrase and alcalase on cytokine and antibody secretion, 
oxidative stress and cell proliferation were compared, the hydrolysates of egg white proteins 
with alcalase differed from the hydrolysates with Neutrase (P < 0.05) by virtue of their 
decreasing effects on the production of TNF- IL-13, IgG1 in MLN, and ROS in splenocytes 
and MLN cells (Table 4.1.3). 
 
Figure 4.1.5. Effect of OVA (O), LYS (L), OM (M), EW (E) and their hydrolysates produced with pepsin 
(P), Neutrase (N), and alcalase (A) (200 μg/mL) on LPS-induced secretion of IgG1 by mouse splenocytes 
(a), and MLNs cells (b). Data are means ± SD of triplicates. * P < 0.05 compared to the LPS-stimulated 
control. • P < 0.05 compared to the respective intact protein.  
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Figure 4.1.6. Effect of OVA (O), LYS (L), OM (M), EW (E) and their hydrolysates produced with pepsin 
(P), Neutrase (N) and alcalase (A) (200 μg/mL) on t-BOOH-induced intracellular ROS generation by 
LPS-stimulated mouse splenocytes (a), and MLN cells (b). Data are expressed as percentage of the LPS-
stimulated control ± SD of triplicates. * P < 0.05 compared to the LPS-stimulated control. • P < 0.05 
compared to the respective intact protein.  
 
 
Figure 4.1.7. Effects of inactivated pepsin (P), Neutrase (N) and alcalase (A), at a concentration 
equivalent to that present in 200 μg/mL of the hydrolysates, on the LPS-induced proliferation (a), 
intracellular ROS generation (b) and secretion of IgG1 (c) by mouse splenocytes. Data are means ± SD of 
duplicates. * P < 0.05 compared to the LPS-stimulated control.  
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Table 4.1.3. Mean values of the effects of 200 g/mL of the hydrolysates of OVA, LYS, OM and EW 
produced with pepsin, Neutrase and alcalase on cytokine and antibody secretion, ROS production and cell 
proliferation by splenocytes and MLN cells stimulated with ConA or LPS. In order to examine the 
influence of the enzyme used to produce the hydrolysates, one-way ANOVA was used, followed by the 
Fisher’s Least Significant Difference test. 
Parameter Pepsin Neutrase Alcalase 
IFN-γ 56414.75 52525.75 55885.75 
TNF-α 969.25ab 1148.00a 876.50b 
IL-13 3412.00
a 3530.75a 2446.75b 
IL-10 4929.25 6035.00 5264.25 
IgG1 produced by splenocytes 14330.00 13361.50 12296.25 
IgG1 produced by NLM cells 1545.50
ab 1772.75a 1242.00b 
IgG2a produced by splenocytes 418.50 457.50 354.75 
IgG2a produced by NLM cells 80.50 81.25 76.75 
ROS produced by splenocytes 65.16
a 68.82a 51.45b 
ROS produced by MLN cells 67.35
b 72.21a 54.32c 
Proliferation induced by ConA 70.85
a 66.58b 68.51ab 
Proliferation  induced by LPS 26.50 28.09 25.53 
a-b Different letters indicate significant differences (P < 0.05) within rows. 
4.1.2. Discussion 
This study shows that peptides released by enzymatic hydrolysis of egg white proteins 
can modulate the immune responses of murine cells to mitogen stimuli in different ways, 
revealing potential activities that could be used for different purposes as Th1- or Th2-skewing 
mediators. Considering the traditional division of the role of Th1 and Th2 responses in cell-
mediated and antibody-mediated immune reactions, Th1-type immune activation involves the 
secretion of IFN-, which acts as an inductor of anti-microbial and anti-tumour defence 
mechanisms through the production of pro-inflammatory cytokines and cytotoxic ROS by 
effector cells; while Th2-type cells synthetize cytokines that help B lymphocytes to develop into 
certain types of IgG and IgE antibody producing cells. Both types of T cells, with the 
contribution of other T lymphocyte subsets, such as Th17 and T reg cells, cross-regulate each 
other, so that an imbalanced response leads to oxidative stress and abnormally amplified 
inflammatory signals, or to food allergy and asthma (Soyer et al., 2013; Becker et al., 2014). 
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The hydrolysates exerted effects different from those of the intact proteins from which 
they derived, with OVA stimulating mainly Th1 cytokines (TNF-), LYS and OM inhibiting 
the release of both Th1 and Th2 cytokines (TNF-, IL-13 and IL-10), and EW mainly inhibiting 
Th2 mediators (IL-13 and IL-10). The hydrolysates of OVA and LYS with alcalase reduced 
ConA- and LPS-stimulated murine lymphocyte proliferation, production of Th2-biased 
cytokines, such as IL-13 and IL-10, and, at low concentrations, also decreased the secretion of 
the Th1 cytokine TNF-. In agreement with these observations, these hydrolysates considerably 
inhibited IgG1-class switching induced by LPS, which is part of the IL-4-mediated Th2 
response, and counteracted the release of ROS induced by an oxidant agent such as t-BOOH. 
Likewise, the hydrolysate of EW with alcalase decreased ConA-induced proliferation, as well as 
both Th1 (TNF-) and Th2 (IL-13, IL-10) responses and ROS generation in spleen and MNL 
cells challenged with t-BOOH, an effect similar to that exerted by the hydrolysate of LYS with 
pepsin that can be interpreted as immunosuppressive. In contrast, the hydrolysates of OVA, 
LYS and EW with Neutrase also decreased the proliferative response to ConA, but increased the 
level of TNF- leading to less pronounced antioxidant effects.  
It is noteworthy that the most potent immunomodulating hydrolysates in this 
experimental system, those produced by Neutrase and alcalase, suppressed the mitogen-induced 
proliferation of lymphocytes even if they exerted distinct effects on the cytokines released. 
Unlike our results, other studies reported that single food peptides (Jiehui et al., 2014) or food 
protein hydrolysates (Mao et al., 2007; Saint-Sauveur et al., 2008; Yang et al., 2009a; Hou et 
al., 2012; Chalamaiah et al., 2014) promoted lymphocyte proliferation induced by ConA, which 
was interpreted as a stimulatory effect on cell-mediated immunity. However, those reports 
assessed cell viability, the number of healthy cells in a sample, rather than cell proliferation, that 
is, the number of dividing cells. In fact, the hydrolysates of egg white proteins assayed did not 
change the number of viable cells (which allows discarding possible toxic effects); despite they 
decreased mitogen-induced proliferation as part of their immunoregulating role. In the cells 
treated with the hydrolysates produced by alcalase, reduced cytokine and antibody secretion 
Hydrolysates of egg white proteins modulate T and B cell responses in mitogen-stimulated murine cells 
94 
 
followed the pattern of T cell proliferation, whereas in the case of those produced by Neutrase, 
it cannot be excluded that the enzyme preparation itself exerted an immunostimulating effect, as 
judged by the increased release of TNF- and IL-10, which would have masked the influence of 
the peptides. 
The existence of egg white protein-derived antioxidant peptides with radical scavenging 
activities, or able to inhibit low density lipoprotein oxidation and ameliorate the blood lipid 
profile and the oxidative status in vivo has already been described (Dávalos et al., 2004; Manso 
et al., 2008; Huang et al., 2010; You et al., 2010). However, while it is recognized that 
antioxidants, such as polyphenols or omega-3 fatty acids, can improve the immune function, to 
the best of our knowledge, there are no previous reports on the capacity of egg proteins 
hydrolysates to modulate the immune response in murine cell cultures. Furthermore, while the 
potential immunomodulating use of peptides has traditionally focused on their ability to prevent 
and repair the damage caused by oxidative stress and inflammatory reactions (Duarte et al., 
2006; Nelson et al., 2007; Phelan et al., 2009; Vernaza et al., 2012; Fernández-Tomé et al., 
2014; Mallet  et al., 2014) by enhancing Th2-type responses (Vinderola et al., 2005; Duarte et 
al., 2006; Nelson et al., 2007; Yang et al., 2009a; Jiehui et al., 2014), or to stimulate the 
secretion of Th1 cytokines without an effect on the release of Th2 cytokines and, thus, to play a 
role in fighting infections (Saint-Sauveur et al., 2008; Phelan et al., 2009); the present results 
suggest that other uses are possible. Thus, the hydrolysates produced with alcalase, able to 
combine Th2-supresive properties with a remarkable antioxidant capacity, could be of interest 
as immunotherapeutic approaches against excessive Th2 responses and inflammatory 
conditions, such as those typical of food allergies (Soyer et al., 2013). 
Even if it is now well known that, in addition to Th2-cytokine producing T cells and 
antibody-producing B cells, other cells of the innate and adaptive immunity play a role in the 
induction and regulation of the inflammatory processes that drive the development of allergy, 
the in vitro model system used appeared useful to evaluate the immunomodulating and 
antioxidant properties of the egg white protein hydrolysates and to discriminate between the 
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impact of those produced with various enzymes on effector lymphocyte activation. It is well 
documented that hydrolysates of the same protein produced with different enzymes differ in the 
immunological response they generate in cultured cells (Phelan et al., 2009; Chalamaiah et al., 
2014); even though, due to the complex peptide composition of most food protein hydrolysates, 
it is expected that they would exert multiple effects through different mechanisms 
(Samaranayaka and Li-Chan, 2011). As compared to the hydrolysates produced by pepsin and 
Neutrase, those produced by alcalase did not show distinct features regarding their RP-HPLC 
profile, albeit they had a smaller molecular mass distribution. We then decided to conduct 
further studies to correlate particular physicochemical characteristics with the 
immunomodulatory properties of egg white protein-derived peptides, as well as to further 
validate these results in more sophisticated in vitro models. 
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Among the features of food proteins that play a role in their capacity to induce an 
allergic response, it is recognized their ability to promote the differentiation and expansion of 
Th2 cells that secrete IL-4, IL-5 and IL-13, favouring Th2 rather than Th1 immunity (Berin and 
Shreffler, 2008). Accordingly, immunomodulating peptides that lack IL-4 inducing capacity but 
hold IFN-γ stimulating properties, able to re-establish the Th1/Th2 balance, stand as an 
interesting option for allergy prevention and treatment (Yang et al., 2010; Wei et al., 2016). 
Nevertheless, despite the apparent opposite effects of Th2 and Th1 immunity, there are 
examples of antioxidant and anti-inflammatory compounds that decrease the effects mediated 
by IFN-γ and the intracellular pathways that accelerate the generation of ROS (Zaknun et al., 
2012), but also reduce the expression of Th2 cytokines and IgE levels in response to food 
allergens in mice (Yano et al., 2007; Zuercher et al., 2010; Masilamani et al., 2011). In this 
respect, previous results (section 4.1) showed that certain enzymatic hydrolysates of egg white 
proteins could not only inhibit the release of Th2- (IL-13) and Th1-cytokines (TNF-α), but also 
reduce the production of IgG1 and the generation of ROS in unspecifically stimulated murine 
cells. 
With the aim to go further in the evaluation of the anti-allergenic potential of the egg 
white protein hydrolysates we assessed their ability to deviate the unbalanced immune status 
representative of food allergy. Thus, the immunomodulating potential of the hydrolysates was 
estimated as their ability to hinder, on the one hand, cytokine and IgE production by Th2-
skewed human PBMCs and, on the other hand, the release of pro-inflammatory factors and ROS 
generation from PBLs subjected to a Th1 stimulus (Fig. 4.2.1). The binding to IgE of egg 
allergic patients was determined and the peptides present in the hydrolysates were identified, as 
a contribution to the characterization of hydrolysates that combine the ability to stimulate T 
lymphocytes and modulate the immune response with a reduced capacity to bind IgE and, 
eventually, trigger clinical symptoms. 
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Figure 4.2.1. Scheme of the experimental procedure followed in section 4.2. ESI-MS/MS, electrospray 
ionization mass/mass; LPS, lipopolysaccharide; LYS, lysozyme; MTT, method based on 3-[4,5-
dimethylthiazol-2-yl]-2-,5-diphenyltetrazoliumbromide; OM, ovomucoid; OVA, ovalbumin; PBLs, 
peripheral blood leukocytes; PBMCs, peripheral blood mononuclear cells; ROS, reactive oxygen species; 
Th, T-helper cell. 
4.2.1. Results 
4.2.1.1. The hydrolysates of egg white proteins with pepsin and alcalase inhibit the release of 
Th2 cytokines and IgE from Th2-primed PBMCs  
PBMCs form 6 non-allergic donors, previously selected from a total of 8 volunteers on 
the basis of a positive induction of Th2 cytokines (IL-5 and IL-13) with anti-CD40 and IL-4, 
released IL-13 (187.05 ± 53.42 pg/mL), IL-5 (78.16 ± 19.24 pg/mL), IFN-γ (125.41 ± 25.63 
pg/mL) and IL-10 (69.36 ± 10.21 pg/mL), following culture with these molecules for 3 days. 
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Levels of IL-13, IL-5 and IL-10 were significantly (P < 0.05) higher than those corresponding to 
the cells cultured with IMDM alone (60.95 ± 29.17, 7.55 ± 4.50 and 17.32 ± 10.87 pg/mL, 
respectively), while those of IFN-γ were significantly lower (IMDM: 296.80 ± 24.84 pg/mL), 
thus reflecting a shift to an augmented Th2/Th1 cytokine profile. In view of the variability of 
the results, the cytokine levels were normalized to those induced by anti-CD40 and IL-4 in each 
of the 6 selected donors (100%). As shown in Fig. 4.2.2, stimulation with LPS significantly 
down regulated the production of Th2 cytokines (IL-13 and IL-5), and up regulated the release 
of the Th1 cytokine IFN-γ and that of IL-10.  
The hydrolysates of OVA and OM with pepsin and alcalase exerted a dose-dependent 
inhibition of the release of IL-13 and IL-5 induced by previous anti-CD40 and IL-4 
conditioning, which was significant, particularly at the highest doses (Figs. 4.2.2a and b). 
Likewise, stimulation with the hydrolysate of LYS with alcalase significantly reduced the levels 
of IL-13 and IL-5 in a dose-dependent manner, although it should be noted that intact LYS also 
produced a Th2-inhibitory effect similar to that exerted by this hydrolysate. The hydrolysates of 
egg white proteins with alcalase did not significantly change the secretion of the Th1 cytokine 
IFN-γ, except for the hydrolysate of LYS with alcalase at 100 µg/mL; while the hydrolysates of 
OVA, LYS and OM with pepsin at 100 and 200 μg/mL stimulated the release of IFN-γ (Fig. 
4.2.2c). 
Conversely, the hydrolysates of OVA and OM with Neutrase increased IL-13 and IL-5 
and that of LYS with Neutrase increased IL-13 (Figs. 4.2.2a and b). In general terms, these 
hydrolysates also stimulated the production of IFN-γ (Fig. 4.2.2c) and, therefore, they could be 
regarded as inducers of both Th2 and Th1 responses. Furthermore, the production of IL-10 was 
significantly enhanced by the hydrolysates of OVA, LYS and OM with Neutrase at the highest 
concentration (200 µg/mL). 
Conditioning of PBMCs with anti-CD40 and IL-4 induced cells to produce IgE. As 
shown in Fig. 4.2.3, incubation with LPS and with the hydrolysates of OVA and OM with  
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Figure 4.2.2. Effects of different concentrations (20, 100 and 200 µg/mL) of OVA (O), LYS (L), OM 
(M), and their hydrolysates with pepsin (P), Neutrase (N) and alcalase (A), as well as the inactivated 
enzymes (IE) at a concentration equivalent to that present in 200 μg/mL of the hydrolysates, on the 
secretion of IL-13 (a), IL-5 (b), IFN-γ (c) and IL-10 (d) by Th2-skewed PBMCs. Data are expressed as 
percentage of the values induced by anti-CD40 and IL-4 ± SEM in 6 donors stimulated in triplicate and * 
indicates significant differences (P < 0.05) compared to this control (100%). 
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pepsin and OVA, LYS and OM with alcalase, that resulted in reduced secretion of IL-5 and IL-
13 (Figs. 4.2.2a and b), also inhibited IgE production by primed B cells. Of note is the 
observation that the hydrolysates of LYS with pepsin enhanced the production of IgE, while 
those of egg white proteins with Neutrase did not change it, despite, in general terms, they 
increased Th2 cytokines.  
The inactivated enzymes did not have any impact on cytokine or IgE secretion, except 
for Neutrase, which inhibited IL-13 and IL-5 production by 20 and 33%, respectively (Figs. 
4.2.2 and 4.2.3). On the other hand, the MTT assay, carried out in order to assess the 
cytotoxicity of the stimulation with anti-CD40 and IL-4, as well as that of the proteins and their 
hydrolysates at a concentration of 200 µg/mL, allowed discarding significant effects on cell 
viability (Fig 4.2.4).  
 
 
Figure 4.2.3. Effects of different concentrations (20, 100 and 200 µg/mL) of OVA (O), LYS (L), OM 
(M), and their hydrolysates with pepsin (P), Neutrase (N) and alcalase (A), as well as the inactivated 
enzymes (IE) at a concentration equivalent to that present in 200 µg/mL of the hydrolysates, on the 
secretion of IgE by Th2-skewed PBMCs. Data are expressed as percentage of the values induced by anti-
CD40 and IL-4 ± SEM in 6 donors stimulated in triplicate and * indicates significant differences (P < 
0.05) compared to this control (100%). 
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Figure 4.2.4. Effects of OVA (O), LYS (L), OM (O), their hydrolysates with pepsin (P), Neutrase (N) 
and Alcalase (A) (200 μg/mL), and the inactivated enzymes (IE) at a concentration equivalent to that 
present in 200 μg/mL of the hydrolysates, on cell viability, determined by the MTT method, of Th2-
skewed PBMCs (a) and non-stimulated PBLs (b). Data are expressed as percentage of the values induced 
by IL-4 and anti-CD40 (a) or of the non-stimulated cells (b) ± SEM.   * indicates significant differences 
(P < 0.05) compared to their respective controls (100%). 
4.2.1.2. The hydrolysates of egg white proteins with pepsin inhibit the release of pro-
inflammatory mediators and the hydrolysates with alcalase hinder ROS generation from Th1-
primed PBLs  
PBLs from 8 donors were previously selected from a total of 10 volunteers on the basis 
of a positive induction of an inflammatory response on stimulation with LPS and IFN-γ, which 
was characterized by the release of mediators such as TNF-α (1048.23 ± 495.12 vs 14.59 ± 8.26 
pg/mL in RPMI incubated cells, P < 0.05) and IL-8 (38467.95 ± 9479.32 vs 986.11 ± 321.86 
pg/mL in RPMI incubated cells, P < 0.05). 
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As shown in Fig. 4.2.5, OVA increased the production of TNF-α and IL-8, while the 
hydrolysates of LYS and OM with pepsin reduced the secretion of TNF-α; and those of OVA, 
LYS and OM with pepsin, and LYS with alcalase, reduced the secretion of IL-8 (Figs. 4.2.5a 
and b). In addition and, in general terms, the hydrolysates of the three proteins with pepsin and 
alcalase neutralized ROS generation by t-BOOH (Fig. 4.2.5c). Inactivated pepsin and alcalase 
did not affect the production of cytokines or ROS, but Neutrase significantly stimulated the 
release of TNF-α and IL-8 (Fig. 4.2.5). Cytotoxicity assessment with MTT did not reveal any 
significant adverse effects of LPS or the hydrolysates at the highest concentration (200 µg/mL) 
on PBLs viability (Fig. 4.2.4).  
Since most antioxidant peptides derived from food sources have molecular mass from 
0.5 to 1.8 kDa (Samaranayaka and Li-Chan, 2011), and considering that the best results, in 
terms of inhibition of the release of pro-inflammatory mediators and oxidative stress in PBLs, 
were obtained in the cells treated with the hydrolysates of the three egg white proteins with 
pepsin and alcalase, these were fractionated to assess the contribution of peptides with 
molecular mass lower than 10 and 3 kDa. The results obtained (Figs. 4.2.5d, e and f) suggest 
that, in general terms, small peptides were responsible for the anti-inflammatory and antioxidant 
effects observed. The fractions of OVA and LYS with pepsin decreased the secretion of TNF-α 
by, approximately, 50% (Fig. 4.2.5d) and, overall, the reduction in the generation of IL-8 and 
ROS was more marked when cells were incubated with the fractions as compared with the 
complete hydrolysates (Figs. 4.2.5e and f). However, the fractions derived from the 
hydrolysates of OM with pepsin exerted a less pronounced effect on all the parameters 
measured.  
4.2.1.3. The hydrolysates with pepsin and Neutrase are recognized by human IgE and contain 
IgE-binding epitopes 
We next examined the binding of the hydrolysates to IgE from sera of egg allergic 
patients (Table 4.2.1). The highest IgE-binding corresponded to OVA, followed by LYS and  
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Figure 4.2.5. Effects of OVA (O), LYS (L), OM (M), their hydrolysates with pepsin (P), Neutrase (N) 
and alcalase (A) (200 µg/mL), the inactivated enzymes (IE) at a concentration equivalent to that present 
in 200 µg/mL of the hydrolysates, and the fractions with molecular mass lower than 10 and 3 kDa on  the 
secretion of TNF-α (a, d) and IL-8 (b, e), and intracellular ROS generation (c, f) by Th1-skewed PBLs. 
Data are expressed as percentage of the values induced by IFN-γ and LPS ± SEM in 8 donors stimulated 
in triplicate and * indicates significant differences (P < 0.05) compared to this control (100%). 
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OM. The hydrolysates of OVA, LYS and OM with pepsin maintained, respectively, 10, 41 and 
14% of the original IgE-binding and that of OVA with Neutrase, 30%. The IgE binding of the 
hydrolysates of OVA with alcalase and LYS and OM with Neutrase and alcalase was negligible. 
RP-HPLC ruled out the existence of intact protein that could account for the residual IgE-
binding of the hydrolysates (Fig. 4.1.2).  
Table 4.2.1. Binding to IgE from sera of egg allergic patients of OVA (O), LYS (L), OM (M) and their 
hydrolysates with pepsin (P), Neutrase (N) and alcalase (A). Results are means of, at least, 3 independent 
experiments and are expressed as EC50, that is, the effective sample concentration (µg/mL) for 50% of 
the maximum binding to IgE.  
 
 EC50 (µg/mL) 
O 2.83 ± 0.23a 
OP 28.57 ± 0.50a 
ON 9.43 ± 0.81a 
OA 2113.5 ± 70.00b 
L 12.81 ± 2.81a 
LP 27.80 ± 0.05a 
LN 1850.00 ± 60.36b 
LA 851.12 ± 31.32c 
M 14.62 ± 0.27a 
MP 193.93 ± 19.73b 
MN 3070.51 ± 75.85c 
MA 2295.34 ± 36.95d 
a-d Different superscripts indicate significant differences (P < 0.05) for each protein (O, L or M). 
The peptides present in the hydrolysates of OVA, LYS and OM were identified by RP-
HPLC-MS/MS (Figs. 4.2.6, 4.2.7 and 4.2.8, respectively). In the hydrolysates of OVA with 
pepsin, Neutrase and alcalase, 140, 104 and 109 peptides were identified, respectively (Fig. 
4.2.6). The hydrolysate of OVA with pepsin only had 11 peptides in common with the 
hydrolysate with Neutrase, and 12 with the hydrolysate with alcalase, while the hydrolysates 
with Neutrase and alcalase shared 10 common sequences. Several of the peptides identified in 
the hydrolysates of OVA with pepsin and Neutrase are comprised within previously described 
high frequency IgE-binding areas of the protein, such as 125-176, 188-198, 326-336 and 370-
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385 (Benedé et al., 2014), which could explain their residual IgE-binding. Of note is the 
observation that the hydrolysate of OVA with pepsin contained peptides with free radical-
scavenging properties, such as YRGGLRPINF, YQIGL, FRADHPFL and RADHPFL [OVA 
(125-134), OVA (212-216), OVA (358-365) and OVA (359-365)] (Dávalos et al., 2004). 
FRADHPFL was also found the hydrolysate of OVA with Neutrase and RADHPFL in the 
hydrolysate of OVA with alcalase.  
In the hydrolysates of LYS with pepsin, Neutrase and alcalase, we identified 96, 95 and 
107 peptides, respectively, that covered the whole LYS sequence, with only 5-8 peptides in 
common among the different hydrolysates (Fig. 4.2.7). As compared with the hydrolysates with 
Neutrase and alcalase, the hydrolysate of LYS with pepsin contained larger peptides within the 
reported IgE-binding areas: 11-27, 57-83 and 108-122 (Jiménez-Saiz et al., 2014). Furthermore, 
many of the fragments had sulfhydryl groups, and since RP-HPLC-MS/MS analyses were 
performed in the presence of a reducing agent (DTT) to aid identification, it is likely that 
disulphide-linked fragments contributed to the IgE-binding. Finally, several peptides in the 
hydrolysate of LYS with alcalase matched sequences previously identified in radical-scavenging 
fractions, such as KRHGLDNYRGY, KRHGLDNY, HGLDNY, and GLDNYRGY [LYS (13-
23), LYS (13-20), LYS (15-20) and LYS (16-23)] (You et al., 2010). The hydrolysate of LYS 
with Neutrase contained the defence peptide IVSDGNGMNAW [LYS (98-108)] (Mine et al., 
2004). 
In the hydrolysates of OM with pepsin, Neutrase and alcalase, 84, 89 and 86 peptides 
were identified, respectively, after disulphide bond reduction with DTT, with very few common 
sequences (3-5 peptides) (Fig. 4.2.8). There are numerous IgE-binding epitopes distributed 
along the OM structure and also many differences in epitope recognition among different egg 
allergic patients (Järvinen et al., 2007). The observation that, comparatively, longer peptides 
were found in the hydrolysate of OM with pepsin and that some of them could be linked by 
disulphide bonds indicates that they could give rise to longer IgE-binding sequences and thus, 
result in a higher recognition by human IgE. 
  
 
 
Figure 4.2.6. . Peptide sequences, identified by RP-HPLC-MS/MS in the hydrolysates of OVA with pepsin (light grey), Neutrase (white) and alcalase (dark grey). ▼: Carbohydrate chain. : Disulphide bond. 
  
 
 
Figure 4.2.7. . Peptide sequences, identified by RP-HPLC-MS/MS in the hydrolysates of LYS with pepsin (light grey), Neutrase (white) and alcalase (dark grey). : Disulphide bond. 
  
 
 
Figure 4.2.8. . Peptide sequences, identified by RP-HPLC-MS/MS in the hydrolysates of OM with pepsin (light grey), Neutrase (white) and alcalase (dark grey). ▼: Carbohydrate chain. : Disulphide bond. 
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4.2.2. Discussion 
Following a validated non-antigen specific model (Holvoet et al., 2013), a Th2-skewed 
cytokine profile was induced in human PBMCs from non-allergic donors. Incubation with anti-
CD40 and IL-4 led to the production of IL-13, IL-5 and IL-10, and reduced the secretion of 
IFN-γ in most, but not all, of the donors assayed, and at different concentrations. Similarly, 
Holvoet et al. reported that the levels of IL-5 were highly donor dependent, although, unlike our 
results, these authors did not find either IFN-γ or IL-10 production after incubation with IMDM 
or with anti-CD40 and IL-4 (Holvoet et al., 2013). PBMCs conditioned with anti-CD40 and IL-
4 not only imitate allergen-specific cells in the cytokine profile, but also in the secretion of IgE 
antibodies, because anti-CD40 induces the proliferation of resting B cells and IL-4 co-stimulates 
anti-CD40 B cell-activation and production of IgE (Rousset et al., 1991). As expected, culture 
with LPS reduced the secretion of IL-13 and IL-5 and increased that of IFN-γ, while it also 
inhibited the release of IgE. Therefore, it redirected the Th2 state in this cell model (Holvoet et 
al., 2013).  
The hydrolysates of egg white proteins with alcalase effectively down-regulated the 
production of Th2 cytokines and the secretion of IgE to the culture media of Th2-skewed 
PBMCs. The hydrolysates with pepsin produced a similar effect, with the exception of the 
hydrolysate of LYS with pepsin, which did not reduce IL-5 and IL-13 production and enhanced 
the secretion of IgE. It has been demonstrated that the inhibition of IgE production by plasma 
cells exerted in vitro by anti-inflammatory substances correlates in vivo (in a mouse model of 
peanut allergy) with suppression of IgE and decreased adverse reactions and plasma histamine 
levels (López-Expósito et al., 2011). Therefore, protein hydrolysates with the ability to prevent 
IgE secretion by B cells might impair the availability of this antibody for participation in mass 
cell activation, offering protection against the development of anaphylactic symptoms. 
Our results show that the hydrolysates of OVA, LYS and OM with alcalase combined in 
vitro neutralization of an excessive Th2 response and reduction of IgE secretion with a low 
Hydrolysates of egg white proteins regulate exacerbated immune responses in human cells in vitro 
114 
 
grade cytokine-stimulating role, which may correlate with an anti-allergic protection in vivo due 
to a homeostatic effect (Holvoet et al., 2013). On the other hand, the hydrolysates of OVA and 
OM with pepsin helped to re-establish the Th1/Th2 balance in the Th2-skewed cells, as they 
simultaneously decreased the production of IL-5 and IL-13 and increased that of IFN-γ. It 
should be noted that both the inhibition of allergen-induced Th1 and Th2 cytokine responses 
(Yang et al., 2009b), as well as the promotion of Th1-biased responses to a detriment of Th2 
ones (Yang et al., 2010), have been associated to the therapeutic effects of egg white peptides in 
mouse models of allergy. 
We next evaluated the anti-inflammatory and antioxidant properties of the hydrolysates 
on cells of the peripheral blood. For this purpose, we used PBLs, that contain, in addition to 
lymphocytes and monocytes (PBMCs), polymorphonuclear cells, which participate, together 
with macrophages, in the initiation and progression of inflammatory processes once being 
recruited to the required sites (Barnes, 2011). In order to induce inflammatory responses, PBLs 
were stimulated with LPS and IFN-γ, which, in agreement with previous results, led to the 
production of TNF-α and IL-8 (Richard et al., 2005). The hydrolysates of LYS and OM with 
pepsin inhibited the release of TNF-α and IL-8 in PBLs treated with inflammatory stimuli and 
also reduced oxidative stress in cells in which ROS generation was induced by t-BOOH 
treatment. This suggests their potential to counteract the inflammatory damage that may arise in 
response to allergic injuries. In turn, the hydrolysates of OVA, LYS and OM with alcalase did 
not avoid the release of pro-inflammatory mediators, but significantly neutralized the oxidative 
stress induced by t-BOOH. It is likely that, in these hydrolysates, except in that of OM with 
pepsin, peptides with molecular mass lower than 10 kDa were responsible for the anti-
inflammatory and antioxidant effects observed. Pepsin digestion of OM gives rise to large 
fragments linked by disulphide bonds (Benedé et al., 2013) and, therefore, the content of free 
low molecular mass peptides in this hydrolysate is probably small.  
Due to the cross-regulatory interaction between Th1 and Th2 immunity, it is 
hypothesized that the suppression of Th1 responses by antioxidant compounds, while beneficial 
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in reducing the side effects of the inflammatory processes, may lead to an up-regulation of Th2-
type cytokines that promotes allergic sensitization and exacerbates allergic symptoms (Zaknun 
et al., 2012). However, in our experiments, we did not observe an inverse regulation of cytokine 
production in the Th2- and Th1-skewed cell models. The hydrolysates of OVA and OM with 
pepsin and the hydrolysates of OVA, LYS and OM with alcalase concurrently down-regulated 
features characteristic of exacerbated Th2 and Th1 responses, which suggests their potential for 
allergy treatment. Conversely, the hydrolysates of OVA, LYS and OM with Neutrase tended to 
promote both Th2 and Th1 activation in the Th2-skewed model and they could not attenuate the 
induction of inflammatory mediators in the Th1-skewed model. In any case, it cannot be 
excluded that the heat-inactivated Neutrase preparation exerted an immunomodulating effect 
that would have biased the influence of the egg white protein derived peptides, particularly on 
the Th1-primed cells. 
The results obtained in these in vitro model systems based on human peripheral blood 
cells artificially skewed towards exacerbated Th2 and Th1 responses basically agree with those 
obtained in mitogen stimulated murine lymphocytes (section 4.1) in the case of the hydrolysates 
produced with alcalase and Neutrase, but not in the case of those produced with pepsin. Overall, 
the present cell models allowed a more precise estimation of the influence of the hydrolysates 
on the cytokine profiles that modulate allergic responses with the use of accessible human cells. 
It should be mentioned that, probably because of the low frequency of allergen-specific T cells, 
previous attempts to assess the immunomodulatory effects of egg proteins on PBMCs from egg 
allergic patients were unsuccessful due to the lack of sufficient stimulation leading to cytokine 
and antibody secretion (results not shown). In this respect, it is worth noting that, although 
allergen-specific T cell lines have been used to overcome the frequency limitation, in vitro 
expansion can alter cell phenotypes or bias the results through the selection of the rapidly 
proliferating clones (Pascal et al., 2013). 
IgE-binding was comparatively higher in the hydrolysates with pepsin (as well as in the 
hydrolysate of OVA with Neutrase), which was related to the length of the peptides formed and 
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the existence of disulphide linked fragments that could carry bivalent epitopes. The low IgE-
binding of the hydrolysates with alcalase could be attributed to the fact that they contained short 
peptides, with molecular masses lower than 1.5 kDa. Pepsin digestion has already been shown 
to reduce the reactivity of IgE from human sera to egg white proteins, such as OVA (Benedé et 
al., 2014), LYS (Jiménez-Saiz et al., 2014), and OM (Benedé et al., 2013). Indeed, pepsin 
hydrolysis of fish and nut allergens effectively down-regulates the allergic responses they cause 
in sensitized humans and mice (Untersmayr et al., 2007; Kulis et al., 2012). The results 
presented in this section show that the hydrolysates of OVA and OM with pepsin modulated 
Th2 cytokines and IgE secretion, while attenuating inflammatory responses. Comparatively, the 
hydrolysates of OVA, LYS and OM with alcalase also equilibrated Th2 differentiation 
efficiently, but exhibited a more reduced IgE-binding. Therefore, it can be hypothesized that 
these hydrolysates would elicit milder allergic reactions while retaining T cell-stimulating 
abilities, which might correlate with an anti-allergic benefit. 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
4.3. Hypoallergenic hydrolysates 
re-equilibrate egg white allergen 
responses induced ex vivo in cells 
from sensitized mice 
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The results obtained so far (sections 4.1 and 4.2) showed that the hydrolysates of OVA 
and OM with pepsin helped to re-establish the Th1/Th2 balance in Th2-biased PBMCs, while 
they also inhibited the release of pro-inflammatory mediators and reduced oxidative stress in 
PBLs treated with inflammatory stimuli. In turn, the hydrolysates of OVA, LYS and OM with 
alcalase, inhibited Th2 differentiation and ROS generation in mitogen stimulated murine 
lymphocytes and peripheral blood cells treated, respectively, with Th2 or Th1-biasing 
mediators. In view of their potential to modulate different phases of the allergic response, we 
assessed the in vivo allergenicity of these hydrolysates by means of PCA tests, and explored the 
possibility that they could modulate cytokine responses to egg allergens ex vivo, using 
splenocytes from BALB/c mice sensitized to individual egg proteins or to their mixtures in 
different proportions (Fig. 4.3.1). Finally, the best candidate for peptide-based IT was 
fractionated, in order to enrich the immunostimulating and immunomodulating peptides, and the 
sequences contained in each fraction were identified by mass spectrometry in an attempt to 
correlate peptide structure and immunoregulatory function (Fig. 4.3.1). 
 
Figure 4.3.1. Scheme of the experimental procedure followed in section 4.3. ESI-MS/MS, electrospray 
ionization mass/mass; LYS, lysozyme; OM, ovomucoid; OVA, ovalbumin; PCA, passive cutaneous 
anaphylaxis assay; RP-HPLC, reverse phase high-performance liquid chromatography. 
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4.3.1. Results 
4.3.1.1. The hydrolysate of OVA with pepsin and the hydrolysates with alcalase do not elicit 
allergic responses in vivo 
The ability of the egg white hydrolysates to trigger cutaneous allergic reactions was 
assessed in vivo using PCA tests with sera of mice mono-sensitized to OVA, LYS or OM (Fig. 
4.3.2). Table 4.3.1 shows the concentrations of specific antibodies of the sera used for passive 
sensitization. Intravenous challenge of mice with the respective allergens caused a significant 
extravasation, as measured by the localized release of Evans blue into the tissues, in the ears 
injected with sera from sensitized mice compared with the control ears, injected with sera from 
naïve mice (Fig. 4.3.2). 
In contrast with the corresponding intact protein, dye extravasation was significantly 
lower in mice challenged with the hydrolysate of OVA with pepsin and with the hydrolysates 
produced with alcalase, which indicates a diminished eliciting capacity (Fig. 4.3.2). However, 
the hydrolysates of LYS and OM with pepsin caused, respectively, a local reaction similar or 
even higher than that of the allergenic protein from which they derive.  
 
Figure 4.3.2. Allergenicity of OVA (O), LYS (L), OM (M) and their hydrolysates with pepsin (P) and 
alcalase (A)  assessed by PCA assays. Allergen-specific dye extravasation was calculated by correcting 
the allergen or hydrolysate induced absorbance with the absorbance of the supernatant of the ear injected 
with pooled naïve sera. Data are expressed as means ± SEM. Different letters indicate statistically 
significant differences (P < 0.05). 
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Table 4.3.1. Levels of specific IgE and IgG1 antibodies against OVA, LYS and OM determined by 
ELISA in sera from mice individually sensitized to the respective egg white allergen and used for PCA 
assays.  
Sensitization Specific IgE (ng/mL) Specific IgG1 (ng/mL) 
Naïve 0.00 ± 0.00 0.00 ± 0.00 
OVA 1020.22 ± 192.98 10667.98 ± 2517.54 
LYS 54.04 ± 12.39  36566.83 ± 5567.85 
OM 869.48 ± 1146.33 29006.36 ± 1036.86 
 
4.3.1.2. The hydrolysates of OVA and LYS with pepsin and alcalase show a low Th2-
stimulating activity in spleen cells from sensitized mice 
Spleen cells from mice sensitized to OVA, LYS or OM were stimulated with the protein 
used in each case for sensitization and its hydrolysates with pepsin and alcalase at various 
concentrations. As expected, incubation with the sensitizing protein induced a significant dose-
dependent release of the Th2 cytokines IL-4 (Fig. 4.3.3a-c) and IL-5 (Fig. 4.3.4a-c). OVA and 
LYS, unlike OM, also increased the production of the Th1 cytokine TNF-α, although no clear 
dose-effect relationships were apparent (Fig. 4.3.5a-c). 
In general terms, hydrolysis of OVA and LYS with pepsin reduced their Th2-
stimulating capacity, while pepsin treatment did not affect the OM-induced secretion of IL-4 
and IL-5. Hydrolysis of OVA, LYS and OM with alcalase abrogated their ability to stimulate 
Th2 responses in spleen cells, yielding Th2 cytokine levels equivalent to those of the negative 
control (RPMI) (Figs. 4.3.3a-c and 4.3.4a-c). The hydrolysates of OVA with pepsin and 
alcalase, at the highest concentrations (150 and 200 µg/mL), enhanced the production of TNF-α 
by the splenocytes compared with the intact protein, whereas no major differences were found 
between LYS, OM and their hydrolysates regarding TNF-α secretion.  
Very similar results, concerning Th2 responses, were found in the splenocytes from 
mice poly-sensitized to the same amount of the three proteins, as well as in those from mice 
sensitized to EW (Figs. 4.3.3d-i and 4.3.4d-i). With respect to Th1 cytokines, the hydrolysates 
of OVA, LYS and OM induced a lower production of TNF-α by the splenocytes from EW-
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sensitized mice than the proteins from which they derive (Fig. 4.3.5d-i). To discard an 
immunostimulating influence of the inactivated enzymes, their effect on splenocytes from EW-
sensitized mice was evaluated at the maximum concentration used in the hydrolysates and no 
significant differences were observed in the production of the Th2 and Th1 cytokines studied as 
compared with the negative control (Table 4.3.2). 
 
Figure 4.3.3. Immunostimulating effects of different concentrations (from 10 to 200 μg/mL) of OVA (O), 
LYS (L), OM (M) and their hydrolysates with pepsin (P) and alcalase (A) on the secretion of IL-4 by 
splenocytes from mono-sensitized (a, b and c), poly-sensitized (d, e and f) and EW-sensitized (g, h and i) 
mice. Data are expressed as means ± SEM. Different letters indicate statistically significant differences  
(P < 0.05). 
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Table 4.3.2. Effects of inactivated pepsin and alcalase, at a concentration equivalent to that present in 200 
μg/mL of the hydrolysates, on the secretion of IL-4, IL-5, TNF-α and IFN-γ by splenocytes from EW-
sensitized mice. The secretion induced by EW is also shown for comparison. Data are expressed as means 
± SEM. Different letters indicate statistically significant differences (P < 0.05) for each cytokine.  
 RPMI Pepsin Alcalase EW 
IL-4 10.6 ± 0.5b 0.8 ± 1.3b 0.4 ± 0.7b 127.9 ± 13.0a 
IL-5 18.9 ± 2.7b 14.3 ± 2.3b 15.1 ± 3.3b 161.7 ± 6.0a 
TNF- 3.4 ± 0.3
b 7.1 ± 3.3b 4.3 ± 2.3b 118.1 ± 10.3a 
IFN- 17.2 ± 0.7
b 17.6 ± 25.8b 31.6 ± 54.2b 1777.4 ± 65.0a 
 
 
Figure 4.3.4. Immunostimulating effects of different concentrations (10, 50, 150 or 200 μg/mL) of OVA 
(O), LYS (L), OM (M) and their hydrolysates with pepsin (P) and alcalase (A) on the secretion of IL-5 by 
splenocytes from mono-sensitized (a, b and c), poly-sensitized (d, e and f) and EW-sensitized (g, h and i) 
mice. Data are expressed as means ± SEM. Different letters indicate statistically significant differences  
(P < 0.05). 
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Figure 4.3.5. Immunostimulating effects of different concentrations (from 10 to 200 μg/mL) of OVA (O), 
LYS (L), OM (M) and their hydrolysates with pepsin (P) and alcalase (A) on the secretion of TNF-α by 
splenocytes from mono-sensitized (a, b and c), poly-sensitized (d, e and f) and EW-sensitized (g, h and i) 
mice. Data are expressed as means ± SEM. Different letters indicate statistically significant differences  
(P < 0.05). 
Overall, our results indicate that the hydrolysates of OVA and LYS with pepsin and 
alcalase promoted a less pronounced ex vivo Th2 activation of spleen cells from sensitized mice 
than the respective intact proteins, with comparable outcomes in simple (mono-sensitized) and 
complex (poly-sensitized or EW-sensitized) models of egg allergy. This prompted us to 
investigate whether they could down-regulate the allergic responses induced by the allergens 
from which they derive. 
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4.3.1.3. The hydrolysate of OVA with pepsin re-equilibrates immune responses induced by 
egg allergens on spleen cells from sensitized mice 
In order to test whether the allergen-induced responses of immune cells from sensitized 
mice could be modulated by the hydrolysates, splenocytes were stimulated with the allergens 
used for sensitization in the presence of their corresponding hydrolysates at a concentration of 
200 μg/mL of each substance, and the impact on the secretion of Th2 and Th1 cytokines was 
determined. OVA-induced production of IL-4 and IL-5 was inhibited by co-incubation of spleen 
cells from both OVA-sensitized and poly-sensitized mice with the hydrolysates of OVA with 
pepsin and alcalase (P < 0.05, Table 4.3.3).  
Table 4.3.3. Immunomodulating effects of the hydrolysates of OVA (O), LYS (L) and OM (M) with 
pepsin (P) and alcalase (A). Splenocytes from mono- and poly-sensitized mice were stimulated with the 
allergen (200 μg/mL) in the absence or presence of the hydrolysates (200 μg/mL), and the secretion of IL-
4, IL-5 and TNF-α was evaluated. Data are expressed as means ± SEM. Different letters indicate 
statistically significant differences (P< 0.05) among each allergen and its hydrolysates for each cytokine 
and type of sensitization. 
 
Mono-sensitized mice Poly-sensitized mice (OVA+LYS+OM) 
 IL-4 IL-5 TNF-α IL-4 IL-5 TNF-α 
OVA 
OVA 
75.3 ± 2.2
a
 478.1 ± 10.9
a
 81.3 ± 6.6
c
 114.6 ± 0.6
a
 142.0 ± 5.8
a
 219.6 ± 4.1
a
 
OVA+OP 28.9 ± 2.1
c
 183.3 ± 9.5
b
 451.9 ± 11.6
a
 24.8 ± 0.6
b
 65.6 ± 3.4
b
 243.7 ± 16.2
a
 
OVA+OA 49.1 ± 2.4
b
 113.5 ± 1.4
c
 124.3 ± 3.4
b
 18.9 ± 3.5
b
 24.0 ± 1.8
c
 208.1 ± 19.0
a
 
LYS 
LYS 
133.6 ± 9.5
a
 493.3 ± 15.3
a
 83.0 ± 8.1
b
 39 ± 2.4
b
 92.3 ± 5.0
b
 106.9 ± 26.4
a
 
LYS+LP 165.3 ± 7.4
a
 389.9 ± 18.4
b
 162.7 ± 8.6
a
 54.5 ± 2.8
a
 121.1 ± 6.5
a
 120.4 ± 12.3
a
 
LYS+LA 161.5 ± 11.1
a
 352.7 ± 15.1
b
 151.0 ± 6.9
a
 35.9 ± 2.4
b
 109.1 ± 2.5
ab
 114.2 ± 7.9
a
 
OM 
OM 
41.2 ± 0.3
a
 59.0 ± 6.7
a
 92.1 ± 5.5
a
 23.2 ± 0.85
b
 37.8 ± 1.9
b
 14.3 ± 4.0
b
 
OM+MP 69.0 ± 12.1
a
 83.9 ± 2.3
a
 91.2 ± 8.2
a
 62.6 ± 11.3
a
 131.0 ± 8.8
a
 92.6 ± 7.5
a
 
OM+MA 54.5 ± 11.5
a
 83.7 ± 8.1
a
 79.8 ± 2.5
a
 16.0 ± 1.2
b
 33.7 ± 2.3
b
 15.8 ± 0.8
b
 
However, the hydrolysates of LYS only modestly reduced the secretion of IL-5 
stimulated by LYS in splenocytes from mice mono-sensitized to this protein. The hydrolysates 
of OM failed to impair the production of these cytokines, which even increased when the 
hydrolysate of OM with pepsin was present in the culture (P < 0.05), in the case of the poly-
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sensitized animals. On the other hand, the hydrolysates of OVA and LYS with both enzymes 
tended to promote the release of the Th1 cytokine TNF-α, when used together with the intact 
proteins for stimulation of the spleen cells from mono-sensitized mice (Table 4.3.3). 
In spleen cells from mice sensitized to EW, the hydrolysates of OVA, unlike those of 
LYS and OM, significantly reduced the EW-induced secretion of both IL-4 and IL-5 (the 
hydrolysate of LYS with pepsin also significantly decreased the release of IL-4). In addition, the 
hydrolysates of OVA and LYS with pepsin increased the production of TNF-α (Table 4.3.4).  
These results thus indicate that the hydrolysate of OVA with pepsin was able to bias allergen-
specific immune responses, helping to restore the Th1/Th2 balance. 
Table 4.3.4. Immunomodulating effects of the hydrolysates of OVA (O), LYS (L) and OM (M) with 
pepsin (P) and alcalase (A). Splenocytes from EW-sensitized mice were stimulated with EW (200 μg/mL) 
in the absence or presence of the hydrolysates (200 μg/mL), and the secretion of IL-4, IL-5, and TNF-α 
was evaluated. Data are expressed as means ± SEM. Different letters indicate statistically significant 
differences (P < 0.05) for each cytokine. 
 
EW-sensitized mice 
IL-4 IL-5 TNF-α 
EW 127.9 ± 13.0
a
 161.7 ± 6.0
a
 118.1  ± 10.3
bcd
 
EW+OP 59.1 ± 11.5
bc
 67.6 ± 13.8
c
 157.7 ± 6.9
a
 
EW+OA 35.6 ± 11.0
c
 18.1 ± 3.4
d
 107.9 ± 15.8
cd
 
EW+LP 104.7 ± 8.3
a
 123.2 ± 7.8
b
 148.6 ± 8.9
ab
 
EW+LA 94.8 ± 6.8
ab
 162.6 ± 2.6
a
 124.7 ± 8.3
a
 
EW+MP 115.9 ± 10.3
a
 130.6 ± 12.3
ab
 96.4 ± 2.2
dc
 
EW+LA 109.3 ± 4.2
a
 135.5 ± 1.5
ab
 83.4 ± 6.6
d
 
4.3.1.4. Chromatographically enriched peptide fractions exert distinct Th2 and Th1 cytokine-
producing effects  
With the aim to enrich and identify bioactive peptide sequences, the hydrolysate of 
OVA with pepsin (OP), which had shown the most promising properties in terms of reduction 
of Th2 immunity and enhancement of Th1 responses, was separated by RP-HPLC at a semi 
preparative scale into 5 fractions (labelled RP-OP1 to RP-OP5) and by anion exchange FPLC in 
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2 fractions (AE-OP1 and AE-OP2). These were collected after about 30 runs to obtain enough 
material to determine protein concentration and immunostimulating and immunomodulating 
activities on splenocytes from EW-sensitized mice, before being analysed by RP-HPLC-
MS/MS. 
In the hydrolysate of OVA with pepsin, RP-HPLC fractions RP-OP1 and RP-OP2 
stimulated the lowest production of the Th2 cytokines IL-4 and IL-5, and RP-OP3, RP-OP4 and 
RP-OP5, the highest. Fraction RP-OP2 considerably reduced the production of both IL-4 and 
IL-5 induced by EW in the splenocytes, while RP-OP4 enhanced the production of IL-4 and did 
not modify that or IL-5 (Fig. 4.3.6a and c). Spleen cells from EW-sensitized mice responded to 
stimulation with fractions RP-OP3, RP-OP4 and RP-OP5 releasing IL-12p70. IL-12 favours 
DC-driven differentiation of CD4+ T cells to IFN-γ-producing Th1 cells when it is present at an 
early stage of T cell activation (Macatonia et al., 1995). Furthermore, when added together with 
EW, RP-OP4 and RP-OP5, as well as OP, enhanced the release of IL-12p70 (Fig. 4.3.6b). 
However, the whole hydrolysate promoted IFN-γ secretion induced by EW to a much higher 
extent than any of the individual RP-HPLC fractions (Fig. 4.3.6d). On the other hand, the first 
fraction obtained by anion exchange chromatography (AE-OP1) induced weaker Th2 (IL-4 and 
IL-5) and Th1 responses (IFN-γ), compared with the second fraction (AE-OP2), although it 
significantly enhanced IFN- γ production by EW (Fig. 4.3.6). 
The peptides present in the hydrolysate of OVA with pepsin and its isolated fractions 
were identified by mass spectrometry (Annexes I-VIII). In the RP-HPLC fractions, peptides 
ranging from 5 to 22 aminoacids were found, with some coincident sequences, mainly between 
contiguous fractions. In turn, in AE-OP1 and AE-OP2, we identified, respectively, 67 and 64 
peptides distributed along the whole OVA molecule, with 16 identical sequences, although they 
shared many analogous peptides with amino- and carboxy-terminal truncations. Fig. 4.3.7 
shows the fragments identified in the most potent immunomodulatory fractions: RP-OP2, RP-
OP4, AE-OP1 and AE-OP2 (their respective RP-HPLC chromatograms are shown in Figs. 4.3.8 
and 4.3.9). The comparison between RP-OP2 and RP-OP4, which exerted distinct Th2 and Th1 
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cytokine-producing effects in combination with EW, showed a different occurrence of 
sequences within wide parts of the protein. In particular, RP-OP4 lacked peptides in the areas 
98-227, 248-275, 285-360 and 366-386. Interestingly, fractions RP-OP2 and AE-OP1, that 
down-regulated Th2 responses, shared 26 peptides in common, some of which, such as those 
within the areas 205-211 and 369-376, were absent from both RP-OP4 and AE-OP2, which 
exerted the opposite effect. However, the complex peptide composition of these fractions 
hindered the identification of sequences that could play a role to diminish Th2 responses and, in 
general, the correlation of peptide structure and immunoregulating function. 
 
Figure 4.3.6. Immunostimulating and immunomodulating effects of the fractions obtained from the 
hydrolysate of OVA with pepsin (OP) by semi-preparative RP-HPLC (RP-OP1 to RP-OP5) and anion 
exchange chromatography (AE-OP1 and AE-OP2). Splenocytes from EW-sensitized mice were 
stimulated with OP and its fractions (200 μg/mL) in the absence or presence of EW (200 μg/mL), and the 
secretion of IL-4 (a), IL-5 (b), IL-12p70 (c) and IFN-γ (d) was evaluated. Data are expressed as means ± 
SEM. Different letters indicate statistically significant differences (P < 0.05). 
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Figure 4.3.7. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the hydrolysate of OVA with pepsin (OP), and in the fractions separated by semi-preparative RP-HPLC: RP-OP2 (white ) and RP-OP4 (light grey  ) and anion exchange 
chromatography: AE-OP1 (white ) and AE-OP2 (light grey ).▼: Carbohydrate chains. : Disulphide bonds. 
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Figure 4.3.8. RP-HPLC patterns of the peptide fractions obtained from the hydrolysate of OVA with 
pepsin (OP) by semi-preparative RP-HPLC: RP-OP2 (a) and RP-OP4 (b). 
 
Figure 4.3.9. RP-HPLC patterns of the peptide fractions obtained from the hydrolysate of OVA with 
pepsin (OP) by anion exchange chromatography: AE-OP1 (a) and AE-OP2 (b). 
4.3.2. Discussion 
This study evidences the immunoregulatory role of OVA hydrolysed with pepsin and 
alcalase on splenocytes from mice orally sensitized to OVA, as well as on splenocytes from 
mice orally sensitized to identical amounts of OVA, OM and LYS. In both models, OVA 
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hydrolysates induced a low Th2 activation and significantly suppressed the release of IL-4 and 
IL-5 promoted by intact OVA, stimulating the secretion of the Th1 cytokine TNF-α. 
Furthermore, OVA hydrolysates combined the capacity to modulate the immune response ex 
vivo with a reduced ability to trigger cutaneous allergic symptoms in vivo in a PCA assay. 
Interestingly, the hydrolysates of OVA, also significantly inhibited the EW-induced 
secretion of IL-4 and IL-5 in mice sensitized to EW, which consists of 54% OVA, 11% OM and 
3.4% w/w LYS. This observation suggests that the sole administration of OVA hydrolysates 
could result in significant protection against bystander allergens. In fact, immunotherapy with 
OM-depleted heated EW effectively protects from allergic reactions to BALB/c mice sensitized 
to EW, despite OM is being considered an immunodominant allergen in this mouse model 
(Jiménez-Saiz et al., 2011). 
The results reported in section 4.2 showed that the hydrolysates of egg white proteins 
with alcalase down-regulated the production of Th2 cytokines and the secretion of IgE by 
human PBMCs from non-allergic donors artificially Th2-skewed by culture with IL-4 and anti-
CD40; while, in the same cell model, hydrolysates with pepsin stimulated the restoration of the 
Th1/Th2 balance by the simultaneous decrease in IL-5 and IL-13 and increase in IFN-γ. The 
present results basically confirm those findings, in accordance with Holvoet et al. (2013), who 
reported parallel outcomes with the non-antigen-specific model of Th2-skewed human PBMCs 
and allergen-primed murine splenocytes. However, the assay using spleen cells from egg white 
protein-sensitized mice provided a more refined characterization of the cytokine responses 
produced by the hydrolysates from OVA, LYS and OM, in line with the proven suitability of 
the BALB/c mouse model to stablish mechanisms and preventive or therapeutic strategies 
against food allergy and the fact that the spleen is a source of both antigen-presenting cells and 
allergen-specific T cells (Yang and Mine, 2009; Pablos-Tanarro et al., 2016). Moreover, the use 
of splenocytes from sensitized BALB/c mice enabled the assessment of the ability of the 
hydrolysates to modulate the specific T cell responses induced by the sensitizing allergens, 
which allowed discriminating OVA hydrolysates as the most promising therapeutic compounds.  
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The observation that complete hydrolysis of OVA and LYS with pepsin reduced their 
ability to promote Th2 effector pathways highlights the importance that resistance to pepsin 
digestion plays in the allergenicity of these proteins (Benedé et al., 2015). In contrast, both 
intact OM and its hydrolysate with pepsin induced very similar cytokine profiles. OM (whose 
structure is stabilized by 9 disulphide bridges) is proteolysed by pepsin in minutes, but the 
resulting peptides form big fragments linked by disulphide bonds (Benedé et al., 2013). OM, 
therefore, behaves as certain food allergens that, despite being digested, retain the T cell 
stimulatory properties of the intact protein, such as Ara h 1 from peanut (Eiwegger et al., 2006). 
This fact disagrees with the outcomes of the experiments with Th2-skewed PBMCs (section 
4.2), in which case the hydrolysate of OM with pepsin down-regulated the production of Th2 
cytokines, pointing up the enhanced capacity of the model used in this section to discriminate 
more accurately among hydrolysates with immunomodulating potential. 
The hydrolysate of OVA with alcalase, unlike that of OVA with pepsin, exerted on 
spleen cells from sensitized mice a negligible Th2-stimulating role. A likely explanation is that 
all the hydrolysates with alcalase contains short peptides, with molecular masses lower than 1.5 
kDa, that provide a poor sequence coverage (sections 4.1 and 4.2). This possibly correlates with 
a low proportion of full length T epitopes with the minimum core sequence of 9 amino acids 
required for recognition by reactive T cells (Prickett et al., 2011).  For its part, the hydrolysate 
of OVA with pepsin could be regarded as a good candidate for peptide-based immunotherapy 
on the grounds of its potential to reduce Th2 responses induced by egg allergens, but also to 
enhance Th1 responses. In fact, the peptides contained in this hydrolysate increased the 
production of DC-derived cytokines, such as IL-12 which, in turn, translated into an enhanced 
capacity to induce Th1 cell activation, as evidenced from the IFN-γ secretion in the spleen cell 
culture. 
Semi-preparative chromatographic separation of OVA hydrolysed with pepsin yielded 
peptide fractions with different immunostimulating and immunomodulating properties. In 
particular, hydrophilic peptides (RP-OP2) and peptides with low affinity for the anion exchange 
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column (AE-OP1) hindered the secretion of Th2 cytokines stimulated by EW in the spleen cells 
from EW-sensitized mice (in contrast to RP-OP4 and AE-OP2, respectively). Cationic host-
defense peptides are known to exert immunomodulating properties beyond their direct 
antimicrobial action through the stimulation of innate immune responses and the modification 
of T and B cell responses (Hilchie et al., 2013). Similarly, cationic peptides, from bovine β-
lactoglobulin, unlike anionic ones, are tolerogenic and prevent β-lactoglobulin sensitization in 
mice (Pecquet et al., 2000). However, despite there were similarities in the peptides contained in 
RP-OP2 and AE-OP1, with common sequences absent from other fractions, it was not possible 
to trace peptide composition to Th2 down-regulating activities. Furthermore, the observation 
that peptide enrichment by reverse-phase and anion-exchange fractionation of the hydrolysate 
did not lead to an increase in its immunomodulating efficiency suggests that factors other than 
peptide hydrophilicity or charge influence the ability to bias an allergic immune response. In 
fact, so far, very little is known regarding the structural and sequence requirements underlying 
the immunoregulatory properties of peptides (Haney and Hancock, 2013). 
It is noteworthy that the whole hydrolysate of OVA with pepsin, as well as all its 
derived fractions, except for RP-OP4, contained several peptides included in the 
immunodominant sequence OVA (323-339), which comprises multiple T cell epitopes restricted 
by the MHC class I-Ad molecule of BALB/c mice, such as OVA (324-332) (SQAVHAAHA), 
OVA (327-335) (VHAAHAEIN) and OVA (329-337) (AAHAEINEA) (Robertson et al., 2000). 
Furthermore, the hydrolysate and certain fractions contained peptides related to OVA (39-50), 
OVA (147-158) and OVA (263-274), which, as well as OVA (329-340), induce proliferation 
and IFN-γ secretion in spleen cell of BALB/c mice subcutaneously sensitized to OVA, without 
stimulating the production of IL-4 (Yang and Mine, 2009). The occurrence in the whole OVA 
hydrolysate of a combination of immunogenic structures with synergistic or adjuvant actions 
could explain its stronger immunomodulating potential as compared with its separated peptide 
fractions (Yang et al., 2009b and 2010; Bøgh et al., 2012).  
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The assessment of the immunostimulating and immunomodulating capacity of 
hydrolysates of egg white proteins on splenocytes from sensitized BALB/c mice showed that 
the hydrolysate of OVA with pepsin stimulated low Th2 responses and also down-regulated Th2 
responses induced by intact egg allergens ex vivo, while contributing to increase Th1 cytokine 
secretion. Hydrolysis of OVA with pepsin appears as a cheap, simple and safe approach for a 
reproducible production of immunomodulating peptides with a reduced ability to trigger allergic 
symptoms. Altogether, these results encouraged us to validate in vivo the potential 
immunomodulating effects of this hydrolysate as a treatment strategy of egg allergy. 
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The previous sections (4.1, 4.2 and 4.3) demonstrated that the hydrolysates of OVA 
with pepsin and alcalase were hypoallergenic in vitro and in vivo (section 4.2 and 4.3). In 
addition, these presented immunomodulating effects not only on unspecific cell models (section 
4.1 and 4.2), but also on a more accurate ex vivo model based on cells from mice sensitized to 
egg allergens (section 4.3). In general, OVA hydrolysed with pepsin and alcalase has shown a 
reduced ability to induce Th2 responses and a marked capacity to decrease the allergic immune 
responses induced by the egg allergens.  
The use of immunomodulating peptides and hydrolysates has previously been suggested 
to avoid the development of allergic symptoms in sensitized individuals or even, as a prior 
strategy, to prevent sensitization to intact allergens (Adel-Patient et al., 2011; Hacini-Rachinel 
et al., 2014; Valenta et al., 2016). However, the preventive usage of allergen derived 
hydrolysates poses a risk in the development of the sensitization against the preparation itself, 
being necessary to assure that these hydrolysates lack sensitizing potential (van Esch et al., 
2013). On the other hand, the therapeutic administration of immunomodulating peptides 
represent a safer alternative to full allergens, as they produce fewer side effects and increase 
adherence to therapy (Yang et al., 2010; Casale and Stokes, 2011; Moldaver and Larché, 2011).  
Given this scenario, the last step of this thesis was the in vivo evaluation of the 
sensitizing capacity, preventive ability and therapeutic effects of OVA hydrolysed with pepsin 
and alcalase in a murine model. For this propose, BALB/c mice were orally administered the 
hydrolysates and their ability to induce the production of specific antibodies, as well as to elicit 
anaphylactic responses, were evaluated. We then studied their potential preventive and 
therapeutic ability in mice sensitized to EW before or after the administration of the 
hydrolysates, respectively, compared with those of the intact OVA. Finally, in order to 
understand the immunological events underlying the sensitization potential, the tolerance 
induction after pre-treatment and the desensitization after therapeutic administration, we 
evaluated the changes in cell populations at systemic levels and also studied the variations on 
relative gene expression at intestinal level.  
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Figure 4.4.1. Scheme of the experimental procedure followed in section 4.4. EW, egg white; Foxp3, 
forkhead box protein P3; GATA-3, trans-acting T-cell-specific transcription factor; Ig, immunoglobulin; 
IL, interleukin; mMCP-1, mouse mast cell protease I; OA, OVA hydrolysed with alcalase; OP, OVA 
hydrolysed with pepsin; OVA, ovalbumin; T-bet, T-box transcription factor; TSLP, thymic stromal 
lymphopoietin.  
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4.4.1. Results 
4.4.1.1. OVA hydrolysed with pepsin lack sensitizing and eliciting capacity, but its hydrolysis 
with alcalase revealed immunogenic and antigenic effects 
EW-specific IgE, IgG1, IgG2a and IgA were only detected in mice administered EW 
plus CT -EW+CT- (Fig. 4.4.2), thus showing that the hydrolysates did not hold sensitizing 
potential to the intact protein from which they derived, that constitutes 54% (w/w) of EW. 
While the hydrolysates were not able to sensitize to OVA, OA plus CT -OA+CT- induced the 
production of OA-specific antibodies, although to a much lower level than the EW-specific 
antibodies generated by EW+CT (Fig. 4.4.3a-d). Administration of OP plus CT -OP+CT- gave 
rise to low, but detectable OP-specific IgG2a, but not to specific IgE, IgG1 or IgA responses, 
which is indicative of a low immunogenicity (Fig. 4.4.3e and f). IgE, IgG1, IgG2a and IgA 
antibodies present in serum from mice sensitized to EW cross-reacted to OA, whereas IgG1 and 
IgG2a antibodies cross-reacted to OP, suggesting that some of the peptides contained in the 
hydrolysates carried epitopes able to bind to the antibodies induced by the administration of 
EW+CT. Mice administered OA+CT, unlike those administered OP+CT, underwent clinical 
signs and temperature drops following oral challenge with the hydrolysate used for 
sensitization. Anaphylactic symptoms were equivalent to those experienced by mice sensitized 
to EW+CT and orally challenged with EW, as it was rectal temperature (Fig. 4.4.4a and b). This 
points out that OA held sensitizing potential, although the induction of specific antibodies did 
not correlate with the ability of the hydrolysate to provoke anaphylaxis. However, subsequent 
i.p. challenge did not increase the severity of symptoms in mice administered OA+CT, leading 
to lower scores and rectal temperature values than the previous oral challenge, as well as to 
negligible serum levels of mMCP-1 (Fig. 4.4.4c and d). 
The assessment of the allergenic potential of the hydrolysates in mice sensitized to EW 
revealed that oral and i.p. challenges with OA elicited significant clinical signs, accompanied by 
temperature drops and release of serum mMCP-1 (Fig. 4.4.4e). This shows that OA was not 
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hypoallergenic, even if OA-induced anaphylaxis was, in general, lower than that provoked by 
EW. Unlike OA, OP did not stimulate allergic reactions in EW+CT administered mice, as 
judged by clinical sings, rectal temperature values and serum mMCP-1 levels. 
 
Figure 4.4.2. Specific antibody responses induced against EW during administration of CT or, EW, OA 
and OP plus CT. Levels of EW-specific IgE (a), IgG1 (b), IgG2a (c) and IgA (d) were determined by 
ELISA in serum samples from CT ( ), EW ( ), OA ( ) and OP ( ) groups collected on weeks 2, 4 and 
6 of the sensitization period. Data are expressed as means ± SEM (n=5). Different letters indicate 
statistically significant differences (P < 0.05) between the groups of mice for the same experimental 
point. 
 
Figure 4.4.3. Specific antibody responses induced against the hydrolysates, OA and OP, during 
administration of CT or, EW, OA and OP plus CT. Levels of specific IgE (a), IgG1 (b), IgG2a (c) and 
IgA (d) against OA, and specific IgG1 (e) and IgG2a (f) against OP, were determined by ELISA in serum 
samples from CT ( ), EW ( ), OA ( ) and OP ( ) groups collected on weeks 2, 4 and 6 of the 
sensitization period. Data are expressed as means ± SEM (n=5). Different letters indicate statistically 
significant differences (P < 0.05) between the groups for the same experimental point. 
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Figure 4.4.4. Systemic anaphylactic responses after oral (a,b) and i.p. (c,d,e) challenge. Sham- (CT) and 
EW-sensitized mice were challenged with EW, while mice administered OA and OP plus CT were 
challenged with the corresponding hydrolysate. Eliciting capacity was determined by challenge of EW-
sensitized mice with OA and OP. Anaphylactic score (a,c) and drop in body temperature (b,d) were 
determined 30 minutes after each challenge. Release of mMCP-1 (e) was quantified in serum samples 
collected after sacrifice (week 6). Data are represented individually for each mouse. Clinical scores are 
expressed as medians and, body temperature and levels of mMCP-1 expressed as means (n=5). Different 
letters indicate statistically significant differences (P < 0.05).  
We next decided to evaluate the binding preferences of the antibodies raised in mice by 
the administration of EW+CT and OA+CT. To this aim, we first conducted PCA assays to 
assess the participation of IgE and IgG1 in the development of allergic responses to EW and 
OA. Heat-treatment of the sera from EW+CT and OA+CT administered mice at 56°C for 3 h, 
0
1
2
3
4
5
S
co
re
CT
EW
EW
EW
EW
OA
EW
OP
OA
OA
OP
OP
Sensitization
Challenge
32
34
36
38
40
ºC
3000
6000
9000
12000
n
g
/m
L
a a
b
c c c
a a a
b
b
b
a
b
bc
c c c
Symptoms (Oral challenge) Temperature (Oral challenge) 
Serum mMCP-1 levels
Symptoms (i.p. challenge) Temperature (i.p. challenge) 
0
1
2
3
4
5
S
co
re
a
b
d cd 32
34
36
38
40
ºC
a a a
c
ab b
CT
EW
EW
EW
EW
OA
EW
OP
OA
OA
OP
OP
CT
EW
EW
EW
EW
OA
EW
OP
OA
OA
OP
OP
CT
EW
EW
EW
EW
OA
EW
OP
OA
OA
OP
OP
Sensitization
Challenge
CT
EW
EW
EW
EW
OA
EW
OP
OA
OA
OP
OP
Sensitization
Challenge
c
d
a) b)
d) d)
e)
In vivo evaluation of the sensitizing capacity and preventive and therapeutic ability of OVA hydrolysates 
144 
 
before their intradermal administration to naïve mice, significantly reduced the extent of dye 
extravasation following intravenous challenge with the protein used for sensitization, although it 
did not eliminate it (Fig. 4.4.5). This suggests that, in addition to the more heat-sensitive IgE 
antibodies, IgG1 antibodies also contributed to anaphylaxis in both cases. Subsequently, 
considering the potential role of IgG1 in allergic manifestations and the fact that the higher 
levels of IgG1 antibodies aided their quantification, we conducted inhibition ELISA 
experiments to examine the binding capacity of IgG1 from EW+CT and OA+CT sensitized 
mice (Fig. 4.4.6).  
 
Figure 4.4.5. PCA assay with unheated and heated (56°C for 3 h) pooled sera from mice administered 
EW or OA plus CT. Allergen-specific dye extravasation was calculated by correcting the EW- or OA-
induced absorbance with the absorbance of the supernatant of the ear injected with pooled control sera. 
Data are means ± SEM (n= 2). Different letters indicate statistically significant differences (P < 0.05).    
IgG1 of sera from EW+CT administered mice had low affinity for OP and lower 
affinity for OA than for EW. Furthermore, these antibodies bound with very low strength the 
fraction of OA with molecular mass below 10 kDa, raising the question as to whether the 
allergic response induced by this hydrolysate on EW sensitized mice was nonspecific, but due to 
an antigenic substance belonging to the enzymatic preparation (Fig. 4.4.6a). In fact, IgG1 
present in sera from OA+CT sensitized mice bound with lower affinity the fraction of the 
hydrolysate with molecular mass below 10 kDa, comprising  the fragments from OVA 
hydrolysis, than the corresponding fraction with molecular mass above 10 kDa, which contained 
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the enzyme, or the inactivated alcalase preparation itself  (Fig. 4.4.6b). These observations 
suggest that the enzyme preparation was immunogenic and highly antigenic.  
 
Figure 4.4.6. IgG1-binding capacity using sera from mice administered EW (a) or OA (b) plus CT. 
Comparison of the inhibitory capacity was assessed by pre-incubation of pooled sera (n=5) obtained at 
sacrifice (week 6) with tenfold dilutions (0.05 pg/mL-500 µg/mL) of inhibitors: EW ( ), OA ( ), OP      
( ), OA above 10 kDa (*), OA below 10kDa ( ) and the enzymatic extract of alcalase ( ). IgG1 
inhibition curves show data expressed as means ± SEM of three independent assays. 
The expression levels of the intestinal Th2-skewing cytokines IL-33, IL-25 and TSLP, 
as well as the transcription factors GATA-3, T-bet and Foxp3 which specify, respectively, the 
development of Th2, Th1 and T reg cells, was assessed in the duodenum 3 h after the i.p. 
challenge (Fig. 4.4.7). A significant upregulation of IL-33 was detected in mice administered 
EW, OA and OP plus CT, and challenged with the respective protein preparation, as compared 
with sham-sensitized mice, whereas IL-25 and TSLP were only upregulated in mice sensitized 
to EW. While it is likely that intestinal injury resulting from mast cell activation due to the oral 
challenge, and not just the sensitization status, influenced the gene regulation of these cytokines 
at the duodenal level, as judged by the different IL-33, IL-25 and TSLP responses induced by 
EW, OA and OP on EW-sensitized mice, these results suggest that challenge with the protein 
preparation used for previous administration with CT boosted intestinal IL-33 and GATA-3 
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expression, even in the absence of detectable intestinal or systemic symptoms (Fig. 4.4.7a and 
d). Meanwhile, administration of OA+CT and OP+CT did not change the expression level of T-
bet or Foxp3 in the duodenum with respect to sham-sensitized mice (Fig. 4.4.7e and f).  
 
Figure 4.4.7. Intestinal expression, determined by RT-qPCR, of IL-33 (a), IL-25 (b), TSLP (c), GATA-3 
(d), T-bet (e) and Foxp3 (f) in duodenum samples of mice administered EW, OA or OP plus CT. Results 
were normalized to β-actin and expressed relative to sham-sensitized group (identified as CT). Data are 
expressed as means ± SEM (n= 5). Different letters indicate statistically significant differences (P < 0.05). 
 
Figure 4.4.8. The percentages of activated Th2 (a), Th1 (b) and T reg (c) cells within the CD4+ 
population in spleens from mice administered CT or, EW, OA and OP plus CT determined by flow 
cytometry. Individual values are represented for each mice and data expressed as means ± SEM (n=5). 
Different letters indicate statistically significant differences (P < 0.05). 
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In parallel with the regulation of the transcription factors GATA-3, T-bet and Foxp3 in 
the intestine, an increased percentage of activated Th2 and Th1 cells, and no change in T reg 
cells, was found in the spleen of mice administered EW+CT. Accordingly, the proportion of 
activated Th2, Th1 and T reg cells were comparable in mice administered OA and OP plus CT 
and in sham-sensitized mice (Fig. 4.4.8). When the specific response of splenocytes from mice 
administered EW, OA and OP plus CT was studied by re-stimulation with the protein 
preparation used for sensitization, the highest release of Th2 (IL-4 and IL-5), Th1 (IFN-γ) and 
regulatory (IL-10) cytokines was found in mice administered EW+CT, while no significant 
production was detected from the spleen cells of mice administered OP+CT (Fig. 4.4.9). The 
spleen cells from mice administered the hydrolysates plus CT did not respond to EW 
stimulation, except for a significant release of IL-17. On the other hand, mice sensitized to 
EW+CT responded to re-stimulation with OA with cytokine levels similar to those induced by 
the negative control (RPMI) and to re-stimulation with OP with a lower release of IL-4 and IL-5 
than that induced by EW, but with equivalent levels of IFN-γ (Fig. 4.4.9). This is in agreement 
with previous results that suggested that OP was able to restore a biased Th2/Th1 balance on 
spleen cells of OVA- and EW-sensitized mice (section 4.3). 
Overall, OP was shown to be hypoallergenic and weakly immunogenic in vivo, but to 
hold critical T cell epitopes that could help to prevent sensitization or restore tolerance to egg 
proteins. For its part, OA exhibited in vivo immunogenicity and primed mice for allergic 
reactions. However, mice administered OA+CT were not particularly prone to intestinal Th2 
priming and subsequent adaptive responses as compared with those administered OP+CT. 
Therefore, in a subsequent step we explored the preventive potential of both hydrolysates. 
4.4.1.2. The protective effect induced by the hydrolysate of OVA with pepsin was mediated by 
the expansion of T reg cells and the production of regulatory cytokines  
Treatment with OVA, OA and OP for 3 weeks, before administration of EW+CT, prevented 
sensitization, as judged by significantly lower levels of serum EW-specific IgE, IgG2a and IgA  
  
 
 
Figure 4.4.9. Effects of EW, OA and OP, on the secretion of IL-4 (a), IL-5 (b), IFN-γ (c) IL-10 (d) and IL-17 (e) by splenocytes from mice administered CT, or EW, OA and 
OP plus CT. RPMI culture medium is presented as negative control. Data are expressed as means ± SEM (n=5). Different letters indicate statistically significant differences  
(P < 0.05). 
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at the end of the experimental period, although only OP significantly decreased EW-specific 
IgG1 levels (Fig. 4.4.10). In addition, pre-treated mice did not experience anaphylaxis following 
oral challenge with EW, except for 2 out of 5 mice treated with OVA, which developed mild 
allergic signs. However, subsequent i.p. challenge led to significant clinical symptoms, 
temperature drops and release of mMCP-1 in mice previously treated with OVA and OA, while 
mice treated with OP were effectively protected against anaphylaxis (Fig. 4.4.11). 
 
Figure 4.4.10. Preventive effect of intragastric administration of OVA, OA and OP on the antibody 
responses. Levels of EW-specific IgE (a), IgG1 (b), IgG2a (c) and IgA (d) were determined by ELISA in 
serum samples from CT ( ), PBS ( ), OVA ( ), OA ( ) and OP ( ) groups collected at the end of the 
preventive treatment (week -1), during EW-sensitization period (week 3) and after challenge (week 6). 
Data are expressed as means ± SEM (n=5). Different letters indicate statistically significant differences (P 
< 0.05) between the groups for the same experimental point. 
Pre-treatment of mice with OVA or OP before sensitization inhibited up-regulation of 
duodenal Th2-skewing cytokines following challenge with EW, except in the case of OA-
treated mice, which showed expression levels of IL-33 similar to those seen in the untreated 
mice (Fig. 4.4.12). In general terms, prevention of sensitization and anaphylaxis by OVA and its 
hydrolysates was related to an increased expression of the regulatory cytokines IL-10 and TGF-
β in the MLNs, as well as to upregulation of IL-17 (Fig. 4.4.13). This was accompanied by a 
decreased expression of GATA-3 in the PPs and MLNs of all the pre-treated animals (Fig. 
4.4.14). In the groups pre-treated with OVA and OP, we also observed downregulation of T-bet 
in the duodenum and upregulation in the PPs. OP, which most effectively inhibited allergy 
development, distinctly upregulated IL-10 in PPs and TGF-β in duodenum and PPs, leading to a 
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significant increased expression of Foxp3 in intestinal lymphoid and non-lymphoid tissues and 
further increasing T-bet in the MLNs (Fig. 4.4.14).  
 
Figure 4.4.11. Effect of intragastric administration of OVA, OA and OP prior to EW sensitization on 
systemic anaphylactic responses after oral (a,b) and i.p. (c,d,e) challenge with EW. Anaphylactic score 
(a,c) and drop in body temperature (b,d) were determined 30 minutes after each challenge. Release of 
mMCP-1 (e) was quantified in serum samples collected after sacrifice (week 6). Data are represented 
individually for each mouse. Clinical scores are expressed as medians and, body temperature and levels of 
mMCP-1 expressed as means (n=5). Different letters indicate statistically significant differences              
(P < 0.05). 
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Figure 4.4.12. Modulation of intestinal expression, determined by RT-qPCR, of IL-33 (a), IL-25 (b) and 
TSLP (c) studied in duodenum samples from mice preventively treated with OVA, OA and OP. Results 
were normalized to β-actin and expressed relative to sham-sensitized group (identified as CT). Data are 
expressed as means ± SEM (n= 5). Different letters indicate statistically significant differences (P < 0.05). 
All treatments reduced the percentage of activated splenic Th2 cells, although only OP 
concomitantly induced an increase in T reg cells (Fig. 4.4.15). Following incubation with the 
allergen, splenocytes from pre-treated mice, and particularly those from mice treated with OVA 
and OP, responded with significantly lower levels of IL-4, IL-5, IL-10 and IL-17 (Fig. 4.4.16). 
Furthermore, secretion of INF-γ was significantly decreased in the EW-stimulated spleen cell 
cultures from the OVA and OP pre-treated groups. 
 
Figure 4.4.13. Modulation of relative gene expression, determined by RT-qPCR, of IL-10 (a), TGF-β (b) 
and IL-17 (c) studied in duodenum (D), PP and MLN samples from mice preventively treated with OVA, 
OA and OP. Results were normalized to β-actin and expressed relative to sham-sensitized group (relative 
expression of calibrator was 1 and it is represented as a discontinuous line in the figure). Data are 
expressed as means ± SEM (n= 5). Different letters indicate statistically significant differences (P < 0.05) 
within each organ and * indicates differences (P < 0.05) compared with the calibrator. 
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Figure 4.4.14. Modulation of relative gene expression, determined by RT-qPCR, of GATA-3 (a), T-bet 
(b) and Foxp3 (c) studied in duodenum (D), PP and MLN samples from mice preventively treated with 
OVA, OA and OP. Results were normalized to β-actin and expressed relative to sham-sensitized group 
(relative expression of calibrator was 1 and it is represented as a discontinuous line in the figure). Data are 
expressed as means ± SEM (n= 5). Different letters indicate statistically significant differences (P < 0.05) 
within each organ and * indicates differences (P < 0.05) compared with the calibrator. 
These results indicate that pre-treatment with OP prevented the development of allergy 
to EW in mice through the enhancement of T reg cells, in contrast with OVA and OA, which 
did not avoid anaphylaxis following systemic challenge. Expression of the regulatory cytokines 
IL-10 and TGF-β, as well as IL-17, in intestinal tissues correlated with hindrance of 
sensitization and with clinical protection against anaphylaxis.  
 
Figure 4.4.15. The percentages of activated Th2 (a), Th1 (b) and T reg (c) cells within the CD4+ 
population in spleens from mice preventively treated with OVA, OA and OP determined by flow 
cytometry. Individual values are represented for each mice and data expressed as means ± SEM (n=5). 
Different letters indicate statistically significant differences (P < 0.05). 
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Figure 4.4.16. Effects EW on the secretion of IL-4 (a), IL-5 (b), IFN-γ (c) IL-10 (d) and IL-17 (e) by splenocytes from mice preventively treated with OVA, OA and OP. 
RPMI culture medium is presented as negative control. Data are expressed as means ± SEM (n=5). Different letters indicate statistically significant differences (P < 0.05). 
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4.4.1.3. The hydrolysate of OVA with pepsin offered a maintained therapeutic protection 
against allergy to EW more efficacious than intact OVA 
In these experiments, once allergy to EW was stablished in mice by administration of 
EW plus CT, these were treated with OVA, OA and OP for 3 weeks and challenged with EW. 
Of note was the appearance of diarrhea, without other noticeable allergic signs, during the first 
week or OVA treatment (results not shown). Treatment with OP reduced significantly the levels 
of EW-specific IgE and IgG1, whereas neither OVA nor OA changed the serum concentration 
of these antibodies with respect to the untreated mice (Fig. 4.4.17a and b). In addition, none of 
the treatments altered the concentration of EW-specific IgG2a, while OVA, as well as OP, led to 
significantly increased levels of fecal IgA (Fig. 4.4.17c and d).  Unlike treatment with OVA, 
which did not avoid anaphylaxis, the hydrolysates, OA and OP, abolished clinical signs and 
temperature changes upon oral challenge with EW (Fig. 4.4.18a and b). However, the 
subsequent i.p. challenge elicited allergy symptoms and temperature drops in OA treated mice 
and to a much lesser extent in OP treated mice. In agreement with the aforesaid, mMCP-1 levels 
were also the lowest in the OP treated animals, followed by those treated with OA (Fig. 
4.4.18e).  
 
Figure 4.4.17. Therapeutic effect of intragastric administration of OVA, OA and OP on the antibody 
responses. Levels of EW-specific IgE (a), IgG1 (b), IgG2a (c) and IgA (d) were determined by ELISA in 
serum samples from CT ( ), PBS ( ), OVA ( ), OA ( ) and OP ( ) groups collected at the end of the 
EW-sensitization period (week 6), three days after the end of the treatment (week 9) and 3 week off the 
therapy (week 12). Data are expressed as means ± SEM (n=5). Different letters indicate statistically 
significant differences (P < 0.05) between the groups for the same experimental point. 
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Figure 4.4.18. Therapeutic effect of intragastric administration of OVA, OA and OP to EW-sensitized 
mice on systemic anaphylactic responses after oral (a,b) and i.p. (c,d,e) challenge with EW. Anaphylactic 
score (a,c) and drop in body temperature (b,d) were determined 30 minutes after each challenge. Release 
of mMCP-1 (e) was quantified in serum samples collected after sacrifice (week 6). Data are represented 
individually for each mouse. Clinical scores are expressed as medians and, body temperature and levels of 
mMCP-1 expressed as means (n=5). Different letters indicate statistically significant differences             
(P < 0.05). 
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Interestingly, reassessment of anaphylaxis 3 weeks after termination of the treatments 
with OVA and OP revealed similar responses in mice treated with OP, while those treated with 
OVA experienced no symptoms or temperature drop upon oral challenge and somehow milder 
changes (albeit not significantly different) upon subsequent i.p. challenge with EW (Fig. 
4.4.18). These observations correlated with lower levels of IgE and IgG1, as compared with the 
point when both treatments were discontinued, and also lower concentrations of IgG2a and IgA 
in the case or OP (Fig. 4.4.17), showing sustained depletion of circulating and intestinal specific 
antibodies.  
All the treatments reduced the expression of IL-33 and IL-25 in the duodenum induced 
by previous EW sensitization and challenge, to levels which, in the case of IL-25, were 
equivalent to those of sham-sensitized mice, while they did not change those of TSLP (Fig. 
4.4.19). The therapeutic effect of OP could be traced to the increased expression of IL-10 and 
IL-17 in PPs and MLNs, and of TGF-β in all the intestinal tissues studied, observed in OP 
treated mice in comparison with OVA and OA treated mice (Fig. 4.4.20). In fact, treatment with 
OP distinctively increased the expression of Foxp3 in these intestinal tissues (Fig. 4.4.21). In 
particular, the least effective OVA treatment did not exert any effect on the expression of 
GATA-3 and T-bet in the MLNs, which might, at least partially, reflect the outcomes of 
challenge with EW in the animals treated with the intact protein; while in the animals treated 
with OP, as well as with OA, that did not experience symptoms after oral challenge, expression 
of GATA-3 and T-bet was decreased (Fig. 4.4.21). 
 
Figure 4.4.19. Modulation of intestinal expression, determined by RT-qPCR, of IL-33 (a), IL-25 (b) and 
TSLP (c) studied in duodenum samples from EW-sensitized mice treated with OVA, OA and OP. Results 
were normalized to β-actin and expressed relative to sham-sensitized group (identified as CT). Data are 
expressed as means ± SEM (n= 5). Different letters indicate statistically significant differences (P < 0.05). 
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Figure 4.4.20. Modulation of relative gene expression, determined by RT-qPCR, of IL-10 (a), TGF-β (b) 
and IL-17 (c) studied in duodenum (D), PP and MLN samples from EW-sensitized mice treated with 
OVA, OA and OP. Results were normalized to β-actin and expressed relative to sham-sensitized group 
(relative expression of calibrator was 1 and it is represented as a discontinuous line in the figure). Data are 
expressed as means ± SEM (n= 5). Different letters indicate statistically significant differences (P < 0.05) 
within each organ and * indicates differences (P < 0.05) compared with the calibrator. 
 
Figure 4.4.21. Modulation of relative gene expression, determined by RT-qPCR, of GATA-3 (a), T-bet 
(b) and Foxp3 (c) studied in duodenum (D), PP and MLN samples from EW-sensitized mice treated with 
OVA, OA and OP. Results were normalized to β-actin and expressed relative to sham-sensitized group 
(relative expression of calibrator was 1 and it is represented as a discontinuous line in the figure). Data are 
expressed as means ± SEM (n= 5). Different letters indicate statistically significant differences (P < 0.05) 
within each organ and * indicates differences (P < 0.05) compared with the calibrator. 
Splenic activated Th2 cells were reduced in OVA and OP treated mice, whereas 
activated Th1 cells were unchanged (Figs. 4.4.22a and b). The percentage of T reg cells was 
specifically enhanced in the OP treated mice (Fig. 4.4.22c). Splenocytes from pre-treated mice, 
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lower level of Th2 and Th1cytokines to EW stimulation. Noteworthy, EW-induced secretion of 
IL-10 and IL-17 from splenoctyes from OP treated mice was higher than that from the spleen 
cells from OVA and OA treated groups (Fig. 4.4.23). Hindrance of cytokine release from spleen 
cells upon EW stimulation was maintained in the OVA and OP groups 3 weeks after 
discontinuation of the respective treatments (Fig. 4.4.23). 
 
Figure 4.4.22. The percentages of activated Th2 (a), Th1 (b) and T reg (c) cells within the CD4+ 
population in spleens from EW-sensitized mice treated with OVA, OA and OP determined by flow 
cytometry. Individual values are represented for each mice and data expressed as means ± SEM (n=5). 
Different letters indicate statistically significant differences (P < 0.05). 
In general terms, OP provided effective immunotherapy with durable effects in EW 
allergic mice. Unlike OVA, OP decreased the levels of EW-specific IgE and IgG1 and hindered 
anaphylaxis upon oral and systemic changes. As it was the case of the preventive trials, 
intestinal T reg cells, IL-10, TGF-β, and IL-17 cells appeared as responsible for the curative 
effects observed. 
4.4.2. Discussion 
In this section, two hydrolysates of the egg allergen OVA, obtained by pepsin and 
alcalase treatment, were assayed for their ability to prevent allergy development and to achieve 
desensitization once allergy was stablished, using a mouse model of IgE-mediated EW 
hypersensitivity. Their suitability for prophylactic and therapeutic applications was compared 
with that of the intact allergen. The hydrolysates had to fulfil the requisite of lacking sensitizing 
and eliciting potential in EW-sensitized mice.  
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Figure 4.4.23. Effects of EW on the secretion of IL-4 (a), IL-5 (b), IFN-γ (c) IL-10 (d) and IL-17 (e) by splenocytes from EW-sensitized mice treated with OVA, OA and OP 
three hours and three weeks off OIT. RPMI culture medium is presented as negative control. Data are expressed as means ± SEM (n=5). Different letters indicate statistically 
significant differences (P < 0.05).
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Unlike OP, OA induced antibody responses and allergic reactions in sensitized mice. 
These results were unexpected in view of the comparatively lower molecular mass of the 
peptides containing in OA in comparison with OP (with 85-97% versus 70% of the peptides 
lower than 1.5 kDa), the negligible binding of the former to IgE from allergic patients (sections 
4.1 and 4.2) and the previous observation that none of the hydrolysates were able to trigger 
cutaneous allergic symptoms in PCA assays using serum of OVA+CT administered mice for 
passive sensitization (section 4.3). The assessment of the binding preferences of the antibodies 
raised in mice by OA+CT administration raised the question as to whether the enzyme 
preparation, and not just OVA-derived peptides, was the antigenic agent. Additionally, alcalase 
was also able to bind IgG1 antibodies raised in mice by EW-sensitization. In fact, it is 
documented that alcalase can induce specific antibodies, but also be recognized by antibodies 
arising from different environmental exposures (Sarlo et al., 2010). While it is likely that the 
OA components may have the ability to combine nonspecifically with the final products of 
immune responses, results from the preventive and therapeutic trials also suggest that they could 
stimulate IL-33 production at the intestinal mucosa and expansion of ILC2, as shown by the 
upregulated duodenal expression of GATA-3, that determines ILC2 differentiation, promoting 
Th2 responses (Noval Rivas et al., 2016). IL33 also activates mast cells, releasing mediators and 
playing a role in the progression of the allergic disease (Saluja et al., 2015). The observation 
that mice administered OA+CT experienced stronger anaphylactic reactions after oral challenge 
with OA as compared with the subsequent i.p. challenge could suggest that anaphylaxis is 
triggered in response to non-specifically driven signals arising from the intestinal epithelium. As 
a result, OA was not effective to induce oral tolerance to EW.  
OP fulfilled the pre-requisite of lacking sensitizing capacity in order to be used to 
prevent allergy development. OP administered orally with CT was weakly immunogenic, 
because it did not induce specific antibodies, except for a negligible production of IgG2a, nor 
allergic sings upon oral or i.p. challenge. In addition, administration of OP for 3 weeks avoided 
subsequent sensitization to EW, as shown by inhibition of the generation of EW-specific IgE, 
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IgG1, IgG2a and IgA, allergic symptoms, body temperature changes and release of mast cell 
mediators. Partially hydrolyzed cow’s milk proteins have been reported to deliver protective 
responses against milk allergy in mice (Fritsché et al., 1997; van Esch et al., 2011b). However, 
in certain cases, intact milk proteins were found to provide more effective protection against 
sensitization, linked to a more pronounced reduction in the levels of allergen specific IgE and/or 
IgG1 (Peng et al., 2004; Adel-Patient et al., 2011 and 2012; van Esch et al., 2011b). 
Nevertheless, in our study, unlike OP, pre-treatment with OVA did not hinder anaphylaxis 
following i.p. challenge with EW. In this respect, it should be noted that EW-specific serum IgE 
and IgG2a levels were similar in OP and OVA pre-treated mice, but EW-specific IgG1 was only 
significantly reduced in the former. 
Anaphylaxis in the mouse has been described to occur through two independent 
pathways: the classical mechanism associated with human allergy, which involves the cross-
linking of IgE bound to FcεRI on mast cells, and an alternative pathway that requires IgG 
antibodies, FcγRIII receptors and macrophages (Finkelman et al., 2016). Because much higher 
antibody and antigen concentrations are required to induce anaphylaxis by the alternative IgG-
mediated pathway, parenteral administration of a relatively large quantity of antigen, as in our 
i.p. challenge tests, after CT-induced sensitization, largely drives IgG-mediated anaphylaxis that 
closely resembles that induced by IgE (Strait et al., 2006). Through PCA experiments with 
heated and unheated sera from EW-sensitized mice, we demonstrated that both specific IgE and 
IgG1 could participate in anaphylaxis in this model. Therefore, the allergic reactions observed 
after i.p. challenge in mice pre-treated with OVA are likely to be due to the lack of a significant 
lowering effect of the treatment on serum IgG1concentrations.  
Our results relate the preventive effects of OVA and OP with a reduced expression in 
mouse intestinal tissues of the transcription factor GATA-3, that induces the differentiation of 
Th2 cells suppressing that of Th1 cells, in agreement with similar approaches using 
hydrolysates or peptides, which reported decreased numbers of activated Th2 cells in the MLNs 
following sensitization and challenge of mice (van Esch et al., 2011b). We also detected a 
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diminished proportion of activated Th2 cells in the spleen and decreased systemic Th2 
responses upon stimulation of the splenocytes with the allergen used for sensitization, also in 
accordance with others (Adel-Patient et al., 2012; Hacini-Rachinel et al., 2014). Changes in the 
Th1 response were less consistent, with upregulated expression of T-bet in PPs and MLNs, but 
no change in the proportion of activated Th1 cells in the spleen and diminished allergen-
stimulated production of IFN-γ. In parallel, with these immunologic changes, OP, unlike OVA, 
upregulated Foxp3, the specific marker of T reg cells that controls their differentiation and 
function, in the intestinal lymphoid tissues and increased the percentage of T reg cells in the 
spleen, in line with other studies that showed a key role of T reg cells induced at the MLN level 
in the prevention of sensitization and development of food allergy (Adel-Patient et al., 2011; 
van Esch et al., 2011b; Meulenbroek et al. 2013; Hacini-Rachinel et al., 2014).  
OP was beforehand a good candidate to be used for allergen immunotherapy on the 
grounds of its lack of IgE reactivity (section 4.2), its reduced ability to trigger allergic 
symptoms in PCA assays and its potential to reduce splenic Th2 responses (release of IL-4 and 
IL-5) induced by egg allergens, but also to enhance Th1 responses (release of TNF-α and IFN-γ) 
(section 4.3). Assessment of the allergenicity of OP by challenge to mice sensitized to EW 
confirmed that it was hypoallergenic, even if there was a low degree of cross reactivity of IgG1 
and IgG2a antibodies of EW-allergic mice to the hydrolysate, likely because oral administration 
of EW plus CT led to sensitization to in vivo pepsin digestion products of OVA.  
As for its use as a therapeutic agent once EW allergy was established, OP decreased 
adverse reactions upon oral and subsequent i.p. challenges with the allergen. This correlated 
with a significant reduction in EW-specific IgE and IgG1 levels. However, treatment with the 
intact OVA for 3 weeks did not change the concentration of EW-specific IgE and IgG1, nor did 
it avoid allergic sings, temperature drops or release of mMCP-1 following challenge with EW. 
Successful desensitization with immunomodulatory hydrolysates or peptides is usually 
accompanied by a significant reduction in allergen-specific IgE levels (Yang et al., 2009b, 2010; 
Rupa and Mine, 2012; Wai et al., 2016). However, the role of other allergen-specific antibodies, 
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such as IgG and IgA is less clear. In view of the probable participation of IgG1 in anaphylaxis 
in our mouse model, decreased serum concentrations of this isotype are likely to account for 
clinical benefits. On the other hand, effective peptide-induced therapy has been attributed to 
increases in allergen-specific IgG2a or IgA levels, which would act as protective blocking 
antibodies in the circulation (Yang et al., 2010; Strait et al., 2011; Kulis et al., 2012; Rupa and 
Mine, 2012; Wai et al., 2016). In line with its weak immunogenicity, treatment with OP for 3 
weeks did not increase the concentration of IgG2a although it enhanced fecal IgA. In fact, 
evidence for induction of blocking antibodies through peptide immunotherapy is scarce, 
because, unlike whole allergens, short peptides selected on the basis of low IgE-binding and 
anti-inflammatory properties hold a restricted potential to drive antibody production (Prickett et 
al., 2015; Valenta et al., 2016). 
Whereas the role of blocking antibodies appears less important in peptide 
immunotherapy than in whole allergen immunotherapy; similarly to conventional 
immunotherapy, down-regulation of T cell proliferative and Th2 cytokine responses (whether 
IL-4, IL-5 or IL-13) to the allergen is usually reported (Yang et al., 2009b, 2010; Rupa and 
Mine, 2012; Kulis et al., 2012; Wai et al., 2016). However, different studies refer either an 
associated increase in Th1 cytokines (Yang et al., 2010; Rupa and Mine, 2012; Wai et al., 2016) 
or a concomitant Th1 decrease (Yang et al., 2009b). Treatment with OVA and OP decreased the 
expression of GATA-3 in the duodenum and PPs and the percentage of splenic activated Th2 
cells, with no change in the percentage of activated Th1 cells. Furthermore, both treatments 
decreased the production of IL-4, IL-5, IFN-γ, IL10 and IL-17 upon splenocyte re-stimulation. 
OP additionally downregulated GATA-3 and T-bet in the MLN, thus showing that it more 
efficiently counterbalanced the immunostimulating effects of CT, which primes, not only Th2 
(IL-4, IL-5 and IL-13), but also Th1 (IFN-γ) and Th17 (IL-17) responses in the MLNs and leads 
to mixed local and systemic cytokine responses (Blázquez and Berin, 2008). Upregulation of 
Foxp3 in intestinal tissues and of the percentage of T reg cells in the spleen of mice treated with 
OP points to a crucial role of these cells in the inhibition of Th1 and Th2 responses and 
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highlights induction of T reg cells as the main mechanism underlying the efficacy of tolerance 
induction by food peptides (Yang et al., 2009b and 2010; Wei et al., 2016). 
While immunotherapy with peptides has demonstrated sustained tolerance with fewer 
adverse events than conventional allergen immunotherapy in clinical trials for cat, house dust 
mite and pollen allergy, it is in a much more exploratory stage in the field of food allergy, where 
it has almost exclusively been assayed in vivo in murine models (Berin, 2014). Moreover, 
almost no studies compared the therapeutic efficacy of food peptides or hydrolysates with that 
of intact allergens or re-assessed protection from anaphylaxis after discontinuation of the 
treatment.  
According to Kulis et al. (2012), immunotherapy with pepsin-hydrolyzed cashew, 
which maintains the immunogenicity of the parent protein and its sensitizing potential but lacks 
eliciting potential, works through the same mechanism as immunotherapy with the intact 
allergen by virtue of the strong Th2-stimulating properties of the hydrolyzate. However, in our 
study, the immunomodulating peptides contained in OP, which were selected on the basis of 
their Th1 stimulating properties and absence of Th2 inducing capacity (section 4.2 and 4.3) 
were more effective that OVA in the induction of tolerance. In addition, repeated OVA gavage 
during immunotherapy treatment, unlike OP gavage, would have worked as a low-level repeated 
intragastric challenge, releasing epithelium-derived cytokines, such as IL-33 and IL-25. 
Furthermore, although no anaphylactic responses were observed, diarrhea during the first week 
of treatment with OVA was a symptomatic feature of IgE-mediated reactions. Stimulation of 
mouse mast cells by IgE cross-linking releases Th2-driving cytokines, such as IL-25, and 
enhances IL-4, acting as an amplifier of Th2 responses (Ikeda et al., 2003; Burton et al., 2014). 
Thus, repeated intragastric challenge induces intestinal IL-33, IL-25 and TSLP signaling and 
enhances Th2 cells, promoting the expansion of mucosal ILC2 and the collaboration between 
these innate cells and allergen-specific Th2 cells, ultimately acting, through IL-4, as a Foxp3 
inhibitor in T cell differentiation (Lee et al., 2016; Noval Rivas et al., 2016). Therefore, the lack 
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of IgE-binding and Th2-priming capacity of OP not only increases safety, but also efficacy of 
immunotherapy. 
Nevertheless, both OVA and OP treatments, offered long term desensitization. In fact, 
protection generated by OP was sustained 3 weeks after discontinuation of the treatment and 
that induced by OVA even increased after that period. This observation differs from the findings 
of Leonard et al. (2012) who reported that EW, administered as immunotherapy to OVA 
sensitized mice induced clinical, protection through desensitization but not immune tolerance. 
The immunological mechanism that appears to provide a long lasting beneficial effect of OVA 
an OP is related to the induction of T reg cells. Furthermore, it is noteworthy that peptides 
resulting from OVA fragmentation offered protection against challenge with whole EW. In this 
respect, it is also hypothesized that the most effective way to provide tolerance towards multiple 
epitopes within an allergenic protein, or even towards other allergens normally co-exposed with 
it, is through the induction of a regulatory function in the T cells primed by the tolerogenic 
substance (Mackenzie et al., 2012). 
The superior potential of OP versus OVA for allergy prevention and therapy linked to T 
reg cell development parallels a more efficient upregulation of the cytokines TGF-β, IL-10 and 
IL-17 in the intestinal tissues. Different cells, including DCs and IECs, express TGF-β and IL-
10 that facilitate the generation of T reg cells. In turn, T reg cells themselves produce TGF-β 
and IL-10 as part of their suppressive role on the conversion of naïve T cells into allergen-
specific Th2 cells and on the production of IL-4 (Palomares et al., 2014; Noval Rivas and 
Chatila, 2016) that, in mice, induces switching to IgE and IgG1 (Mestas and Hughes, 2004). 
TGF-β is a very important immunosuppressive cytokine through its critical function as a direct 
antagonist of Th1 development, affecting IFN-γ and T-bet, as well as of Th2 differentiation, but 
also as an inducer of T reg cells. However, an inflammatory stimulus, such as IL-6, suppresses 
the generation of TGF-β-induced T reg cells, allowing the diversion to IL-17 producing T cells, 
a process that, in the context of allergic diseases, can redirect a regulatory response towards a 
pro-inflammatory pathogenic phenotype (Bettelli et al., 2006; Veldhoen et al., 2006; Massoud et 
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al., 2016). Thus, T reg and Th17 cells arise in the periphery through a common intermediate that 
simultaneously upregulates both Foxp3 and RORγt, the Th17 master transcription factor, which 
in the mice represents a stable, suppressor effector T reg lineage, and competition of T reg with 
Th17 for their reciprocal development from this common precursor controls T reg or Th17 
development (Lochner et al., 2015). Furthermore, it is now known that the microbiota  induces 
T reg cells bearing RORγt that differentiate along a pathway that also leads to Th17 cells, and 
that both, RORγt+ T reg and Th17 cells, contribute to the control of exacerbated Th2 responses 
(Ohnmacht et al., 2015; Chinthrajah et al., 2016). In fact, T reg cells not only suppress the 
function of Th17 cells, but also support their development, since low levels of IL-17 in the 
intestine are beneficial and protect from inflammation (Lochner et al., 2015). Therefore, the 
concomitant upregulation of TGF-β, IL-10 and IL-17 observed in the intestinal tissues of mice, 
either preventive or therapeutically treated with OP, could work together in the inhibition of 
Th2 and inflammatory responses contributing to a balanced immune response. 
In conclusion, OP was hypoallergenic and weakly immunogenic and offered preventive 
and therapeutic protection against allergy to EW through the induction of T reg cells and the 
upregulation of TGF-β, IL-10 and IL-17 in intestinal tissues. This restrained the differentiation 
of Th2 cells and led to low Th2 and Th1 systemic responses following allergen stimulation. OP 
was more efficacious than intact OVA in desensitizing mice by virtue of its lower allergenicity 
and its immunomodulating capacity. In general terms, our screening strategy proved useful to 
select the critical hydrolysate that combined desired tolerance with the absence of undesired 
effects of IgE-crosslinking and inflammatory cell activation, although in vivo testing of OA 
revealed immunogenic and antigenic capacities not previously detected by in vitro methods. 
This study provides evidence for the essential role of T reg in the prevention of allergy 
development and in the promotion of long term desensitization to allergens as well as of linked-
epitope suppression. 
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Based on the results obtained in this thesis, the following conclusions can be drawn: 
First: The hydrolysates of egg white proteins produced with alcalase, and that of 
ovalbumin with pepsin, are hypoallergenic revealing a low IgE-binding capacity demonstrated 
in vitro and in vivo. 
Second: The enzymatic treatment of egg white proteins with alcalase, together with the 
ovalbumin hydrolysed with pepsin, contain modulating peptides able to decrease the release of 
Th2-biased cytokines and inhibit inflammatory events in murine cells unspecifically stimulated 
with T and B cells mitogens.     
Third: The hydrolysates prepared with alcalase, and that of ovalbumin with pepsin, 
help to re-establish the Th1/Th2 balance in a model of Th2-skewed peripheral blood 
mononuclear cells. In addition, these hydrolysates also inhibit the release of pro-inflammatory 
mediators and reduce oxidative stress in peripheral blood leukocytes treated with inflammatory 
stimuli. 
Fourth: The hydrolysate of ovalbumin with pepsin shows immunomodulatoting effects 
on splenocytes from BALB/c mice sensitized to individual egg proteins, or their mixture in 
different proportion. This hydrolysate stimulates slight immune responses and down-regulates 
Th2 cytokine profile induced by intact egg allergens ex vivo, contributing to increase the 
secretion of Th1-biased cytokines. 
Fifth: Ovalbumin hydrolysed with alcalase induces low Th2 responses in spleen cells 
from mice sensitized to egg white proteins in different proportions. However, this hydrolysate 
reveals immunogenic properties when it is administered together with cholera toxin to BALB/c 
mice and an antigenic ability offered to a murine model of egg allergy. 
Sixth: The hydrolysate of ovalbumin with pepsin is weakly immunogenic and offers 
preventive and therapeutic protection against allergy to egg white through the induction of 
regulatory T cells and the upregulation of TGF-β, IL-10 and IL-17 in intestinal tissues. 
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Seventh: The therapeutic administration of ovalbumin hydrolysed with pepsin is more 
efficacious in egg white-sensitized mice than the intact protein it derives from, by virtue of its 
lower allergenicity and its immunomodulating capacity. 
Finally, in the light of the results achieved, the screening strategy followed in this work 
proved useful to select the ovalbumin enzymatically treated with pepsin as a critical hydrolysate 
that combines tolerance induction with the absence of undesired effects of IgE-crosslinking and 
inflammatory cell activation. Together, this doctoral thesis stands the hydrolysate of ovalbumin 
with pepsin as a simple to obtain, cheap and safe candidate to be used in the prevention and 
treatment of egg allergy. 
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A partir de los resultados obtenidos en esta tesis, se pueden extraer las siguientes 
conclusiones: 
Primera: Los hidrolizados de clara de huevo producidos con alcalasa, y el de 
ovalbúmina con pepsin, son hipoalergénicos presentando una baja capacidad de unión a IgE que 
se demostró tanto in vitro como in vivo. 
Segunda: El tratamiento de las proteínas de la clara de huevo con alcalasa, junto con la 
ovalbúmina hidrolizada con pepsin, contienen péptidos modulantes capaces de disminuir la 
liberación de citoquinas del tipo Th2 y de inhibir eventos inflamatorios en células de ratón 
inespecíficamente estimuladas con mitógenos de células T y B.  
Tercera: Los hidrolizados preparados con alcalasa, y el de ovalbúmina con pepsina, 
ayudan a restablecer el balance Th1/Th2 en un modelo de células mononucleares humanas de 
sangre periférica polarizadas hacia una respuesta Th2. Además, estos hidrolizados también 
inhiben la liberación de mediadores pro-inflamatorios en leucocitos humanos de sangre 
periférica derivados hacia una respuesta del tipo Th1.  
Cuarta: La ovalbúmina hidrolizada con pepsina muestra efectos inmunomodulantes en 
esplenocitos de ratones BALB/c sensibilizados a las proteínas del huevo, individualmente o en 
su mezcla a diferentes proporciones. Este hidrolizado produce una débil estimulación de la 
respuesta inmune a la vez que es capaz de disminuir el perfil de citoquinas Th2 inducido por el 
propio alérgeno ex vivo mediante el aumento de la secreción de citoquinas del tipo Th1.  
Quinta: El hidrolizado de ovalbúmina con alcalasa induce una escasa respuesta Th2 en 
células de bazo procedentes de ratones sensibilizados a las proteínas de la clara de huevo, 
individualmente o en diferentes proporciones. Sin embargo, este hidrolizado posee propiedades 
inmungénicas cuando es administrado junto con toxina de cólera a ratones BALB/c y muestra 
un marcado carácter antigénico cuando es suministrado a un modelo múrido de alergia al huevo.  
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Sexta: La ovalbúmina hidrolizada con pepsina es escasamente inmunogénica y confiere 
protección, tanto preventiva como terapéutica, frente a la alergia al huevo a través de la 
inducción de células T reguladoras y la producción de TGF-β, IL-10 e IL-17 a nivel intestinal.  
Séptima: La administración terapéutica del hidrolizado de ovalbúmina con pepsina es 
más eficaz que el uso de la proteína intacta de la que proviene debido a su menor alergenicidad 
y a su capacidad inmunomodulante.  
Finalmente, a la luz de estos resultados, se puede establecer que la estrategia de 
evaluación seguida en este trabajo fue útil para la selección de la ovalbúmina hidrolizada con 
pepsina como una preparación que combina la capacidad de inducir tolerancia con la ausencia 
de efectos indeseables derivados del entrecruzamiento de las moléculas de IgE o de la 
activación inflamatoria a nivel celular. En su conjunto, esta tesis doctoral revela al hidrolizado 
de ovalbúmina con pepsina como un posible candidato sencillo de obtener, barato y seguro para 
ser utilizado en la prevención y el tratamiento de la alergia al huevo.  
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Annexe I. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the hydrolysate of 
ovalbumin with pepsin. 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
1204.6 1204.6 1+ 23 20.8 17 - 26 KELKVHHANE  
947.5 947.5 1+ 22 20.5 19 - 26 LKVHHANE  
834.4 834.4 1+ 16 16.0 20 - 26 KVHHANE  
566.2 566.3 1+ 13 31.5 30 - 34 YCPIA  
522.2 522.3 1+ 19 30.4 42 - 46 VYLGA  
765.4 765.4 1+ 8 26.5 42 - 48 VYLGAKD  
953.5 953.5 1+ 45 26.3 42 - 50 VYLGAKDST  
1210.6 1210.6 1+ 15 26.0 42 - 52 VYLGAKDSTRT  
783.4 1565.8 2+ 11 29.2 42 - 55 VYLGAKDSTRTQIN  
948.5 948.5 1+ 9 19.7 44 - 52 LGAKDSTRT  
660.0 1318.7 2+ 16 19.9 45 - 56 GAKDSTRTQINK  
707.3 707.4 1+ 8 13.9 47 - 52 KDSTRT  
948.4 948.5 1+ 12 23.4 47 - 54 KDSTRTQI  
1062.6 1062.6 1+ 7 20.2 47 - 55 KDSTRTQIN  
676.4 676.4 1+ 10 37.5 61 - 66 DKLPGF  
848.4 848.4 1+ 25 34.8 61 - 68 DKLPGFGD  
566.1 566.2 1+ 15 13.9 72 - 77 AQCGTS  
665.3 665.3 1+ 10 21.8 72 - 78 AQCGTSV  
779.3 779.3 1+ 6 19.0 72 - 79 AQCGTSVN  
878.4 878.4 1+ 7 27.3 72 - 80 AQCGTSVNV  
755.4 755.4 1+ 21 28.6 78 - 84 VNVHSSL  
656.3 656.3 1+ 21 25.0 79 - 84 NVHSSL  
758.4 758.4 1+ 6 28.3 85 - 90 RDILNQ  
929.5 929.5 1+ 13 20.9 89 - 96 NQITKPND  
1028.5 1028.5 1+ 12 25.6 89 - 97 NQITKPNDV  
687.3 687.4 1+ 17 19.7 91 - 96 ITKPND  
949.5 949.5 1+ 18 28.1 91 - 98 ITKPNDVY  
1036.5 1036.5 1+ 12 26.1 91 - 99 ITKPNDVYS  
533.1 533.3 1+ 16 22.8 101 - 105 SLASR  
646.4 646.4 1+ 5 32.9 101 - 106 SLASRL  
667.2 667.3 1+ 11 21.1 107 - 111 YAEER  
830.4 830.4 1+ 21 24.4 107 - 112 YAEERY  
790.4 790.4 1+ 19 38.9 110 - 115 ERYPIL  
719.4 719.4 1+ 20 24.7 119 - 124 LQCVKE  
832.4 832.5 1+ 43 34.8 119 - 125 LQCVKEL  
807.4 807.4 1+ 6 29.2 125 - 131 LYRGGLE  
694.4 694.4 1+ 7 24.8 126 - 131 YRGGLE  
1018.5 1018.5 1+ 5 32.0 126 - 134 YRGGLEPIN  
1165.6 1165.6 1+ 12 42.3 126 - 135 YRGGLEPINF  
633.2 633.3 1+ 18 13.8 136 - 141 QTAADQ  
704.2 704.3 1+ 10 16.8 136 - 142 QTAADQA  
731.4 731.4 1+ 6 26.7 143 - 148 RELINS  
747.3 747.4 1+ 9 29.8 146 - 151 INSWVE  
749.3 749.3 1+ 11 25.2 149 - 154 WVESQT  
920.4 920.4 1+ 5 24.3 149 - 156 WVESQTNG  
734.3 734.3 1+ 12 14.9 150 - 156 VESQTNG  
506.0 506.2 1+ 17 7.5 152 - 156 SQTNG  
727.5 727.5 1+ 17 36.0 157 - 162 IIRNVL  
1126.6 1126.7 1+ 9 33.6 157 - 166 IIRNVLQPSS  
630.3 630.3 1+ 28 21.5 161 - 166 VLQPSS  
729.4 729.4 1+ 16 28.8 161 - 167 VLQPSSV  
844.4 844.4 1+ 11 26.7 161 - 168 VLQPSSVD  
1059.5 1059.5 1+ 11 25.0 161 - 170 VLQPSSVDSQ  
632.3 632.3 1+ 7 20.4 163 - 168 QPSSVD  
719.2 719.3 1+ 17 17.0 164 - 170 PSSVDSQ  
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652.2 652.3 1+ 10 20.1 168 - 173 DSQTAM  
537.2 537.2 1+ 9 20.0 169 - 173 SQTAM  
515.2 515.3 1+ 11 27.6 174 - 178 VLVNA  
953.4 953.4 1+ 13 21.8 189 - 196 FKDEDTQA  
806.3 806.4 1+ 18 16.0 190 - 196 KDEDTQA  
593.3 593.3 1+ 14 42.5 195 - 199 QAMPF  
879.4 879.4 1+ 13 35.6 197 - 203 MPFRVTE  
1007.5 1007.5 1+ 7 34.1 197 - 204 MPFRVTEQ  
748.4 748.4 1+ 19 30.1 198 - 203 PFRVTE  
876.4 876.5 1+ 8 28.6 198 - 204 PFRVTEQ  
779.4 779.4 1+ 13 26.6 199 - 204 FRVTEQ  
815.4 815.4 1+ 10 17.8 204 - 210 QESKPVQ  
946.5 946.5 1+ 5 25.5 204 - 211 QESKPVQM  
687.3 687.4 1+ 16 17.4 205 - 210 ESKPVQ  
818.4 818.4 1+ 15 25.3 205 - 211 ESKPVQM  
949.4 949.4 1+ 19 30.6 205 - 212 ESKPVQMM  
593.3 593.3 1+ 22 38.6 213 - 217 YQIGL  
710.3 710.4 1+ 5 34.5 218 - 223 FRVASM  
565.2 565.3 1+ 9 19.5 224 - 228 ASEKM  
806.4 806.4 1+ 19 28.6 224 - 230 ASEKMKI  
1048.6 1048.6 1+ 13 33.2 224 - 232 ASEKMKILE  
761.5 761.5 1+ 7 32.3 227 - 232 KMKILE  
874.6 874.5 1+ 14 41.9 227 - 233 KMKILEL  
615.4 615.4 1+ 16 39.4 229 - 233 KILEL  
823.4 823.4 1+ 14 39.6 233 - 240 LPFASGTM  
579.3 579.3 1+ 20 23.5 234 - 239 PFASGT  
797.3 797.3 1+ 20 28.4 234 - 241 PFASGTMS  
685.3 685.4 1+ 19 34.1 244 - 249 VLLPDE  
829.3 829.4 1+ 13 37.3 246 - 253 LPDEVSGL  
722.3 722.4 1+ 13 42.6 257 - 262 ESIINF  
619.3 619.3 1+ 18 21.5 263 - 267 EKLTE  
822.4 822.4 1+ 5 41.3 267 - 273 EWTSSNV  
594.2 594.3 1+ 8 19.2 268 - 272 WTSSN  
901.5 901.5 1+ 16 25.9 275 - 281 EERKIKV  
1177.7 1177.7 1+ 11 36.8 275 - 283 EERKIKVYL  
935.6 935.6 1+ 11 27.7 276 - 282 ERKIKVY  
1048.6 1048.7 1+ 7 36.4 276 - 283 ERKIKVYL  
662.3 662.3 1+ 13 26.3 284 - 288 PRMKM  
725.3 725.3 1+ 6 29.8 307 - 313 FSSSANL  
374.9 748.4 2+ 17 26.5 309 - 316 SSANLSGI  
521.1 521.3 1+ 12 20.7 314 - 319 SGISSA  
1132.6 1132.6 1+ 16 23.8 323 - 333 KISQAVHAAHA  
605.4 605.3 1+ 6 16.2 327 - 332 AVHAAH  
676.3 676.4 1+ 26 18.6 327 - 333 AVHAAHA  
805.4 805.4 1+ 20 18.4 327 - 334 AVHAAHAE  
918.5 918.5 1+ 46 27.2 327 - 335 AVHAAHAEI  
1161.6 1161.6 1+ 23 24.2 327 - 337 AVHAAHAEINE  
605.3 605.3 1+ 11 17.6 328 - 333 VHAAHA  
632.3 632.3 1+ 11 16.5 334 - 339 EINEAG  
675.3 675.3 1+ 11 15.3 336 - 341 NEAGRE  
687.4 687.4 1+ 7 21.9 338 - 344 AGREVVG  
845.4 845.4 1+ 22 22.6 338 - 346 AGREVVGSA  
432.1 432.2 1+ 19 18.1 342 - 346 VVGSA  
632.3 632.3 1+ 6 20.3 342 - 348 VVGSAEA  
790.4 790.4 1+ 14 25.1 346 - 354 AEAGVDAAS  
550.2 550.2 1+ 17 17.0 354 - 358 SVSEE  
1131.6 1131.6 1+ 7 40.5 358 - 366 EFRADHPFL  
1002.5 1002.5 1+ 11 39.9 359 - 366 FRADHPFL  
742.4 742.4 1+ 10 27.9 360 - 365 RADHPF  
855.5 855.4 1+ 18 36.4 360 - 366 RADHPFL  
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1046.5 1046.5 1+ 21 32.6 367 - 375 FCIKHIATN  
785.4 785.4 1+ 8 24.5 368 - 374 CIKHIAT  
899.5 899.5 1+ 13 22.7 368 - 375 CIKHIATN  
970.5 970.5 1+ 12 24.5 368 - 376 CIKHIATNA  
682.4 682.4 1+ 12 23.4 369 - 374 IKHIAT  
796.4 796.5 1+ 16 21.3 369 - 375 IKHIATN  
701.4 701.4 1+ 9 42.2 372 - 378 IATNAVL  
629.3 629.3 1+ 5 33.6 379 - 383 FFGRC  
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Annexe II. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the Fraction 1 of the 
hydrolysate of ovalbumin with pepsin separated by semi-preparative RP-HPLC (RP-OP1). 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
835.5 835.4 1+ 15 15.6 45 - 52 GAKDSTRT  
734.4 734.3 1+ 13 15.0 150 - 156 VESQTNG  
806.4 806.4 1+ 33 15.9 190 - 196 KDEDTQA  
687.5 687.4 1+ 16 17.3 205 - 210 ESKPVQ  
619.4 619.3 1+ 15 21.3 263 - 267 EKLTE  
594.3 594.3 1+ 16 19.1 268 - 272 WTSSN  
676.4 676.4 1+ 16 18.3 327 - 333 AVHAAHA  
805.4 805.4 1+ 25 18.1 327 - 334 AVHAAHAE  
692.3 692.3 1+ 23 18.9 352 - 358 AASVSEE  
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Annexe III. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the Fraction 2 of the 
hydrolysate of ovalbumin with pepsin separated by semi-preparative RP-HPLC (RP-OP2). 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
1204.8 1204.6 1+ 37 20.4 17 - 26 KELKVHHANE  
947.6 947.5 1+ 38 20.3 19 - 26 LKVHHANE  
522.3 522.3 1+ 17 30.0 42 - 46 VYLGA  
765.5 765.4 1+ 16 26.1 42 - 48 VYLGAKD  
953.6 953.5 1+ 35 25.9 42 - 50 VYLGAKDST  
605.9 1210.6 2+ 8 25.6 42 - 52 VYLGAKDSTRT  
1190.7 1190.6 1+ 7 20.2 45 - 55 GAKDSTRTQIN  
1133.7 1133.6 1+ 11 20.0 46 - 55 AKDSTRTQIN  
858.6 858.5 1+ 21 23.3 51 - 57 RTQINKV  
848.6 848.4 1+ 19 34.5 61 - 68 DKLPGFGD  
755.5 755.4 1+ 18 28.2 78 - 84 VNVHSSL  
656.4 656.3 1+ 23 24.6 79 - 84 NVHSSL  
758.5 758.4 1+ 13 27.9 85 - 90 RDILNQ  
929.6 929.5 1+ 28 20.6 89 - 96 NQITKPND  
687.4 687.4 1+ 19 19.4 91 - 96 ITKPND  
786.5 786.4 1+ 18 24.1 91 - 97 ITKPNDV  
830.5 830.4 1+ 21 24.0 107 - 112 YAEERY  
790.5 790.4 1+ 14 38.8 110 - 115 ERYPIL  
887.6 887.5 1+ 27 37.0 111 - 117 RYPILPE  
904.6 904.5 1+ 15 35.9 126 - 133 YRGGLEPI  
731.4 731.4 1+ 8 26.3 143 - 148 RELINS  
920.5 920.4 1+ 22 23.8 149 - 156 WVESQTNG  
727.5 727.5 1+ 7 35.8 157 - 162 IIRNVL  
729.5 729.4 1+ 14 28.4 161 - 167 VLQPSSV  
931.6 931.5 1+ 14 25.7 161 - 169 VLQPSSVDS  
1059.6 1059.5 1+ 28 24.7 161 - 170 VLQPSSVDSQ  
515.2 515.3 1+ 18 27.3 174 - 178 VLVNA  
953.5 953.4 1+ 18 21.5 189 - 196 FKDEDTQA  
879.5 879.4 1+ 9 35.2 197 - 203 MPFRVTE  
1007.6 1007.5 1+ 11 33.7 197 - 204 MPFRVTEQ  
818.5 818.4 1+ 21 25.0 205 - 211 ESKPVQM  
761.5 761.5 1+ 21 31.9 227 - 232 KMKILE  
579.4 579.3 1+ 16 23.1 234 - 239 PFASGT  
710.4 710.3 1+ 11 30.8 234 - 240 PFASGTM  
716.4 716.3 1+ 24 31.3 247 - 253 PDEVSGL  
722.5 722.4 1+ 10 42.5 257 - 262 ESIINF  
901.7 901.5 1+ 18 25.4 275 - 281 EERKIKV  
1048.7 1048.7 1+ 11 36.2 276 - 283 ERKIKVYL  
662.5 662.3 1+ 8 25.9 284 - 288 PRMKM  
875.5 875.5 1+ 8 27.1 319 - 326 AESLKISQ  
1132.7 1132.6 1+ 11 23.4 323 - 333 KISQAVHAAHA  
676.4 676.4 1+ 41 18.1 327 - 333 AVHAAHA  
805.6 805.4 1+ 11 18.1 327 - 334 AVHAAHAE  
918.5 918.5 1+ 20 26.8 327 - 335 AVHAAHAEI  
1161.7 1161.6 1+ 21 23.8 327 - 337 AVHAAHAEINE  
687.3 687.4 1+ 24 21.5 338 - 344 AGREVVG  
845.5 845.4 1+ 17 22.3 338 - 346 AGREVVGSA  
889.5 889.4 1+ 11 33.8 359 - 365 FRADHPF  
855.5 855.4 1+ 16 36.2 360 - 366 RADHPFL  
682.5 682.4 1+ 14 22.9 369 - 374 IKHIAT  
796.5 796.5 1+ 17 21.0 369 - 375 IKHIATN  
867.6 867.5 1+ 19 22.8 369 - 376 IKHIATNA  
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Annexe IV. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the Fraction 3 of the 
hydrolysate of ovalbumin with pepsin separated by semi-preparative RP-HPLC (RP-OP3). 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
783.4 1565.8 2+ 9 28.6 42 - 55 VYLGAKDSTRTQIN  
847.5 1693.9 2+ 12 27.1 42 - 56 VYLGAKDSTRTQINK  
676.4 676.4 1+ 28 37.2 61 - 66 DKLPGF  
935.5 935.4 1+ 11 34.1 61 - 69 DKLPGFGDS  
1028.4 1028.5 1+ 7 25.3 89 - 97 NQITKPNDV  
949.5 949.5 1+ 26 27.8 91 - 98 ITKPNDVY  
1036.6 1036.5 1+ 13 25.9 91 - 99 ITKPNDVYS  
646.4 646.4 1+ 8 32.5 101 - 106 SLASRL  
790.5 790.4 1+ 19 38.7 110 - 115 ERYPIL  
807.4 807.4 1+ 6 38.1 125 - 131 LYRGGLE  
1150.1 2299.2 2+ 6 31.4 142 - 161 ARELINSWVESQTNGIIRNV  
1225.8 1225.7 1+ 8 36.9 157 - 167 IIRNVLQPSSV  
879.5 879.4 1+ 15 35.2 197 - 203 MPFRVTE  
1007.6 1007.5 1+ 23 33.7 197 - 204 MPFRVTEQ  
748.4 748.4 1+ 12 29.8 198 - 203 PFRVTE  
876.5 876.5 1+ 8 33.6 198 - 204 PFRVTEQ  
761.5 761.5 1+ 15 31.9 227 - 232 KMKILE  
928.5 928.4 1+ 18 36.6 234 - 242 PFASGTMSM  
829.2 829.4 1+ 14 37.0 246 - 253 LPDEVSGL  
722.4 722.4 1+ 18 42.4 257 - 262 ESIINF  
1048.8 1048.7 1+ 7 36.1 276 - 283 ERKIKVYL  
919.7 919.6 1+ 11 35.7 277 - 283 RKIKVYL  
1132.8 1132.6 1+ 20 23.6 323 - 333 KISQAVHAAHA  
1002.6 1002.5 1+ 7 39.6 359 - 366 FRADHPFL  
855.5 855.4 1+ 25 36.2 360 - 366 RADHPFL  
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Annexe V. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the Fraction 4 of the 
hydrolysate of ovalbumin with pepsin separated by semi-preparative RP-HPLC (RP-OP4). 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
903.5 1805.9 2+ 9 35.6 28 - 43 IFYCPIAIMSALAMVY  
783.4 1565.8 2+ 21 28.6 42 - 55 VYLGAKDSTRTQIN  
676.4 676.4 1+ 15 37.1 61 - 66 DKLPGF  
848.5 848.4 1+ 16 34.5 61 - 68 DKLPGFGD  
949.6 949.5 1+ 11 27.8 91 - 98 ITKPNDVY  
632.5 632.4 1+ 8 34.2 227 - 231 KMKIL  
874.6 874.5 1+ 21 41.5 227 - 233 KMKILEL  
746.6 746.4 1+ 23 43.3 228 - 233 MKILEL  
556.3 556.3 1+ 16 34.1 244 - 248 VLLPD  
1177.9 1177.7 1+ 24 36.3 275 - 283 EERKIKVYL  
647.5 647.4 1+ 9 29.9 281 - 285 VYLPR  
855.6 855.4 1+ 9 36.1 360 - 366 RADHPFL  
699.5 699.3 1+ 8 37.3 361 - 366 ADHPFL  
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Annexe VI. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the Fraction 5 of the 
hydrolysate of ovalbumin with pepsin separated by semi-preparative RP-HPLC (RP-OP5). 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
1210.8 1210.6 1+ 8 25.7 42 - 52 VYLGAKDSTRT  
783.5 1565.8 2+ 15 28.6 42 - 55 VYLGAKDSTRTQIN  
676.4 676.4 1+ 31 37.1 61 - 66 DKLPGF  
848.4 848.4 1+ 18 34.4 61 - 68 DKLPGFGD  
755.6 755.4 1+ 23 28.3 78 - 84 VNVHSSL  
949.6 949.5 1+ 20 27.8 91 - 98 ITKPNDVY  
1036.6 1036.5 1+ 17 25.8 91 - 99 ITKPNDVYS  
790.5 790.4 1+ 17 38.6 110 - 115 ERYPIL  
791.5 2372.2 3+ 7 78.0 150 - 171 VESQTNGIIRNVLQPSSVDSQT  
727.6 727.5 1+ 16 35.8 157 - 162 IIRNVL  
1225.8 1225.7 1+ 11 36.8 157 - 167 IIRNVLQPSSV  
879.6 879.4 1+ 9 35.2 197 - 203 MPFRVTE  
710.4 710.4 1+ 8 34.1 218 - 223 FRVASM  
761.5 761.5 1+ 24 31.9 227 - 232 KMKILE  
615.5 615.4 1+ 11 39.2 229 - 233 KILEL  
823.4 823.4 1+ 14 39.3 233 - 240 LPFASGTM  
710.3 710.3 1+ 22 30.7 234 - 240 PFASGTM  
829.5 829.4 1+ 8 36.9 246 - 253 LPDEVSGL  
722.5 722.4 1+ 25 42.4 257 - 262 ESIINF  
919.8 919.6 1+ 16 35.5 277 - 283 RKIKVYL  
1132.8 1132.6 1+ 33 23.5 323 - 333 KISQAVHAAHA  
1161.7 1161.6 1+ 11 23.9 327 - 337 AVHAAHAEINE  
1002.7 1002.5 1+ 11 39.5 359 - 366 FRADHPFL  
855.6 855.4 1+ 16 36.0 360 - 366 RADHPFL  
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Annexe VII. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the Fraction 1 of the 
hydrolysate of ovalbumin with pepsin separated by anion exchange chromatography (AE-OP1). 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
1204.8 1204.6 1+ 26 19.9 17 - 26 KELKVHHANE  
716.4 1431.8 2+ 24 24.9 17 - 28 KELKVHHANENI  
947.7 947.5 1+ 13 19.6 19 - 26 LKVHHANE  
834.5 834.4 1+ 21 15.6 20 - 26 KVHHANE  
706.4 706.3 1+ 24 15.0 21 - 26 VHHANE  
522.3 522.3 1+ 20 29.4 42 - 46 VYLGA  
765.4 765.4 1+ 17 25.3 42 - 48 VYLGAKD  
783.4 1565.8 2+ 22 27.8 42 - 55 VYLGAKDSTRTQIN  
652.4 1303.7 2+ 9 22.6 44 - 55 LGAKDSTRTQIN  
716.5 1431.8 2+ 7 21.4 44 - 56 LGAKDSTRTQINK  
835.4 835.4 1+ 17 14.7 45 - 52 GAKDSTRT  
934.5 934.5 1+ 13 19.4 48 - 55 DSTRTQIN  
676.5 676.4 1+ 29 36.4 61 - 66 DKLPGF  
755.5 755.4 1+ 26 27.4 78 - 84 VNVHSSL  
656.4 656.3 1+ 22 23.8 79 - 84 NVHSSL  
929.5 929.5 1+ 22 20.2 89 - 96 NQITKPND  
1028.6 1028.5 1+ 19 24.7 89 - 97 NQITKPNDV  
687.4 687.4 1+ 23 19.0 91 - 96 ITKPND  
786.5 786.4 1+ 14 23.6 91 - 97 ITKPNDV  
949.5 949.5 1+ 29 27.0 91 - 98 ITKPNDVY  
1036.6 1036.5 1+ 16 25.1 91 - 99 ITKPNDVYS  
646.5 646.4 1+ 7 31.7 101 - 106 SLASRL  
790.5 790.4 1+ 15 37.8 110 - 115 ERYPIL  
661.5 661.4 1+ 8 37.6 111 - 115 RYPIL  
1165.7 1165.6 1+ 7 41.9 126 - 135 YRGGLEPINF  
616.5 616.3 1+ 9 43.6 141 - 145 QAREL  
727.5 727.5 1+ 10 34.6 157 - 162 IIRNVL  
630.4 630.3 1+ 21 21.0 161 - 166 VLQPSS  
729.5 729.4 1+ 23 28.0 161 - 167 VLQPSSV  
879.5 879.4 1+ 15 34.3 197 - 203 MPFRVTE  
1007.6 1007.5 1+ 12 32.7 197 - 204 MPFRVTEQ  
687.4 687.4 1+ 22 17.0 205 - 210 ESKPVQ  
818.5 818.4 1+ 11 24.1 205 - 211 ESKPVQM  
949.5 949.4 1+ 24 29.6 205 - 212 ESKPVQMM  
593.3 593.3 1+ 24 38.0 213 - 217 YQIGL  
710.4 710.4 1+ 8 32.9 218 - 223 FRVASM  
563.3 563.3 1+ 15 22.3 219 - 223 RVASM  
806.5 806.4 1+ 13 26.7 224 - 230 ASEKMKI  
1048.7 1048.6 1+ 21 31.9 224 - 232 ASEKMKILE  
761.5 761.5 1+ 22 30.8 227 - 232 KMKILE  
874.6 874.5 1+ 15 41.4 227 - 233 KMKILEL  
692.4 692.4 1+ 8 33.4 233 - 239 LPFASGT  
823.5 823.4 1+ 12 39.2 233 - 240 LPFASGTM  
910.5 910.4 1+ 24 37.0 233 - 241 LPFASGTMS  
579.3 579.3 1+ 8 22.7 234 - 239 PFASGT  
710.4 710.3 1+ 22 30.1 234 - 240 PFASGTM  
797.4 797.3 1+ 19 27.4 234 - 241 PFASGTMS  
722.4 722.4 1+ 11 42.4 257 - 262 ESIINF  
593.3 593.3 1+ 12 42.1 258 - 262 SIINF  
594.3 594.3 1+ 17 18.7 268 - 272 WTSSN  
1177.8 1177.7 1+ 8 35.4 275 - 283 EERKIKVYL  
673.5 673.4 1+ 16 17.2 276 - 280 ERKIK  
1048.8 1048.7 1+ 9 34.8 276 - 283 ERKIKVYL  
662.4 662.3 1+ 10 24.7 284 - 288 PRMKM  
725.4 725.3 1+ 9 28.9 307 - 313 FSSSANL  
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1132.8 1132.6 1+ 22 22.9 323 - 333 KISQAVHAAHA  
891.5 891.4 1+ 16 22.8 325 - 333 SQAVHAAHA  
605.4 605.3 1+ 17 15.7 327 - 332 AVHAAH  
676.4 676.4 1+ 42 17.7 327 - 333 AVHAAHA  
605.4 605.3 1+ 21 17.2 328 - 333 VHAAHA  
687.4 687.4 1+ 22 21.0 338 - 344 AGREVVG  
845.5 845.4 1+ 22 21.9 338 - 346 AGREVVGSA  
1002.6 1002.5 1+ 24 38.7 359 - 366 FRADHPFL  
855.5 855.4 1+ 11 34.1 360 - 366 RADHPFL  
682.5 682.4 1+ 21 22.4 369 - 374 IKHIAT  
796.5 796.5 1+ 16 20.5 369 - 375 IKHIATN  
867.6 867.5 1+ 13 22.5 369 - 376 IKHIATNA  
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Annexe VIII. Peptide sequences, identified by RP-HPLC-MS/MS (ESI-MS/MS), in the Fraction 2 of the 
hydrolysate of ovalbumin with pepsin separated by anion exchange chromatography (AE-OP2). 
Measured 
M/z 
Calculated 
MH+ 
z 
Mascot 
Score 
Rt(min) Range Sequence 
508.2 508.2 1+ 15 17.7 6, - 10 AASME  
753.5 753.5 1+ 18 20.5 17 - 22 KELKVH  
1204.7 1204.6 1+ 34 20.3 17 - 26 KELKVHHANE  
789.9 1578.8 2+ 8 26.5 17 - 29 KELKVHHANENIF  
706.4 706.3 1+ 13 15.1 21 - 26 VHHANE  
522.2 522.3 1+ 9 29.7 42 - 46 VYLGA  
765.5 765.4 1+ 15 25.8 42 - 48 VYLGAKD  
953.6 953.5 1+ 30 25.7 42 - 50 VYLGAKDST  
848.5 848.4 1+ 24 34.0 61 - 68 DKLPGFGD  
935.6 935.4 1+ 14 33.7 61 - 69 DKLPGFGDS  
827.5 827.4 1+ 8 23.5 81 - 87 HSSLRDI  
687.4 687.4 1+ 15 19.3 91 - 96 ITKPND  
949.6 949.5 1+ 9 27.4 91 - 98 ITKPNDVY  
1036.6 1036.5 1+ 6 25.5 91 - 99 ITKPNDVYS  
919.6 919.5 1+ 15 38.8 109 - 115 EERYPIL  
790.5 790.4 1+ 14 38.2 110 - 115 ERYPIL  
807.5 807.4 1+ 13 28.3 125 - 131 LYRGGLE  
694.4 694.4 1+ 12 24.3 126 - 131 YRGGLE  
734.4 734.3 1+ 17 13.6 150 - 156 VESQTNG  
844.5 844.4 1+ 19 26.2 161 - 168 VLQPSSVD  
931.6 931.5 1+ 18 25.7 161 - 169 VLQPSSVDS  
517.4 517.3 1+ 10 16.6 163 - 167 QPSSV  
620.3 620.3 1+ 11 15.5 167 - 172 VDSQTA  
653.4 653.3 1+ 18 19.1 189 - 193 FKDED  
754.4 754.3 1+ 14 19.9 189 - 194 FKDEDT  
882.5 882.4 1+ 10 19.6 189 - 195 FKDEDTQ  
953.5 953.4 1+ 18 21.2 189 - 196 FKDEDTQA  
879.5 879.4 1+ 8 34.7 197 - 203 MPFRVTE  
593.4 593.3 1+ 26 38.1 213 - 217 YQIGL  
740.5 740.4 1+ 13 45.6 213 - 218 YQIGLF  
1065.6 1065.5 1+ 13 45.4 231 - 240 LELPFASGTM  
579.3 579.3 1+ 29 23.0 234 - 239 PFASGT  
710.3 710.3 1+ 23 30.4 234 - 240 PFASGTM  
928.5 928.4 1+ 8 36.3 234 - 242 PFASGTMSM  
798.4 798.5 1+ 12 40.7 243 - 249 LVLLPDE  
685.4 685.4 1+ 40 33.5 244 - 249 VLLPDE  
1041.7 1041.6 1+ 15 41.8 244 - 253 VLLPDEVSGL  
829.5 829.4 1+ 17 36.8 246 - 253 LPDEVSGL  
504.1 504.3 1+ 7 16.0 250 - 254 VSGLE  
718.5 718.4 1+ 6 28.7 254 - 259 EQLESI  
575.3 575.3 1+ 13 26.8 257 - 261 ESIIN  
722.4 722.4 1+ 19 42.3 257 - 262 ESIINF  
763.5 763.4 1+ 9 37.0 260 - 265 INFEKL  
619.4 619.3 1+ 10 20.7 263 - 267 EKLTE  
824.4 824.3 1+ 9 23.3 266 - 272 TEWTSSN  
594.3 594.3 1+ 23 18.9 268 - 272 WTSSN  
706.4 706.3 1+ 15 34.9 300 - 306 AMGITDV  
536.1 536.2 1+ 20 25.9 301 - 305 MGITD  
635.4 635.3 1+ 21 34.3 301 - 306 MGITDV  
504.2 504.3 1+ 23 27.7 302 - 306 GITDV  
651.3 651.3 1+ 15 40.6 302 - 307 GITDVF  
468.2 468.3 1+ 15 17.0 327 - 331 AVHAA  
605.4 605.3 1+ 20 15.7 327 - 332 AVHAAH  
676.4 676.4 1+ 18 18.1 327 - 333 AVHAAHA  
805.5 805.4 1+ 35 17.9 327 - 334 AVHAAHAE  
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918.6 918.5 1+ 26 26.4 327 - 335 AVHAAHAEI  
1032.6 1032.5 1+ 27 22.7 327 - 336 AVHAAHAEIN  
1161.7 1161.6 1+ 31 23.6 327 - 337 AVHAAHAEINE  
854.4 854.4 1+ 14 21.7 330 - 337 AAHAEINE  
974.6 974.5 1+ 7 22.1 338 - 347 AGREVVGSAE  
561.3 561.3 1+ 9 18.1 342 - 347 VVGSAE  
692.3 692.3 1+ 9 18.4 352 - 358 AASVSEE  
1131.6 1131.6 1+ 11 39.8 358 - 366 EFRADHPFL  
855.5 855.4 1+ 25 35.4 360 - 366 RADHPFL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
